PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 17911642-0 2007 Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. Hydralazine 100-111 mitogen-activated protein kinase 1 Homo sapiens 60-63 17911642-1 2007 T cells from patients with lupus or treated with the lupus-inducing drug hydralazine have defective ERK phosphorylation. Hydralazine 73-84 mitogen-activated protein kinase 1 Homo sapiens 100-103 17911642-3 2007 We therefore analyzed the PMA stimulated ERK pathway phosphorylation cascade in CD4(+) T cells from patients with lupus and in hydralazine-treated cells. Hydralazine 127-138 mitogen-activated protein kinase 1 Homo sapiens 41-44 17911642-5 2007 Pharmacologic inhibition of PKCdelta or transfection with a dominant negative PKCdelta mutant caused demethylation of the TNFSF7 (CD70) promoter and CD70 overexpression similar to lupus and hydralazine-treated T cells. Hydralazine 190-201 protein kinase C delta Homo sapiens 78-86 17911642-6 2007 These results suggest that defective T cell PKCdelta activation may contribute to the development of idiopathic and hydralazine-induced lupus through effects on T cell DNA methylation. Hydralazine 116-127 protein kinase C delta Homo sapiens 44-52 17878758-3 2007 Only hydralazine lowered AngII hypertension. Hydralazine 5-16 angiotensinogen Rattus norvegicus 25-30 17620346-3 2007 The in vitro covalent binding was inhibited in the presence of beta-aminopropionitrile, D-penicillamine, and hydralazine, which suggested that the aldehyde group of allysine in human elastin was relevant to the covalent binding. Hydralazine 109-120 elastin Homo sapiens 183-190 17429947-9 2007 KA-mediated fibril formation by apoC-II was inhibited by the addition of the amine-containing compound hydralazine and the lipid-binding protein apoA-I. Hydralazine 103-114 apolipoprotein C2 Homo sapiens 32-39 18070451-0 2007 [Effect of Hydralazine on demethylation status and expression of APC gene, proliferation and apoptosis of human cervical cancer cell lines]. Hydralazine 11-22 APC regulator of WNT signaling pathway Homo sapiens 65-68 18070451-3 2007 The expression of beta-catenin protein which correlates closely with APC was detected by SP method after treatment with Hydralazine. Hydralazine 120-131 catenin beta 1 Homo sapiens 18-30 18070451-3 2007 The expression of beta-catenin protein which correlates closely with APC was detected by SP method after treatment with Hydralazine. Hydralazine 120-131 APC regulator of WNT signaling pathway Homo sapiens 69-72 18070451-7 2007 APC gene in HeLa and CaSki cell lines which were treated by 40 micromol/L Hydralazine for 72 hours was demethylated and expressed positively, the expression of APC mRNA in HeLa, CaSki and SiHa cell lines increased to 10.35, 11.40 and 0.73 times respectively. Hydralazine 74-85 APC regulator of WNT signaling pathway Homo sapiens 0-3 18070451-7 2007 APC gene in HeLa and CaSki cell lines which were treated by 40 micromol/L Hydralazine for 72 hours was demethylated and expressed positively, the expression of APC mRNA in HeLa, CaSki and SiHa cell lines increased to 10.35, 11.40 and 0.73 times respectively. Hydralazine 74-85 APC regulator of WNT signaling pathway Homo sapiens 160-163 18070451-9 2007 beta-catenin protein can be expressed in cell membrane after treatment with Hydralazine. Hydralazine 76-87 catenin beta 1 Homo sapiens 0-12 18070451-10 2007 CONCLUSION: APC gene methylation plays an important role in the carcinogenesis of cervical cells and can re-express after the treatment with Hydralazine which also could inhibit the growth of the cervical cancer cells. Hydralazine 141-152 APC regulator of WNT signaling pathway Homo sapiens 12-15 17485601-13 2007 In old rats treated with hydralazine, reactive oxygen species level was reduced in endothelial and smooth muscle cells, and AT2R-dependent contraction was abolished. Hydralazine 25-36 angiotensin II receptor, type 2 Rattus norvegicus 124-128 17485601-15 2007 Hydralazine suppressed AT2R-dependent reactive oxygen species production and AT2R-dependent contraction, improving FMD. Hydralazine 0-11 angiotensin II receptor, type 2 Rattus norvegicus 23-27 17485601-15 2007 Hydralazine suppressed AT2R-dependent reactive oxygen species production and AT2R-dependent contraction, improving FMD. Hydralazine 0-11 angiotensin II receptor, type 2 Rattus norvegicus 77-81 17375804-1 2007 The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057). Hydralazine 186-197 angiotensin I converting enzyme Homo sapiens 269-298 17404230-3 2007 Using mice expressing transgenic human Igs, we found that hydralazine impairs up-regulation of RAG-2 gene expression and reduces secondary Ig gene rearrangements. Hydralazine 58-69 recombination activating 2 Homo sapiens 95-100 17404230-7 2007 We also postulate that inhibition of the Erk signaling pathway contributes to the pathogenesis of hydralazine-induced lupus and idiopathic human lupus. Hydralazine 98-109 mitogen-activated protein kinase 1 Homo sapiens 41-44 17375804-1 2007 The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057). Hydralazine 186-197 angiotensin I converting enzyme Homo sapiens 300-303 17324262-8 2007 Most importantly, the antitumor effect of hydralazine and valproate in cervical cancer may at least partially depend on an up-regulating effect on p53 gene and on the valproate-induced hyperacetylation of p53 protein, protecting it from degradation by E6. Hydralazine 42-53 tumor protein p53 Homo sapiens 147-150 17324262-8 2007 Most importantly, the antitumor effect of hydralazine and valproate in cervical cancer may at least partially depend on an up-regulating effect on p53 gene and on the valproate-induced hyperacetylation of p53 protein, protecting it from degradation by E6. Hydralazine 42-53 tumor protein p53 Homo sapiens 205-208 17172824-8 2007 The mice treated with hydralazine showed a significant increase in pimonidazole accumulation (37.2%, p = 0.03), though the CAIX positive fraction was unchanged (14.2%). Hydralazine 22-33 carbonic anhydrase 9 Mus musculus 123-127 17192185-0 2006 Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. Hydralazine 134-145 MHC class I polypeptide-related sequence A Homo sapiens 17-36 17710582-7 2007 RESULTS: Our data suggest that clonidine can stimulate anti-inflammatory IL-10 production from PBMC while decreasing pro-inflammatory TNF-alpha, whereas low doses of hydralazine increased the production of IL-10, TNF-alpha, and IL-6 from preeclamptic PBMCs. Hydralazine 166-177 interleukin 10 Homo sapiens 206-211 17710582-7 2007 RESULTS: Our data suggest that clonidine can stimulate anti-inflammatory IL-10 production from PBMC while decreasing pro-inflammatory TNF-alpha, whereas low doses of hydralazine increased the production of IL-10, TNF-alpha, and IL-6 from preeclamptic PBMCs. Hydralazine 166-177 tumor necrosis factor Homo sapiens 213-222 17710582-7 2007 RESULTS: Our data suggest that clonidine can stimulate anti-inflammatory IL-10 production from PBMC while decreasing pro-inflammatory TNF-alpha, whereas low doses of hydralazine increased the production of IL-10, TNF-alpha, and IL-6 from preeclamptic PBMCs. Hydralazine 166-177 interleukin 6 Homo sapiens 228-232 17710582-8 2007 There was a reduction in IL-10, TNF-alpha, and IL-6 production with increasing doses of clonidine and hydralazine by placentas in preeclampsia. Hydralazine 102-113 interleukin 10 Homo sapiens 25-30 17710582-8 2007 There was a reduction in IL-10, TNF-alpha, and IL-6 production with increasing doses of clonidine and hydralazine by placentas in preeclampsia. Hydralazine 102-113 interleukin 6 Homo sapiens 47-51 17385063-4 2007 Hydroxylamine hypotension was enhanced by the SSAO inhibitor isoniazid and the SSAO substrate methylamine, a pattern shared by hydralazine. Hydralazine 127-138 amine oxidase copper containing 2 Homo sapiens 46-50 17385063-4 2007 Hydroxylamine hypotension was enhanced by the SSAO inhibitor isoniazid and the SSAO substrate methylamine, a pattern shared by hydralazine. Hydralazine 127-138 amine oxidase copper containing 2 Homo sapiens 79-83 17385063-6 2007 It was concluded that hydroxylamine exerts hypotension partly through conversion to nitric oxide and partly by a "hydralazine-like" mechanism involving SSAO inhibition. Hydralazine 114-125 amine oxidase copper containing 2 Homo sapiens 152-156 17263919-5 2007 Hydralazine used as carbonyl scavenger prevented PDGFRbeta inhibition in vitro and in vivo In conclusion, PDGFRbeta is a target for 4-HNE, acrolein and oxidative stress and its progressive inhibition may contribute to defective SMC proliferation and decrease the stability of a vulnerable plaque. Hydralazine 0-11 platelet derived growth factor receptor, beta polypeptide Mus musculus 49-58 17263919-5 2007 Hydralazine used as carbonyl scavenger prevented PDGFRbeta inhibition in vitro and in vivo In conclusion, PDGFRbeta is a target for 4-HNE, acrolein and oxidative stress and its progressive inhibition may contribute to defective SMC proliferation and decrease the stability of a vulnerable plaque. Hydralazine 0-11 platelet derived growth factor receptor, beta polypeptide Mus musculus 106-115 17043664-7 2006 The deposition of lipids and upregulation of PDGF-B, PDGF-D, and PDGFR-beta induced by administration of angiotensin II were all suppressed by the selective angiotensin II type 1 (AT(1)) receptor antagonist losartan, but not by the nonspecific vasodilator hydralazine. Hydralazine 256-267 platelet derived growth factor subunit B Rattus norvegicus 45-51 17183730-15 2006 CONCLUSIONS: Hydralazine and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors. Hydralazine 13-24 histone deacetylase 9 Homo sapiens 76-80 17043664-7 2006 The deposition of lipids and upregulation of PDGF-B, PDGF-D, and PDGFR-beta induced by administration of angiotensin II were all suppressed by the selective angiotensin II type 1 (AT(1)) receptor antagonist losartan, but not by the nonspecific vasodilator hydralazine. Hydralazine 256-267 platelet derived growth factor receptor beta Rattus norvegicus 65-75 17043664-7 2006 The deposition of lipids and upregulation of PDGF-B, PDGF-D, and PDGFR-beta induced by administration of angiotensin II were all suppressed by the selective angiotensin II type 1 (AT(1)) receptor antagonist losartan, but not by the nonspecific vasodilator hydralazine. Hydralazine 256-267 angiotensinogen Rattus norvegicus 105-119 17043664-7 2006 The deposition of lipids and upregulation of PDGF-B, PDGF-D, and PDGFR-beta induced by administration of angiotensin II were all suppressed by the selective angiotensin II type 1 (AT(1)) receptor antagonist losartan, but not by the nonspecific vasodilator hydralazine. Hydralazine 256-267 angiotensinogen Rattus norvegicus 157-171 16914424-6 2006 In 10-wk-old sympathectomized SHR fed a 0.6% NaCl diet, medullary p47phox and gp91phox expression was 40% less than in hydralazine-treated SHR. Hydralazine 119-130 cytochrome b-245 beta chain Rattus norvegicus 78-86 16914424-7 2006 Also, after a 1.8% NaCl diet, medullary p47phox mRNA expression was lower in sympathectomized than in hydralazine-treated SHR. Hydralazine 102-113 neutrophil cytosolic factor 1 Rattus norvegicus 40-47 16859210-11 2006 We also found, significant differences in resting CPPI between PPH responders and no responders patients to hydralazine [0.273 +/- 0.04, 0.507 +/- 0.142 watts/m2, respectively, p < 0.01]. Hydralazine 108-119 cathepsin C Homo sapiens 50-54 16462814-6 2006 This is the case for the inherited variation in the pharmacokinetics and pharmacodynamics of drugs such as hydralazine or isoniazid, which is due to polymorphisms in the N-acetyltransferase-2 (NAT2) gene, which allows splitting the population into three categories: slow, intermediate, and fast metabolizers. Hydralazine 107-118 N-acetyltransferase 2 Homo sapiens 170-191 16462814-6 2006 This is the case for the inherited variation in the pharmacokinetics and pharmacodynamics of drugs such as hydralazine or isoniazid, which is due to polymorphisms in the N-acetyltransferase-2 (NAT2) gene, which allows splitting the population into three categories: slow, intermediate, and fast metabolizers. Hydralazine 107-118 N-acetyltransferase 2 Homo sapiens 193-197 16741022-8 2006 Hydralazine and both dosages of benidipine significantly reduced upregulated cardiac ET-1 levels in OLETF rats. Hydralazine 0-11 endothelin 1 Rattus norvegicus 85-89 16741022-11 2006 In contrast, hydralazine treatment also normalizes cardiac ET-1 levels while significantly reducing blood pressure. Hydralazine 13-24 endothelin 1 Rattus norvegicus 59-63 16612254-6 2006 RESULTS: Placental production of IL-10 was not affected by clonidine, but decreased significantly after incubation of the tissue with diazoxide, hydralazine or furosemide. Hydralazine 145-156 interleukin 10 Homo sapiens 33-38 16612254-7 2006 Production of IL-10 by PBMCs increased significantly: by from 3.4 +/- 2.7% [16.3 pg/ml (range 6.1-21.5 pg/ml)] to 24.5 +/- 3.3% [30.4 pg/ml (range 16.9-34.8 pg/ml)] with increasing concentrations of clonidine (0.08-1.3 microg/ml), and by 8.8 +/- 3.5% [4.1 pg/ml (range 3.0-17.8 pg/ml)] and 17.2 +/- 1.9% [22.6 pg/ml (range 13.2-23.2 pg/ml)] with lower doses of hydralazine (6.3 and 12.5 microg/ml) (all P values < 0.05). Hydralazine 361-372 interleukin 10 Homo sapiens 14-19 16612254-8 2006 There was a stepwise reduction in production of TNF-alpha and IL-6 with increasing doses of diazoxide, hydralazine and furosemide by placentas and PBMCs from these women with normal pregnancies. Hydralazine 103-114 tumor necrosis factor Homo sapiens 48-57 16612254-8 2006 There was a stepwise reduction in production of TNF-alpha and IL-6 with increasing doses of diazoxide, hydralazine and furosemide by placentas and PBMCs from these women with normal pregnancies. Hydralazine 103-114 interleukin 6 Homo sapiens 62-66 16612254-9 2006 CONCLUSION: Our data suggest that the antihypertensive drugs clonidine and hydralazine can stimulate production of the circulating anti-inflammatory cytokine IL-10, whereas furosemide and diazoxide inhibit the production of this cytokine and the proinflammatory cytokines TNF-alpha and IL-6 by placentas and PBMCs. Hydralazine 75-86 interleukin 10 Homo sapiens 158-163 16612254-9 2006 CONCLUSION: Our data suggest that the antihypertensive drugs clonidine and hydralazine can stimulate production of the circulating anti-inflammatory cytokine IL-10, whereas furosemide and diazoxide inhibit the production of this cytokine and the proinflammatory cytokines TNF-alpha and IL-6 by placentas and PBMCs. Hydralazine 75-86 tumor necrosis factor Homo sapiens 272-281 16612254-9 2006 CONCLUSION: Our data suggest that the antihypertensive drugs clonidine and hydralazine can stimulate production of the circulating anti-inflammatory cytokine IL-10, whereas furosemide and diazoxide inhibit the production of this cytokine and the proinflammatory cytokines TNF-alpha and IL-6 by placentas and PBMCs. Hydralazine 75-86 interleukin 6 Homo sapiens 286-290 16303857-8 2006 Similarly, the stimulation of PRC caused by hydralazine was the same in WT and A1AR-/- mice. Hydralazine 44-55 adenosine A1 receptor Mus musculus 79-83 16955753-1 2006 Cardiovascular drugs such as lovastatin, simvastatin, amlodipine besylate, nifedipine, and hydralazine hydrochloride inhibit cholesterol esterase (CEase) in vitro. Hydralazine 91-116 carboxyl ester lipase Homo sapiens 125-145 16527993-8 2006 The aldehyde scavengers DNPH and Hydralazine prevented both oxLDL- and 4HNE-induced structural modification and PDGFRbeta signaling dysfunction in cells and in vivo. Hydralazine 33-44 platelet derived growth factor receptor beta Homo sapiens 112-121 16326922-8 2006 Hydralazine/hydrochlorothiazide normalized systolic blood pressure (BP) and abolished mRNA up-regulation of hypertrophic markers sk-alpha-actin and BNP and of preproAM, CLR, RAMP2, and RAMP3 but did not normalize cardiomyocyte width nor preproIMD or RAMP1 mRNA expression. Hydralazine 0-11 natriuretic peptide B Rattus norvegicus 148-151 16326922-8 2006 Hydralazine/hydrochlorothiazide normalized systolic blood pressure (BP) and abolished mRNA up-regulation of hypertrophic markers sk-alpha-actin and BNP and of preproAM, CLR, RAMP2, and RAMP3 but did not normalize cardiomyocyte width nor preproIMD or RAMP1 mRNA expression. Hydralazine 0-11 calcitonin receptor like receptor Rattus norvegicus 169-172 16326922-8 2006 Hydralazine/hydrochlorothiazide normalized systolic blood pressure (BP) and abolished mRNA up-regulation of hypertrophic markers sk-alpha-actin and BNP and of preproAM, CLR, RAMP2, and RAMP3 but did not normalize cardiomyocyte width nor preproIMD or RAMP1 mRNA expression. Hydralazine 0-11 receptor activity modifying protein 2 Rattus norvegicus 174-179 16326922-8 2006 Hydralazine/hydrochlorothiazide normalized systolic blood pressure (BP) and abolished mRNA up-regulation of hypertrophic markers sk-alpha-actin and BNP and of preproAM, CLR, RAMP2, and RAMP3 but did not normalize cardiomyocyte width nor preproIMD or RAMP1 mRNA expression. Hydralazine 0-11 receptor activity modifying protein 3 Rattus norvegicus 185-190 16326922-8 2006 Hydralazine/hydrochlorothiazide normalized systolic blood pressure (BP) and abolished mRNA up-regulation of hypertrophic markers sk-alpha-actin and BNP and of preproAM, CLR, RAMP2, and RAMP3 but did not normalize cardiomyocyte width nor preproIMD or RAMP1 mRNA expression. Hydralazine 0-11 receptor activity modifying protein 1 Rattus norvegicus 250-255 16955753-1 2006 Cardiovascular drugs such as lovastatin, simvastatin, amlodipine besylate, nifedipine, and hydralazine hydrochloride inhibit cholesterol esterase (CEase) in vitro. Hydralazine 91-116 carboxyl ester lipase Homo sapiens 147-152 16371432-8 2006 Aortae of mice treated with Ang II antagonism had fewer elastin breaks together with less immunostaining for the powerful elastolytic enzyme cathepsin S. None of these benefits was observed in the hydralazine-treated mice despite equivalent reduction in BP. Hydralazine 197-208 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 28-34 16289107-7 2005 Hydralazine dose-dependently decreased the chemiluminescence signal induced by peroxynitrite from SIN-1 and by superoxide from HX/XO in a cell free system, by superoxide in smooth muscle cells and mitochondria acutely challenged with GTN. Hydralazine 0-11 MAPK associated protein 1 Homo sapiens 98-103 17357303-0 2006 Effect of hydralazine on CD3-zeta chain expression in Jurkat T cells. Hydralazine 10-21 CD247 molecule Homo sapiens 25-39 17357303-2 2006 Hydralazine (HYD) inhibits expression of DNA methyltransferase 1 (DNMT1) and may cause a lupus-like disease in man. Hydralazine 0-11 DNA methyltransferase 1 Homo sapiens 41-64 17357303-2 2006 Hydralazine (HYD) inhibits expression of DNA methyltransferase 1 (DNMT1) and may cause a lupus-like disease in man. Hydralazine 0-11 DNA methyltransferase 1 Homo sapiens 66-71 16330679-5 2006 Ang II enhanced vascular alpha8, beta1, beta3 integrins and osteopontin expression, which were significantly reduced by losartan, [Sar1-Ile8]-Ang II, and hydralazine. Hydralazine 154-165 angiotensinogen Rattus norvegicus 0-6 16330679-5 2006 Ang II enhanced vascular alpha8, beta1, beta3 integrins and osteopontin expression, which were significantly reduced by losartan, [Sar1-Ile8]-Ang II, and hydralazine. Hydralazine 154-165 secreted phosphoprotein 1 Rattus norvegicus 25-71 16289107-9 2005 Finally, hydralazine normalized impaired cGK-I activity as well as impaired vascular ALDH-2 activity. Hydralazine 9-20 protein kinase cGMP-dependent 1 Homo sapiens 41-46 16371432-4 2006 Apolipoprotein E-deficient spontaneously hyperlipidemic mice underwent uninephrectomy (UNx) or sham operation (sham) followed by treatment with Ang II receptor antagonist losartan or hydralazine for 12 wk. Hydralazine 183-194 apolipoprotein E Mus musculus 0-16 16262664-12 2005 Approximately twice as many p-ERK1/2-positive neurons were seen in the intermediate NTS and rostral VLM following hydralazine compared with the vehicle. Hydralazine 114-125 mitogen activated protein kinase 3 Rattus norvegicus 30-36 16391708-5 2005 Ang II increased blood pressure (176+/-2 mmHg vs. 115+/-1 mmHg in controls, p<0.01), which was attenuated by spironolactone (147+/-4 mmHg, p<0.01) and prevented by hydralazine (124+/-2 mmHg, p<0.01). Hydralazine 170-181 angiotensinogen Rattus norvegicus 0-6 16391708-6 2005 Ang II enhanced left ventricular interstitial collagen type I/III deposition (4.1%+/-0.1% vs. 3.1%+/-0.2%, p<0.05), and this was attenuated by spironolactone but not hydralazine. Hydralazine 169-180 angiotensinogen Rattus norvegicus 0-6 16391708-7 2005 Ang II-induced cardiac perivascular fibrosis was prevented by spironolactone and hydralazine. Hydralazine 81-92 angiotensinogen Rattus norvegicus 0-6 16391708-9 2005 Ang II-enhanced NFkappaB activity, and VCAM-1 expression was reduced by spironolactone and hydralazine, whereas aortic hypertrophy was prevented by spironolactone and slightly reduced by hydralazine. Hydralazine 91-102 angiotensinogen Rattus norvegicus 0-6 16391708-9 2005 Ang II-enhanced NFkappaB activity, and VCAM-1 expression was reduced by spironolactone and hydralazine, whereas aortic hypertrophy was prevented by spironolactone and slightly reduced by hydralazine. Hydralazine 91-102 vascular cell adhesion molecule 1 Rattus norvegicus 39-45 16391708-9 2005 Ang II-enhanced NFkappaB activity, and VCAM-1 expression was reduced by spironolactone and hydralazine, whereas aortic hypertrophy was prevented by spironolactone and slightly reduced by hydralazine. Hydralazine 187-198 angiotensinogen Rattus norvegicus 0-6 16289107-9 2005 Finally, hydralazine normalized impaired cGK-I activity as well as impaired vascular ALDH-2 activity. Hydralazine 9-20 aldehyde dehydrogenase 2 family member Homo sapiens 85-91 15833808-5 2005 ACE2 mRNA in the thoracic aorta of olmesartan-treated rats (n = 8) was fivefold greater (P < 0.05) than that in vehicle-treated rats (n = 16), whereas atenolol (n = 8) or hydralazine (n = 8) had no effect. Hydralazine 171-182 angiotensin I converting enzyme 2 Rattus norvegicus 0-4 16181550-3 2005 The mRNA expression profile of ER alpha isoforms (ERalpha-A, ERalpha-B and ERalpha-C) and coding region in ER alpha gene were analyzed by using RT-PCR, after hydralazine treatment. Hydralazine 158-169 estrogen receptor 1 Homo sapiens 31-39 15879118-6 2005 Procainamide is a competitive DNA methyltransferase (Dnmt) inhibitor, hydralazine inhibits ERK pathway signaling thereby decreasing Dnmt expression, and in lupus T cells decreased ERK pathway signaling causing a similar Dnmt decrease. Hydralazine 70-81 mitogen-activated protein kinase 1 Homo sapiens 91-94 15879118-6 2005 Procainamide is a competitive DNA methyltransferase (Dnmt) inhibitor, hydralazine inhibits ERK pathway signaling thereby decreasing Dnmt expression, and in lupus T cells decreased ERK pathway signaling causing a similar Dnmt decrease. Hydralazine 70-81 DNA methyltransferase 1 Homo sapiens 132-136 15879118-6 2005 Procainamide is a competitive DNA methyltransferase (Dnmt) inhibitor, hydralazine inhibits ERK pathway signaling thereby decreasing Dnmt expression, and in lupus T cells decreased ERK pathway signaling causing a similar Dnmt decrease. Hydralazine 70-81 DNA methyltransferase 1 Homo sapiens 132-136 15879118-9 2005 CD70 (TNFSF7) is a B cell costimulatory molecule overexpressed on CD4(+) lupus T cells as well as procainamide and hydralazine treated T cells, and contributes to excessive B cell stimulation in vitro and in lupus. Hydralazine 115-126 CD70 molecule Homo sapiens 0-4 15879118-9 2005 CD70 (TNFSF7) is a B cell costimulatory molecule overexpressed on CD4(+) lupus T cells as well as procainamide and hydralazine treated T cells, and contributes to excessive B cell stimulation in vitro and in lupus. Hydralazine 115-126 CD70 molecule Homo sapiens 6-12 15879118-10 2005 In this report we identify a genetic element that suppresses CD70 expression when methylated, and which demethylates in lupus and in T cells treated with Dnmt and ERK pathway inhibitors including procainamide and hydralazine. Hydralazine 213-224 CD70 molecule Homo sapiens 61-65 15879118-10 2005 In this report we identify a genetic element that suppresses CD70 expression when methylated, and which demethylates in lupus and in T cells treated with Dnmt and ERK pathway inhibitors including procainamide and hydralazine. Hydralazine 213-224 DNA methyltransferase 1 Homo sapiens 154-158 15879118-10 2005 In this report we identify a genetic element that suppresses CD70 expression when methylated, and which demethylates in lupus and in T cells treated with Dnmt and ERK pathway inhibitors including procainamide and hydralazine. Hydralazine 213-224 mitogen-activated protein kinase 1 Homo sapiens 163-166 16116337-1 2005 Previous work has shown that inhibitors of the predominantly vascular enzyme semicarbazide-sensitive amine oxidase (SSAO) potentiate the hypotensive response to hydralazine, itself a SSAO inhibitor, in anesthetized rats. Hydralazine 161-172 amine oxidase, copper containing 3 Rattus norvegicus 77-114 16116337-1 2005 Previous work has shown that inhibitors of the predominantly vascular enzyme semicarbazide-sensitive amine oxidase (SSAO) potentiate the hypotensive response to hydralazine, itself a SSAO inhibitor, in anesthetized rats. Hydralazine 161-172 amine oxidase, copper containing 3 Rattus norvegicus 116-120 16116337-1 2005 Previous work has shown that inhibitors of the predominantly vascular enzyme semicarbazide-sensitive amine oxidase (SSAO) potentiate the hypotensive response to hydralazine, itself a SSAO inhibitor, in anesthetized rats. Hydralazine 161-172 amine oxidase, copper containing 3 Rattus norvegicus 183-187 16116337-10 2005 The charactertistics of hydralazine potentiation by bromoethylamine were considered compatible with the mechanism of SSAO inhibition by the amine. Hydralazine 24-35 amine oxidase, copper containing 3 Rattus norvegicus 117-121 16004861-7 2005 Recently, the combination of isosorbide dinitrate and hydralazine has been demonstrated to improve survival in African Americans with New York Heart Association class III and IV heart failure, and represents an adjunctive treatment option when added to standard medical therapy consisting of ACE inhibitors, beta blockers, digoxin, diuretics, and aldosterone antagonists. Hydralazine 54-65 angiotensin I converting enzyme Homo sapiens 292-295 16181550-3 2005 The mRNA expression profile of ER alpha isoforms (ERalpha-A, ERalpha-B and ERalpha-C) and coding region in ER alpha gene were analyzed by using RT-PCR, after hydralazine treatment. Hydralazine 158-169 estrogen receptor 1 Homo sapiens 107-115 16181550-8 2005 Hydralazine, served as a demethylating agent enables to restore the expression of ER alpha gene. Hydralazine 0-11 estrogen receptor 1 Homo sapiens 82-90 15710752-4 2005 In SHR treated with candesartan (MAP=146 mm Hg) or hydralazine (16 mg/kg per day; MAP=145 mm Hg), AT2R-induced contraction was reduced by 50%. Hydralazine 51-62 angiotensin II receptor, type 2 Rattus norvegicus 98-102 15537880-9 2004 When hypotension was induced with hydralazine, NK3-R internalization was observed within 5 min (p < 0.005). Hydralazine 34-45 tachykinin receptor 3 Rattus norvegicus 47-52 15792354-8 2005 Furthermore, we analyzed the effect of an angiotensin II type 1 receptor blocker (ARB) and hydralazine (Hy) on PKC regulation in SHHF rat left ventricle (LV). Hydralazine 91-102 protein kinase C, gamma Rattus norvegicus 111-114 15277329-9 2004 Oral treatment of ApoE-/- mice with either hydralazine or irbesartan reduced systolic blood pressure to the same level; however, only AT1 receptor antagonist treatment reduced atherosclerotic lesion formation and improved endothelial function. Hydralazine 43-54 apolipoprotein E Mus musculus 18-22 15607619-4 2004 RESULTS: The expression of HO-1 and iNOS in aorta increased with the SBP elevation during the development of SHR and was attenuated when the hypertension was lowered with the vasodilator hydralazine. Hydralazine 187-198 heme oxygenase 1 Rattus norvegicus 27-31 15607619-4 2004 RESULTS: The expression of HO-1 and iNOS in aorta increased with the SBP elevation during the development of SHR and was attenuated when the hypertension was lowered with the vasodilator hydralazine. Hydralazine 187-198 nitric oxide synthase 2 Rattus norvegicus 36-40 15192023-0 2004 Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Hydralazine 30-41 hypoxia inducible factor 1 subunit alpha Homo sapiens 56-87 15342105-5 2004 The functional implications of this pathway in cardiovascular functions were verified using Fos protein induction in response to hypotension induced by continuous intravenous administration of hydralazine-hydrochloride. Hydralazine 193-218 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 92-95 15192023-0 2004 Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Hydralazine 30-41 vascular endothelial growth factor A Homo sapiens 89-123 15180496-5 2004 In some instances, covalent binding of the toxic metabolite to CYP leads to the formation of anti-CYP antibodies and immune-mediated hepatotoxicity (hydralazine, tienilic acid). Hydralazine 149-160 peptidylprolyl isomerase G Homo sapiens 63-66 15192023-4 2004 Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation. Hydralazine 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 15192023-4 2004 Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation. Hydralazine 0-11 endothelin 1 Homo sapiens 96-142 15192023-4 2004 Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation. Hydralazine 0-11 vascular endothelial growth factor A Homo sapiens 148-182 15192023-4 2004 Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation. Hydralazine 0-11 vascular endothelial growth factor A Homo sapiens 184-188 15192023-5 2004 Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity. Hydralazine 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 80-90 15192023-6 2004 In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels. Hydralazine 9-20 hypoxia inducible factor 1 subunit alpha Homo sapiens 29-39 15192023-6 2004 In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels. Hydralazine 9-20 vascular endothelial growth factor A Homo sapiens 44-48 15192023-6 2004 In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels. Hydralazine 9-20 vascular endothelial growth factor A Homo sapiens 96-100 15213263-4 2004 When hydralazine was administered to the mutant mice fed a high-salt diet, BP was reduced to 72.5 +/- 1.3 mmHg, with decreases in the levels of renal eNOS mRNA and protein expression to about half of those found in nontreated group. Hydralazine 5-16 nitric oxide synthase 3, endothelial cell Mus musculus 150-154 14644766-8 2004 Long-term administration of hydralazine normalized the blood pressure and prevented the LV dilation in NOS3(-/-) mice but did not prevent the LV hypertrophy, dysfunction, and fibrosis associated with NOS3 deficiency after TAC. Hydralazine 28-39 nitric oxide synthase 3, endothelial cell Mus musculus 103-107 15076159-6 2004 RESULTS: The rise in SBP induced by Ang II (P < 0.001) was prevented by apocynin and hydralazine. Hydralazine 88-99 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 36-42 14767494-6 2004 RESULTS: Hydralazine treatment in obese animals attenuated obesity-related renin-angiotensin system (RAS) activation. Hydralazine 9-20 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 75-80 14978244-6 2004 We report that hydralazine abolished the immunoreactivity of an acrolein-modified model protein (bovine serum albumin), but only if the drug was added to the protein within 30 min of commencing modification by acrolein. Hydralazine 15-26 albumin Homo sapiens 104-117 15174896-6 2004 Although these polymorphisms have major effects on the pharmacokinetic profiles of both commonly used antihypertensive drugs such as metoprolol (CYP2D6), and lesser used drugs such as hydralazine (NAT2), methyldopa (COMT), and minoxidil (SULT1A1), they have not been shown to influence variation in the antihypertensive effect of these drugs at conventional doses. Hydralazine 184-195 N-acetyltransferase 2 Homo sapiens 197-201 14747377-13 2004 Furthermore, although hydralazine significantly reduced JNK activity (-56 +/- 3%), ERK1/ERK2 activities were unaffected. Hydralazine 22-33 mitogen-activated protein kinase 8 Rattus norvegicus 56-59 14996408-0 2004 Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Hydralazine 47-58 prostaglandin-endoperoxide synthase 2 Mus musculus 76-81 14996408-3 2004 Hydralazine at 0.1-10 mM significantly reduced NO(*) generation, and this effect was attributable to an inhibition of NOS-2 gene expression and protein synthesis. Hydralazine 0-11 nitric oxide synthase 2 Rattus norvegicus 118-123 14996408-4 2004 At 1-10 mM, hydralazine also effectively blocked COX-2 gene expression which perfectly correlated with a reduction of protein levels and PGE(2) synthesis. Hydralazine 12-23 prostaglandin-endoperoxide synthase 2 Mus musculus 49-54 15174896-6 2004 Although these polymorphisms have major effects on the pharmacokinetic profiles of both commonly used antihypertensive drugs such as metoprolol (CYP2D6), and lesser used drugs such as hydralazine (NAT2), methyldopa (COMT), and minoxidil (SULT1A1), they have not been shown to influence variation in the antihypertensive effect of these drugs at conventional doses. Hydralazine 184-195 catechol-O-methyltransferase Homo sapiens 216-220 15174896-6 2004 Although these polymorphisms have major effects on the pharmacokinetic profiles of both commonly used antihypertensive drugs such as metoprolol (CYP2D6), and lesser used drugs such as hydralazine (NAT2), methyldopa (COMT), and minoxidil (SULT1A1), they have not been shown to influence variation in the antihypertensive effect of these drugs at conventional doses. Hydralazine 184-195 sulfotransferase family 1A member 1 Homo sapiens 238-245 12738711-11 2003 RESULTS: Hydralazine and procainamide induced de-methylation and re-expression of the ER, RARbeta, and p16 genes in cultured cells. Hydralazine 9-20 retinoic acid receptor beta Homo sapiens 90-97 15286391-6 2004 Mice receiving CD4+ T cells demethylated by a variety of agents, including procainamide and hydralazine, develop a lupuslike disease. Hydralazine 92-103 CD4 antigen Mus musculus 15-18 15255812-7 2003 Studies linking inhibition of SSAO to hydralazine hypotension are reviewed and a general hypothesis relating both actions is presented. Hydralazine 38-49 amine oxidase copper containing 2 Homo sapiens 30-34 15255812-10 2003 hydralazine vasodilation is the consequence of vascular SSAO inhibition. Hydralazine 0-11 amine oxidase copper containing 2 Homo sapiens 56-60 12970383-0 2003 Semicarbazide-sensitive amine oxidase substrates potentiate hydralazine hypotension: possible role of hydrogen peroxide. Hydralazine 60-71 amine oxidase, copper containing 3 Rattus norvegicus 0-37 12970383-1 2003 The relation between inhibition of semicarbazide-sensitive amine oxidase (SSAO) and vasodilation by hydralazine (HYD) was evaluated in chloralose/urethane-anesthetized rats pretreated with various substrates of the enzyme and subsequently administered a threshold hypotensive dose of the vasodilator. Hydralazine 100-111 amine oxidase, copper containing 3 Rattus norvegicus 35-72 12970383-1 2003 The relation between inhibition of semicarbazide-sensitive amine oxidase (SSAO) and vasodilation by hydralazine (HYD) was evaluated in chloralose/urethane-anesthetized rats pretreated with various substrates of the enzyme and subsequently administered a threshold hypotensive dose of the vasodilator. Hydralazine 100-111 amine oxidase, copper containing 3 Rattus norvegicus 74-78 12729848-10 2003 The combination of hydralazine and isosorbide dinitrate might be useful in patients (especially in African Americans) who cannot tolerate ACE inhibitors or valsartan because of hypotension or renal dysfunction. Hydralazine 19-30 angiotensin I converting enzyme Homo sapiens 138-141 12738711-11 2003 RESULTS: Hydralazine and procainamide induced de-methylation and re-expression of the ER, RARbeta, and p16 genes in cultured cells. Hydralazine 9-20 cyclin dependent kinase inhibitor 2A Homo sapiens 103-106 12738711-13 2003 Hydralazine re-expressed the p16 gene longer as compared with 5-aza-deoxycytidine. Hydralazine 0-11 cyclin dependent kinase inhibitor 2A Homo sapiens 29-32 12738711-15 2003 In addition, the treatment with oral hydralazine demethylated and re-expressed the RARbeta and p16 genes in the cervical and head and cancer patients. Hydralazine 37-48 retinoic acid receptor beta Homo sapiens 83-90 12738711-15 2003 In addition, the treatment with oral hydralazine demethylated and re-expressed the RARbeta and p16 genes in the cervical and head and cancer patients. Hydralazine 37-48 cyclin dependent kinase inhibitor 2A Homo sapiens 95-98 12629037-9 2003 L-NAME caused a 2.2-fold/1.8-fold increase in p70S6K/ERK activity in myocardium compared with the control, both of which were attenuated by both amlodipine and benidipine but not hydralazine. Hydralazine 179-190 Eph receptor B1 Rattus norvegicus 53-56 12748489-7 2003 Administration of betamethasone (BMZ) and/or hydralazine (HYD) was significantly associated with a lower IL-18 compared with controls (159 +/- 50 pg/mL vs 224 +/- 75 pg/mL, P =.002). Hydralazine 45-56 interleukin 18 Homo sapiens 105-110 12632429-0 2003 Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Hydralazine 0-11 mitogen-activated protein kinase 1 Mus musculus 50-87 12632429-1 2003 OBJECTIVE: To determine whether hydralazine might decrease DNA methyltransferase (DNMT) expression and induce autoimmunity by inhibiting extracellular signal-regulated kinase (ERK) pathway signaling. Hydralazine 32-43 DNA methyltransferase (cytosine-5) 1 Mus musculus 59-80 12632429-1 2003 OBJECTIVE: To determine whether hydralazine might decrease DNA methyltransferase (DNMT) expression and induce autoimmunity by inhibiting extracellular signal-regulated kinase (ERK) pathway signaling. Hydralazine 32-43 DNA methyltransferase (cytosine-5) 1 Mus musculus 82-86 12632429-1 2003 OBJECTIVE: To determine whether hydralazine might decrease DNA methyltransferase (DNMT) expression and induce autoimmunity by inhibiting extracellular signal-regulated kinase (ERK) pathway signaling. Hydralazine 32-43 mitogen-activated protein kinase 1 Mus musculus 137-174 12632429-1 2003 OBJECTIVE: To determine whether hydralazine might decrease DNA methyltransferase (DNMT) expression and induce autoimmunity by inhibiting extracellular signal-regulated kinase (ERK) pathway signaling. Hydralazine 32-43 mitogen-activated protein kinase 1 Mus musculus 176-179 12632429-2 2003 METHODS: The effect of hydralazine on DNMT was tested in vitro using enzyme inhibition studies, and in vivo by measuring messenger RNA (mRNA) levels and enzyme activity. Hydralazine 23-34 DNA methyltransferase (cytosine-5) 1 Mus musculus 38-42 12632429-6 2003 Instead, hydralazine inhibited ERK pathway signaling, thereby decreasing DNMT1 and DNMT3a mRNA expression and DNMT enzyme activity similar to mitogen-activated protein kinase kinase (MEK) inhibitors. Hydralazine 9-20 mitogen-activated protein kinase 1 Mus musculus 31-34 12632429-6 2003 Instead, hydralazine inhibited ERK pathway signaling, thereby decreasing DNMT1 and DNMT3a mRNA expression and DNMT enzyme activity similar to mitogen-activated protein kinase kinase (MEK) inhibitors. Hydralazine 9-20 DNA methyltransferase (cytosine-5) 1 Mus musculus 73-78 12632429-6 2003 Instead, hydralazine inhibited ERK pathway signaling, thereby decreasing DNMT1 and DNMT3a mRNA expression and DNMT enzyme activity similar to mitogen-activated protein kinase kinase (MEK) inhibitors. Hydralazine 9-20 DNA methyltransferase 3A Mus musculus 83-89 12632429-6 2003 Instead, hydralazine inhibited ERK pathway signaling, thereby decreasing DNMT1 and DNMT3a mRNA expression and DNMT enzyme activity similar to mitogen-activated protein kinase kinase (MEK) inhibitors. Hydralazine 9-20 DNA methyltransferase (cytosine-5) 1 Mus musculus 73-77 12632429-8 2003 CONCLUSION: Hydralazine reproduces the lupus ERK pathway signaling abnormality and its effects on DNMT expression, and inhibiting this pathway induces autoimmunity. Hydralazine 12-23 mitogen-activated protein kinase 1 Mus musculus 45-48 12632429-8 2003 CONCLUSION: Hydralazine reproduces the lupus ERK pathway signaling abnormality and its effects on DNMT expression, and inhibiting this pathway induces autoimmunity. Hydralazine 12-23 DNA methyltransferase (cytosine-5) 1 Mus musculus 98-102 12632429-9 2003 Hydralazine-induced lupus could be caused in part by inducing the same ERK pathway signaling defect that occurs in idiopathic lupus. Hydralazine 0-11 mitogen-activated protein kinase 1 Mus musculus 71-74 12538209-4 2003 Nitroglycerin, hydralazine, and nicardipine produced concentration-dependent relaxation of U46619-preconstricted HUA segments from normotensive and PIH patients. Hydralazine 15-26 pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included) Homo sapiens 148-151 11370014-6 2001 First, we examined Fos production by FG-labeled RVLM neurons after 2 hours of hydralazine-induced hypotension (to 73 +/- 2 mm Hg) in conscious rats. Hydralazine 78-89 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 19-22 12419014-12 2002 The metabolism of 80 micro M ZAL to M2 in liver cytosol preparations was markedly inhibited by the aldehyde oxidase inhibitors chlorpromazine, promethazine, hydralazine and menadione. Hydralazine 157-168 aldehyde oxidase 1 Homo sapiens 99-115 12163700-4 2002 Procainamide and hydralazine, two drugs that cause a lupus-like disease, also inhibit T cell DNA methylation, increase LFA-1 expression and induce autoreactivity in vitro and autoimmunity in vivo, supporting the association of DNA hypomethylation and autoimmunity. Hydralazine 17-28 integrin subunit alpha L Homo sapiens 119-124 11705813-3 2001 METHODS AND RESULTS: Male apoE/eNOS DKO mice were treated with hydralazine in their drinking water (250 mg/L) using a dose that lowers the blood pressure to levels seen in apoE KO mice. Hydralazine 63-74 apolipoprotein E Mus musculus 26-30 11705813-3 2001 METHODS AND RESULTS: Male apoE/eNOS DKO mice were treated with hydralazine in their drinking water (250 mg/L) using a dose that lowers the blood pressure to levels seen in apoE KO mice. Hydralazine 63-74 nitric oxide synthase 3, endothelial cell Mus musculus 31-35 11705813-3 2001 METHODS AND RESULTS: Male apoE/eNOS DKO mice were treated with hydralazine in their drinking water (250 mg/L) using a dose that lowers the blood pressure to levels seen in apoE KO mice. Hydralazine 63-74 apolipoprotein E Mus musculus 172-176 11705813-5 2001 Hydralazine-treated, normotensive male apoE/eNOS DKO mice developed increased aortic lesion areas (30.0+/-2.8%, n=11) compared with male apoE KO mice (14.6+/-0.8%, n=7). Hydralazine 0-11 apolipoprotein E Mus musculus 39-43 11705813-5 2001 Hydralazine-treated, normotensive male apoE/eNOS DKO mice developed increased aortic lesion areas (30.0+/-2.8%, n=11) compared with male apoE KO mice (14.6+/-0.8%, n=7). Hydralazine 0-11 nitric oxide synthase 3, endothelial cell Mus musculus 44-48 11705813-7 2001 Four of 11 hydralazine-treated male apoE/eNOS DKO mice developed abdominal aortic aneurysms. Hydralazine 11-22 apolipoprotein E Mus musculus 36-40 11705813-7 2001 Four of 11 hydralazine-treated male apoE/eNOS DKO mice developed abdominal aortic aneurysms. Hydralazine 11-22 nitric oxide synthase 3, endothelial cell Mus musculus 41-45 12544451-7 2003 RESULTS: Ang II increased blood pressure significantly (P <0.01); this was partially prevented by spironolactone (P <0.01) and nearly normalized by hydralazine (P <0.01). Hydralazine 154-165 angiotensinogen Rattus norvegicus 9-15 12544451-8 2003 Media thickness, media:lumen ratio and media cross-sectional area of mesenteric resistance arteries increased under Ang II or aldosterone (P <0.01) and this was partially prevented by spironolactone (P <0.01), but not by hydralazine. Hydralazine 227-238 angiotensinogen Rattus norvegicus 116-122 12544451-9 2003 Compared with the control or Ang II + spironolactone groups, rats treated with Ang II with or without hydralazine presented stiffer vessels, with leftward shift of the stress-strain relationship and a raised slope of the incremental elastic modulus-stress relationship (P <0.05). Hydralazine 102-113 angiotensinogen Rattus norvegicus 29-35 12544451-9 2003 Compared with the control or Ang II + spironolactone groups, rats treated with Ang II with or without hydralazine presented stiffer vessels, with leftward shift of the stress-strain relationship and a raised slope of the incremental elastic modulus-stress relationship (P <0.05). Hydralazine 102-113 angiotensinogen Rattus norvegicus 79-85 12360107-1 2002 The slow arylamine -acetyltransferase 2 (NAT2) phenotype frequently has been assumed to be associated with an elevated risk to develop a lupus-like syndrome after administration of drugs such as procainamide or hydralazine. Hydralazine 211-222 N-acetyltransferase 2 Homo sapiens 41-45 12082016-11 2002 A reported clinical association of Tp53 immunopositive colorectal cancers with use of the antihypertensive agents was extended by the demonstration of hydralazine and nifedipine as Tp53-inducers. Hydralazine 151-162 tumor protein p53 Homo sapiens 35-39 11840475-10 2002 The RVLM of six unanesthetized rats subjected to 2 hours of hydralazine-induced hypotension contained tenfold more c-Fos-ir DNPI/VGLUT2 neurons than that of six saline-treated controls. Hydralazine 60-71 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 115-120 11840475-10 2002 The RVLM of six unanesthetized rats subjected to 2 hours of hydralazine-induced hypotension contained tenfold more c-Fos-ir DNPI/VGLUT2 neurons than that of six saline-treated controls. Hydralazine 60-71 solute carrier family 17 member 6 Rattus norvegicus 124-128 11840475-10 2002 The RVLM of six unanesthetized rats subjected to 2 hours of hydralazine-induced hypotension contained tenfold more c-Fos-ir DNPI/VGLUT2 neurons than that of six saline-treated controls. Hydralazine 60-71 solute carrier family 17 member 6 Rattus norvegicus 129-135 11821713-6 2002 RESULTS: In vivo irbesartan, amlodipine and hydrochlorothiazide/hydralazine produced similar falls in blood pressure, from 162 +/- 4 to 125 +/- 5, 132 +/- 4 and 131 +/- 6 mmHg, respectively, but irbesartan caused a greater reduction in superoxide and p22phox; superoxide levels in carotid arteries being 3.1 +/- 0.3, 1.1 +/- 0.2, 1.9 +/- 0.3 and 2.0 +/- 0.3 nmoles/mg per min, respectively. Hydralazine 64-75 cytochrome b-245 alpha chain Rattus norvegicus 251-258 11799094-5 2002 The norepinephrine-induced increase in 8-epi-PGF(2alpha) levels could be completely normalized by 3 different classes of antihypertensive drugs: prazosin, an alpha-adrenergic receptor blocker; hydralazine, a nonspecific vasodilator; and losartan, a specific angiotensin type 1 (AT(1)) receptor antagonist. Hydralazine 193-204 placental growth factor Rattus norvegicus 45-48 11680515-5 2001 Using this rabbit model of thromboembolic stroke, this hypothesis is now expanded to compare two clinically relevant anti-hypertensive agents, atenolol (NO-dependent) and hydralazine (NO-independent), for their ability to improve t-PA-mediated clot lysis following aspirin pre-treatment. Hydralazine 171-182 plasminogen activator, tissue type Homo sapiens 230-234 11695240-9 2001 The results of our study on the effect of hydralazine on IFP in SAF and LPB tumour model are in accordance to previously reported studies. Hydralazine 42-53 FAS antisense RNA 1 Homo sapiens 64-67 28095223-1 2001 Our goal was to assess the cardiovascular and renal protection afforded by angiotensin II type 1-receptor blockade against NG-nitro-L-arginine methyl ester (L-NAME)-exacerbated hypertension in young spontaneously hypertensive rats (SHR), in comparison with the antihypertensive drug, hydralazine. Hydralazine 284-295 angiotensin II receptor, type 1b Rattus norvegicus 75-105 11302941-4 2001 The increase of tresperimus plasma levels induced by the administration of hydralazine, an irreversible in vivo inhibitor of semicarbazide-sensitive amine oxidase (SSAO), reflected the major involvement of this enzyme in tresperimus metabolism. Hydralazine 75-86 amine oxidase, copper containing 3 Rattus norvegicus 125-162 11302941-4 2001 The increase of tresperimus plasma levels induced by the administration of hydralazine, an irreversible in vivo inhibitor of semicarbazide-sensitive amine oxidase (SSAO), reflected the major involvement of this enzyme in tresperimus metabolism. Hydralazine 75-86 amine oxidase, copper containing 3 Rattus norvegicus 164-168 11274226-4 2001 BP in the ACEI- and AT1R-Ant-treated groups remained significantly decreased, compared with the untreated and hydralazine-treated groups. Hydralazine 110-121 angiotensin II receptor, type 1a Rattus norvegicus 20-24 11322632-3 2001 Of these agents, hydralazine and L-canavanine produced a relaxing effect on endothelin-1-contracted muscle that was significantly greater than relaxing effect on carbachol-contracted muscle. Hydralazine 17-28 endothelin 1 Bos taurus 76-88 11230308-8 2001 To test this, the angiotensin II-induced increase in blood pressure was prevented by coadministration of the vasodilator, hydralazine (15 mg/kg per day). Hydralazine 122-133 angiotensinogen Homo sapiens 18-32 11230308-9 2001 Hydralazine alone decreased blood pressure (-27+/-3 mm Hg) and increased mouse renin mRNA 2.4-fold. Hydralazine 0-11 renin Homo sapiens 79-84 11230308-10 2001 Human renin mRNA was unresponsive to this vasodilator-induced fall in pressure and despite the normalization of blood pressure by hydralazine, high-dose angiotensin II still caused a 2.1-fold increase in human renin mRNA. Hydralazine 130-141 angiotensinogen Homo sapiens 153-167 11305783-5 2001 The experiments with modified S9 mix allow the conclusion that the antioxidant enzymes catalase and superoxide dismutase present in S9 liver fraction play a role in the protection of cells from the genotoxic action of hydralazine and dihydralazine. Hydralazine 218-229 catalase Mus musculus 87-95 11173339-7 2000 This finding partly differs from previous studies where Fos expression occurred by other reasons such as hypovolemia, hemorrhage, nitroprusside or hydralazine etc. Hydralazine 147-158 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 56-59 11168946-9 2001 Ang II induced increased positivity of TUNEL, and PCNA was blocked completely by losartan, but only partially by hydralazine. Hydralazine 113-124 angiotensinogen Rattus norvegicus 0-6 11236005-8 2001 We studied the effects of the antihypertensive drugs captopril, hydralazine, and nifedipine and found that, regardless of their effect on blood pressure or hypertrophy, all three eliminated ANP immunoproducts from the majority of the left ventricular myocytes and reduced the level of ANP mRNA, captopril being the most effective. Hydralazine 64-75 natriuretic peptide A Rattus norvegicus 190-193 11130783-1 2000 Inducing T cell LFA-1 overexpression by transfection, or by treatment with DNA methylation inhibitors including 5-azacytidine, procainamide and hydralazine, causes MHC-specific T cell autoreactivity in vitro and autoimmunity in vivo. Hydralazine 144-155 integrin subunit alpha L Homo sapiens 16-21 11040228-6 2000 Inversely, hydralazine significantly increased the cardiac ERK activity in SHRSP by enhancing its phosphorylation. Hydralazine 11-22 Eph receptor B1 Rattus norvegicus 59-62 11096488-7 1999 The combination of hydralazine and isosorbide dinitrate is an acceptable alternative therapy for patients who cannot take ACE inhibitors. Hydralazine 19-30 angiotensin I converting enzyme Homo sapiens 122-125 10938248-1 2000 Injection of rats either with diazoxide (25 mg/kg iv), isoproterenol (0.33 mg/kg sc), or hydralazine (HDZ) (10 mg/kg ip) decreased arterial blood pressure from approximately 120 to 70-80 mmHg and stimulated renin secretion. Hydralazine 89-100 renin Rattus norvegicus 207-212 10938248-1 2000 Injection of rats either with diazoxide (25 mg/kg iv), isoproterenol (0.33 mg/kg sc), or hydralazine (HDZ) (10 mg/kg ip) decreased arterial blood pressure from approximately 120 to 70-80 mmHg and stimulated renin secretion. Hydralazine 102-105 renin Rattus norvegicus 207-212 10693882-2 2000 However, there have been reports suggesting that hydralazine, propylthiouracil, and several other drugs may cause some cases of APV, and the majority of these cases have been associated with antimyeloperoxidase (anti-MPO) ANCA. Hydralazine 49-60 myeloperoxidase Homo sapiens 217-220 10693882-4 2000 METHODS: In this study, we determined the prevalence of exposure to hydralazine, propylthiouracil, and other drugs previously implicated in APV among 30 patients with vasculitis and the highest titers of anti-MPO antibodies newly detected in our laboratory between 1994 and 1998. Hydralazine 68-79 myeloperoxidase Homo sapiens 209-212 10693882-13 2000 CONCLUSION: These data suggest that a sizable proportion of cases of APV with high titers of anti-MPO antibodies are drug-associated, especially following exposure to hydralazine or propylthiouracil. Hydralazine 167-178 myeloperoxidase Homo sapiens 98-101 10567181-7 1999 Treatment with hydralazine abolished the induction of IGF-I mRNA, which indicates that Ang II induces cardiac IGF-I mRNA expression through a pressor-mediated mechanism. Hydralazine 15-26 insulin-like growth factor 1 Rattus norvegicus 54-59 10567181-7 1999 Treatment with hydralazine abolished the induction of IGF-I mRNA, which indicates that Ang II induces cardiac IGF-I mRNA expression through a pressor-mediated mechanism. Hydralazine 15-26 angiotensinogen Rattus norvegicus 87-93 10567181-7 1999 Treatment with hydralazine abolished the induction of IGF-I mRNA, which indicates that Ang II induces cardiac IGF-I mRNA expression through a pressor-mediated mechanism. Hydralazine 15-26 insulin-like growth factor 1 Rattus norvegicus 110-115 10924066-8 2000 The selective AT(1)-receptor antagonist, losartan, completely, but hydralazine only partially, suppressed angiotensin II-induced granulation tissue formation and HO-1 upregulation. Hydralazine 67-78 angiotensinogen Rattus norvegicus 106-120 10948091-13 2000 Renal vasculopathy was accompanied by increased tissue factor expression on macrophages and vessels of untreated and hydralazine-treated dTGR, which was markedly reduced by bosentan. Hydralazine 117-128 coagulation factor III, tissue factor Homo sapiens 48-61 11061213-4 2000 Hydralazine is a potent SSAO inhibitor and pretreatment with this irreversible inactivator resulted in a nearly complete loss of radioactive deposits in the tissues. Hydralazine 0-11 amine oxidase, copper containing 3 Mus musculus 24-28 10905545-6 2000 Each compound attenuated carbonylation of a model protein, bovine serum albumin, during reactions with acrolein at neutral pH and 37 degrees C. However, the most efficient agent was hydralazine, which strongly suppressed carbonylation under these conditions. Hydralazine 182-193 albumin Mus musculus 66-79 10444561-0 1999 Fos expression in brain stem nuclei of pregnant rats after hydralazine-induced hypotension. Hydralazine 59-70 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 0-3 9886895-8 1998 In the hydralazine group, tissue Ang II and catecholamine concentrations and the heart-to-body weight ratio were not different from those in the untreated group. Hydralazine 7-18 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 33-39 10327602-1 1999 Previous studies have shown that chronic treatment of SHR (spontaneously hypertensive) rats with the antihypertensive drugs captopril, hydralazine and terazosin results in changes in the specific activities of the antioxidant enzymes glutathione peroxidase, catalase and Cu/Zn superoxide dismutase in liver and myocardium. Hydralazine 135-146 catalase Rattus norvegicus 258-266 9746122-8 1998 Further, vehicle- and hydralazine-treated rats were characterized by elevated steady-state messenger (m)RNA levels of fibronectin (2.7- and 2.8-fold, P< 0.005), collagen I (2.0- and 1.8-fold, P < 0.0005), collagen III (both 2.2-fold, P < 0.001) and laminin B (1.6- and 1.6-fold, P < 0.005). Hydralazine 22-33 fibronectin 1 Rattus norvegicus 118-129 8915446-0 1996 Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Hydralazine 49-60 renin Canis lupus familiaris 68-73 9612245-14 1998 Hydralazine treatment normalized blood pressure in ANG II-infused rats. Hydralazine 0-11 angiotensinogen Rattus norvegicus 51-57 9612245-15 1998 The effect of ANG II to decrease body weight was augmented in hydralazine-treated rats. Hydralazine 62-73 angiotensinogen Rattus norvegicus 14-20 9582107-11 1998 Fibronectin expression was marked in the control and hydralazine groups. Hydralazine 53-64 fibronectin 1 Mus musculus 0-11 9740313-8 1998 By inhibiting SSAO irreversibly with hydralazine before giving 14C-methylamine to the mice, it was possible to determine the resynthesis rate of SSAO in different tissues. Hydralazine 37-48 amine oxidase, copper containing 3 Mus musculus 14-18 9740313-8 1998 By inhibiting SSAO irreversibly with hydralazine before giving 14C-methylamine to the mice, it was possible to determine the resynthesis rate of SSAO in different tissues. Hydralazine 37-48 amine oxidase, copper containing 3 Mus musculus 145-149 9403559-5 1997 When we normalized blood pressure in angiotensin II-treated rats through oral administration of the nonspecific vasodilator hydralazine (15 mg x kg[-1] x d[-1]), aortic MCP-1 mRNA expression was significantly reduced. Hydralazine 124-135 angiotensinogen Rattus norvegicus 37-51 9362314-4 1997 Hydralazine also elicited substantial increases in plasma levels of both OT and VP. Hydralazine 0-11 arginine vasopressin Rattus norvegicus 80-82 9242466-9 1997 In addition, changes in tumor microenvironment were detected by 19F MRS. An increase in hypoxia induced by hydralazine treatment of RIF-1 tumor-bearing mice was associated with a 2.4-fold increase in 19FRI compared to untreated controls. Hydralazine 107-118 replication timing regulatory factor 1 Mus musculus 132-137 9444886-10 1997 By 4 weeks, IGF-I mRNA levels in the enalapril- and nifedipine-treated groups were significantly lower than those in the untreated and hydralazine-treated groups. Hydralazine 135-146 insulin-like growth factor 1 Rattus norvegicus 12-17 9323082-4 1997 Treatment with either losartan (25 mg x kg(-1) x d(-1)) or hydralazine (15 mg x kg(-1) x d(-1)), both of which prevented the Ang II-induced hypertension, blocked HO-1 mRNA upregulation. Hydralazine 59-70 heme oxygenase 1 Rattus norvegicus 162-166 9452775-8 1997 In the case of contraindication or impossibility of using angiotensin converting enzyme inhibitors, a combination of high doses of nitrates and hydralazine may be justified. Hydralazine 144-155 angiotensin I converting enzyme Homo sapiens 58-87 8915446-1 1996 OBJECTIVE: To study long-term effects of enalapril, an angiotensin-converting enzyme inhibitor, and hydralazine, an arteriodilator, on renin-angiotensin-aldosterone system and fluid balance before and after administration of furosemide. Hydralazine 100-111 renin Canis lupus familiaris 135-140 8890799-6 1996 In studies of long-term vasodilator therapy in patients with chronic aortic regurgitation, a reduction in left ventricular volumes and regurgitant fraction, with or without an increase in ejection fraction, has been observed during treatment with hydralazine, nifedipine and ACE inhibitors. Hydralazine 247-258 angiotensin I converting enzyme Homo sapiens 275-278 8743541-8 1996 Moreover, treatment of hypertensive SHR with an angiotensin II type 1 receptor antagonist or hydralazine caused a decrease in PTHrP expression in the aortae with the lowering of blood pressure. Hydralazine 93-104 parathyroid hormone-like hormone Rattus norvegicus 126-131 8675699-4 1996 Some of these agents, such as procainamide, hydralazine, and UV-light inhibit T cell DNA methylation, increase lymphocyte function-associated antigen 1 (LFA-1) (CD11a/CD18) expression, and induce autoreactivity in vitro, and adoptive transfer of T cells that are made autoreactive by this mechanism causes a lupuslike disease. Hydralazine 44-55 integrin beta 2 Mus musculus 111-151 8675699-4 1996 Some of these agents, such as procainamide, hydralazine, and UV-light inhibit T cell DNA methylation, increase lymphocyte function-associated antigen 1 (LFA-1) (CD11a/CD18) expression, and induce autoreactivity in vitro, and adoptive transfer of T cells that are made autoreactive by this mechanism causes a lupuslike disease. Hydralazine 44-55 integrin beta 2 Mus musculus 153-158 8675699-4 1996 Some of these agents, such as procainamide, hydralazine, and UV-light inhibit T cell DNA methylation, increase lymphocyte function-associated antigen 1 (LFA-1) (CD11a/CD18) expression, and induce autoreactivity in vitro, and adoptive transfer of T cells that are made autoreactive by this mechanism causes a lupuslike disease. Hydralazine 44-55 integrin alpha L Mus musculus 161-166 8675699-4 1996 Some of these agents, such as procainamide, hydralazine, and UV-light inhibit T cell DNA methylation, increase lymphocyte function-associated antigen 1 (LFA-1) (CD11a/CD18) expression, and induce autoreactivity in vitro, and adoptive transfer of T cells that are made autoreactive by this mechanism causes a lupuslike disease. Hydralazine 44-55 integrin beta 2 Mus musculus 167-171 8856488-13 1996 In the second protocol, hydralazine (1 and 10 mg/kg, administered intraperitoneally) significantly enhanced both the renal secretion of renin and the renal spillover of norepinephrine (NE), thus confirming that hydralazine can increase renin release by unloading arterial baroreceptors and increasing sympathetic tone to the kidneys. Hydralazine 24-35 renin Rattus norvegicus 136-141 8856488-13 1996 In the second protocol, hydralazine (1 and 10 mg/kg, administered intraperitoneally) significantly enhanced both the renal secretion of renin and the renal spillover of norepinephrine (NE), thus confirming that hydralazine can increase renin release by unloading arterial baroreceptors and increasing sympathetic tone to the kidneys. Hydralazine 24-35 renin Rattus norvegicus 236-241 8856488-13 1996 In the second protocol, hydralazine (1 and 10 mg/kg, administered intraperitoneally) significantly enhanced both the renal secretion of renin and the renal spillover of norepinephrine (NE), thus confirming that hydralazine can increase renin release by unloading arterial baroreceptors and increasing sympathetic tone to the kidneys. Hydralazine 211-222 renin Rattus norvegicus 136-141 8856488-15 1996 caffeine (10 micrograms/kg/min) on hydralazine-induced (1 and 10 mg/kg, administered intraperitoneally) changes in renal secretion of renin and renal NE spillover were investigated. Hydralazine 35-46 renin Rattus norvegicus 134-139 8856488-19 1996 caffeine significantly (p = 0.03) enhanced the increase in renal renin secretion induced by 1 and 10 mg/kg hydralazine (for 1 mg/kg hydralazine delta of 6.4 +/- 46.7 and 142.4 +/- 142.9 renin activity/min/kg body weight in control and caffeine-treated animals, respectively; for 10 mg/kg hydralazine, delta 227.8 +/- 73.9 and 600.8 +/- 168.9 renin activity/min/kg body weight in control and caffeine-treated animals, respectively). Hydralazine 107-118 renin Rattus norvegicus 65-70 8856488-19 1996 caffeine significantly (p = 0.03) enhanced the increase in renal renin secretion induced by 1 and 10 mg/kg hydralazine (for 1 mg/kg hydralazine delta of 6.4 +/- 46.7 and 142.4 +/- 142.9 renin activity/min/kg body weight in control and caffeine-treated animals, respectively; for 10 mg/kg hydralazine, delta 227.8 +/- 73.9 and 600.8 +/- 168.9 renin activity/min/kg body weight in control and caffeine-treated animals, respectively). Hydralazine 132-143 renin Rattus norvegicus 65-70 8856488-19 1996 caffeine significantly (p = 0.03) enhanced the increase in renal renin secretion induced by 1 and 10 mg/kg hydralazine (for 1 mg/kg hydralazine delta of 6.4 +/- 46.7 and 142.4 +/- 142.9 renin activity/min/kg body weight in control and caffeine-treated animals, respectively; for 10 mg/kg hydralazine, delta 227.8 +/- 73.9 and 600.8 +/- 168.9 renin activity/min/kg body weight in control and caffeine-treated animals, respectively). Hydralazine 132-143 renin Rattus norvegicus 65-70 8856488-20 1996 The enhanced renin-secretion response to hydralazine in caffeine-treated rats was accompanied by augmented hydralazine-induced increase in renal NE spillover (p = 0.035). Hydralazine 41-52 renin Rattus norvegicus 13-18 8856488-20 1996 The enhanced renin-secretion response to hydralazine in caffeine-treated rats was accompanied by augmented hydralazine-induced increase in renal NE spillover (p = 0.035). Hydralazine 107-118 renin Rattus norvegicus 13-18 8818569-3 1996 Therefore, the effects of treatment with hydrazine or one of the therapeutic hydrazines phenelzine and hydralazine on rat hepatic and renal CYP2E1 and GST-alpha expression were investigated. Hydralazine 103-114 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 140-146 8645575-8 1996 Hydralazine, which may cause tumour hypoxia and lower pHi as well as pHe, caused cytotoxity when given alone by chronic infusion, and enhanced the cytotoxicity due to nigericin. Hydralazine 0-11 glucose-6-phosphate isomerase 1 Mus musculus 54-57 8645592-2 1996 Alcohol use as well as medication with hydralazine-containing antihypertensive drugs, but not heredity were associated with p53 staining. Hydralazine 39-50 tumor protein p53 Homo sapiens 124-127 8647943-5 1996 The vasodilator hydralazine and the AT1 receptor antagonist losartan had comparable effects to reverse angiotensin II-induced hypertension, but only losartan blocked the changes in body weight and in circulating IGF I and its binding proteins produced by angiotensin II. Hydralazine 16-27 angiotensinogen Rattus norvegicus 103-117 8647943-5 1996 The vasodilator hydralazine and the AT1 receptor antagonist losartan had comparable effects to reverse angiotensin II-induced hypertension, but only losartan blocked the changes in body weight and in circulating IGF I and its binding proteins produced by angiotensin II. Hydralazine 16-27 insulin-like growth factor 1 Rattus norvegicus 212-217 8542262-5 1995 In this study, ten patients with hydralazine-induced vasculitis had antibodies with specificities for both myeloperoxidase and lactoferrin. Hydralazine 33-44 myeloperoxidase Homo sapiens 107-122 8682064-8 1995 A study in 804 men with congestive heart failure who received either enalapril or hydralazine plus isosorbide dinitrate showed the greatest reduction in mortality after 2 years in enalapril treated patients with plasma noradrenaline levels > 900 pg.ml-1 or plasma renin levels > 16 ng.ml-1.h-1. Hydralazine 82-93 renin Homo sapiens 267-272 8754362-9 1996 For patients who cannot take an ACE inhibitor the combination of hydralazine and nitrates may offer some prognostic benefit. Hydralazine 65-76 angiotensin I converting enzyme Homo sapiens 32-35 8690857-6 1995 In contrast, phenylephrine and hydralazine treatments resulted in different, yet reproducible, patterns of Fos expression in the brain, with hydralazine evoking Fos expression in more brain regions than phenylephrine. Hydralazine 31-42 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 107-110 8690857-6 1995 In contrast, phenylephrine and hydralazine treatments resulted in different, yet reproducible, patterns of Fos expression in the brain, with hydralazine evoking Fos expression in more brain regions than phenylephrine. Hydralazine 31-42 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 161-164 8690857-6 1995 In contrast, phenylephrine and hydralazine treatments resulted in different, yet reproducible, patterns of Fos expression in the brain, with hydralazine evoking Fos expression in more brain regions than phenylephrine. Hydralazine 141-152 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 161-164 8690857-7 1995 Brain regions containing Fos-positive neurons in rats treated with hydralazine included nucleus tractus solitarius, area postrema, caudal ventrolateral medulla, rostral ventrolateral medulla, bed nucleus of the stria terminalis, amygdala, paraventricular nucleus, supraoptic nucleus, subfornical organ and the Islands of Calleja. Hydralazine 67-78 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 25-28 8589285-6 1995 Therapeutic conclusions can be drawn from the observation that both losartan and hydralazine/furosemide reduced osteopontin expression, macrophage infiltration, transforming growth factor-beta expression, and interstitial fibrosis, but did not prevent the decrease in GFR. Hydralazine 81-92 secreted phosphoprotein 1 Rattus norvegicus 112-123 7533141-3 1995 We also investigated the effects of antihypertensive treatment with the angiotensin II antagonist hydralazine or reserpine on nNOS mRNA expression. Hydralazine 98-109 nitric oxide synthase 1 Rattus norvegicus 126-130 7554808-8 1995 Oral isosorbide dinitrate plus hydralazine improves survival in patients with CHF, and should be administered to patients with CHF and abnormal or normal LV ejection fraction who cannot tolerate ACE inhibitor therapy or in whom CHF persists despite therapy with diuretics plus ACE inhibitors. Hydralazine 31-42 angiotensin I converting enzyme Homo sapiens 277-280 7660828-1 1995 AIM: To examine possible direct effects of the vasodilators hydralazine and KRN2391 on the activities of protein kinase A (PKA), protein kinase G (PKG), and protein kinase C (PKC). Hydralazine 60-71 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 105-121 7660828-1 1995 AIM: To examine possible direct effects of the vasodilators hydralazine and KRN2391 on the activities of protein kinase A (PKA), protein kinase G (PKG), and protein kinase C (PKC). Hydralazine 60-71 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 123-126 7660828-4 1995 RESULTS: Hydralazine (0.03-10 mmol.L(-1)) inhibited the activities of both PKA and PKG with IC50 of 1.2 and 2.5 mmol.L(-1), respectively, but had little effect on PKC. Hydralazine 9-20 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 75-78 7660828-8 1995 CONCLUSION: Hydralazine alters the activity of PKG and PKA, which may have implications for the vasodilator activity. Hydralazine 12-23 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 55-58 7533141-8 1995 This reduced expression of nNOS mRNA in the decapsular portion of the adrenal gland of SHR seemed to be a result of hypertension in the SHR, because administration of either an angiotensin II antagonist (TCV-116) or hydralazine upregulated nNOS mRNA expression in both SHR and WKY. Hydralazine 216-227 nitric oxide synthase 1 Rattus norvegicus 27-31 7933398-13 1994 Isosorbide dinitrate and hydralazine hydrochloride should be tried in patients who cannot tolerate ACE inhibitors or who have refractory symptoms. Hydralazine 25-50 angiotensin I converting enzyme Homo sapiens 99-102 7535621-3 1994 Recent work has shown that some environmental agents associated with lupus, such as procainamide, hydralazine and ultraviolet light, will inhibit T cell DNA methylation, increase LFA-1 expression and induce autoreactivity. Hydralazine 98-109 integrin subunit alpha L Homo sapiens 179-184 7946512-0 1994 Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. Hydralazine 100-111 myeloperoxidase Homo sapiens 46-61 7529152-13 1994 Thus, Hydralazine appears to activate guanylate cyclase, leading to increased cyclic GMP in fetal arterial vascular smooth muscle to cause vasorelaxation. Hydralazine 6-17 5'-nucleotidase, cytosolic II Homo sapiens 85-88 8141390-2 1994 After hydralazine-induced hypotension or sinoaortic denervation, two treatments that reduce baroreceptor afferent activity, numerous Fos-positive neurons were observed in the RVLM. Hydralazine 6-17 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 133-136 8206611-4 1994 Prazosin, hydralazine, or L-arginine added to the drinking water all lowered the angiotensin II-induced increase in blood pressure but did not attenuate the increase in fibronectin mRNA expression. Hydralazine 10-21 angiotensinogen Rattus norvegicus 81-95 8137508-10 1994 Normalization of blood pressure during Ang II infusion by either hydralazine or prazosin had different effects on the level of fibronectin steady-state mRNA, indicating that blood pressure elevation was not the principal factor responsible for fibronectin induction. Hydralazine 65-76 fibronectin 1 Rattus norvegicus 127-138 8141390-3 1994 The number of Fos-positive neurons in the RVLM was counted in brain stem sections from hydralazine-treated rats that had been previously injected with Fluorogold into the upper thoracic spinal cord to label spinally projecting RVLM neurons as well as stained for phenylethanolamine-N-methyltransferase (PNMT) as a marker of C1 neurons. Hydralazine 87-98 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 14-17 8141390-3 1994 The number of Fos-positive neurons in the RVLM was counted in brain stem sections from hydralazine-treated rats that had been previously injected with Fluorogold into the upper thoracic spinal cord to label spinally projecting RVLM neurons as well as stained for phenylethanolamine-N-methyltransferase (PNMT) as a marker of C1 neurons. Hydralazine 87-98 phenylethanolamine-N-methyltransferase Rattus norvegicus 263-301 8141390-3 1994 The number of Fos-positive neurons in the RVLM was counted in brain stem sections from hydralazine-treated rats that had been previously injected with Fluorogold into the upper thoracic spinal cord to label spinally projecting RVLM neurons as well as stained for phenylethanolamine-N-methyltransferase (PNMT) as a marker of C1 neurons. Hydralazine 87-98 phenylethanolamine-N-methyltransferase Rattus norvegicus 303-307 8141390-4 1994 The results indicate that approximately 80% of the C1 neurons expressed Fos in response to hydralazine injection; this was true of spinally projecting C1 neurons as well as those C1 neurons that were not labeled with Fluorogold. Hydralazine 91-102 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 72-75 8141390-5 1994 Furthermore, in hydralazine-treated rats, the majority of Fluorogold-labeled Fos-positive neurons contained PNMT. Hydralazine 16-27 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 77-80 8141390-5 1994 Furthermore, in hydralazine-treated rats, the majority of Fluorogold-labeled Fos-positive neurons contained PNMT. Hydralazine 16-27 phenylethanolamine-N-methyltransferase Rattus norvegicus 108-112 8141402-1 1994 The blood pressure was decreased after chronic treatment with enalapril, MK-954, and hydralazine in deoxycorticosterone acetate (DOCA)-salt-induced malignant hypertension of spontaneously hypertensive rats (SHR); however, ventricular weight and plasma brain natriuretic peptide (BNP) concentration were decreased after enalapril and MK-954 but not after hydralazine. Hydralazine 85-96 natriuretic peptide B Rattus norvegicus 252-277 8141402-1 1994 The blood pressure was decreased after chronic treatment with enalapril, MK-954, and hydralazine in deoxycorticosterone acetate (DOCA)-salt-induced malignant hypertension of spontaneously hypertensive rats (SHR); however, ventricular weight and plasma brain natriuretic peptide (BNP) concentration were decreased after enalapril and MK-954 but not after hydralazine. Hydralazine 85-96 natriuretic peptide B Rattus norvegicus 279-282 7685441-9 1993 Dose-response curves of resistance arteries to ET-1 were significantly blunted in untreated hypertensive rats (maximum active tension = 2.3 +/- 0.3 vs 3.4 +/- 0.1 N/m in control, p < 0.01), metoprolol-treated (2.2 +/- 0.4 N/m), and hydralazine-treated rats (2.1 +/- 0.5 N/m), and were normalized in cilazapril (3.3 +/- 0.1 N/m) and unclipped rats (3.2 +/- 0.1 N/m). Hydralazine 235-246 endothelin 1 Rattus norvegicus 47-51 8137873-0 1994 Pharmacological study of several effects of hydralazine in the bisected rat vas deferens. Hydralazine 44-55 arginine vasopressin Rattus norvegicus 76-79 8137873-1 1994 We have studied several effects of hydralazine in the bisected rat vas deferens. Hydralazine 35-46 arginine vasopressin Rattus norvegicus 67-70 8137873-2 1994 Hydralazine produced a shift to the left of the concentration-response curve for noradrenaline, with potentiation of the maximal response in both portions of the vas deferens. Hydralazine 0-11 arginine vasopressin Rattus norvegicus 162-165 7889210-5 1994 The AII receptor density was significantly increased by treatment with TCV-116 and enalapril as compared with hydralazine treatment or no treatment. Hydralazine 110-121 angiotensinogen Rattus norvegicus 4-7 7903389-10 1993 Furthermore, the discrepancy in the PRA responses to equipotent hypotensive doses of hydralazine and losartan indicates that beta adrenoceptor activation in the kidney, probably the result of blockade of AII-mediated inhibition of renin secretion, contributes to the renin-releasing effect of the AT1 receptor antagonist losartan. Hydralazine 85-96 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 231-236 7903389-10 1993 Furthermore, the discrepancy in the PRA responses to equipotent hypotensive doses of hydralazine and losartan indicates that beta adrenoceptor activation in the kidney, probably the result of blockade of AII-mediated inhibition of renin secretion, contributes to the renin-releasing effect of the AT1 receptor antagonist losartan. Hydralazine 85-96 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 267-272 8298811-6 1993 Similar inhibition of the depressor and potentiation of the pressor actions of ET-1 were observed when the MABP which had been elevated by L-NMMA or L-NAME was titrated to normotensive levels with hydralazine or diazoxide before injection of ET-1. Hydralazine 197-208 endothelin 1 Rattus norvegicus 79-83 7515732-7 1993 Administration of 5 mg/kg of hydralazine following dosing with the PFOB emulsion reduced the 19F signal intensity from the murine tumors RIF-1 and KHT and from the human tumour HT29 with no or little reduction in the SCCVII/Ha murine and HX118 human tumours. Hydralazine 29-40 replication timing regulatory factor 1 Mus musculus 137-142 7686923-1 1993 Human antigen-specific CD4+ T cells become autoreactive after treatment with various DNA methylation inhibitors, including 5-azacytidine, procainamide, and hydralazine. Hydralazine 156-167 CD4 antigen Mus musculus 23-26 7508709-5 1994 Treatment of skin fibroblasts with hydralazine (50 microM), which increases the mRNAs for both the alpha and the beta subunits of prolyl hydroxylase (PH) and the mRNAs for lysyl hydroxylase, also increased LO mRNA by fourfold over a 72-h time course. Hydralazine 35-46 lysyl oxidase Homo sapiens 206-208 8373356-3 1993 with a monoclonal anti-(Z-DNA) antibody Z22, we found that hydralazine provoked the Z-DNA conformation in poly(dG-m5dC).poly(dG-m5dC) at 250-500 microM concentration. Hydralazine 59-70 small nucleolar RNA, C/D box 79 Homo sapiens 40-43 8373356-4 1993 The supercoiled form of hydralazine-treated plasmid bound to Z22 in a gel-retardation assay. Hydralazine 24-35 small nucleolar RNA, C/D box 79 Homo sapiens 61-64 8248010-0 1993 Interaction of myeloperoxidase and elastase enzyme activity with the antihypertensive agents hydralazine and dihydralazine. Hydralazine 93-104 myeloperoxidase Homo sapiens 15-30 8248010-1 1993 Autoantibodies directed against myeloperoxidase and elastase have been found in patients developing hydralazine-induced lupus and hydralazine-induced isolated glomerulonephritis. Hydralazine 100-111 myeloperoxidase Homo sapiens 32-60 8248010-1 1993 Autoantibodies directed against myeloperoxidase and elastase have been found in patients developing hydralazine-induced lupus and hydralazine-induced isolated glomerulonephritis. Hydralazine 130-141 myeloperoxidase Homo sapiens 32-60 8248010-2 1993 The aim of this study was to investigate influence of hydralazine and dihydralazine upon myeloperoxidase and elastase enzyme activity. Hydralazine 54-65 myeloperoxidase Homo sapiens 89-104 8248010-3 1993 Using a 4-aminoantipyrin in vitro system, dihydralazine was 2.5 times as potent in inhibiting myeloperoxidase activity as compared to hydralazine. Hydralazine 44-55 myeloperoxidase Homo sapiens 94-109 1337335-1 1992 Two mouse-human heterohybridomas secreting human antibodies to myeloperoxidase (MPO) were derived from the peripheral blood of a patient who developed microscopic polyarteritis as the result of long-term treatment with hydralazine. Hydralazine 219-230 myeloperoxidase Homo sapiens 63-78 8019200-0 1993 Mutagenicity of B(a)P in the presence of some hydralazine derivatives. Hydralazine 46-57 prohibitin 2 Homo sapiens 16-21 1337335-1 1992 Two mouse-human heterohybridomas secreting human antibodies to myeloperoxidase (MPO) were derived from the peripheral blood of a patient who developed microscopic polyarteritis as the result of long-term treatment with hydralazine. Hydralazine 219-230 myeloperoxidase Homo sapiens 80-83 1626511-6 1992 In group A, hemodynamic changes induced by hydralazine were accompanied by a decrease in plasma norepinephrine from 822 to 518 pg/ml (p less than 0.01) and an increase in plasma vasopressin from 8.4 to 45.2 pg/ml (p less than 0.001). Hydralazine 43-54 arginine vasopressin Homo sapiens 178-189 1503904-17 1992 Our results show that the combination of nigericin and hydralazine (with or without amiloride) can kill cells in rodent solid tumours and that cell killing is associated with a reduction in the mean pHi of tumour cells. Hydralazine 55-66 glucose-6-phosphate isomerase 1 Mus musculus 199-202 1513252-1 1992 Localized 31P NMR spectroscopy was used to evaluate the spatial heterogeneity of the metabolic response of RIF-1 tumors to hydralazine. Hydralazine 123-134 replication timing regulatory factor 1 Homo sapiens 107-112 1542128-10 1992 RESULTS: Hydralazine significantly reduced the 19F signal intensity in the murine tumors RIF-1 and KHT and in the HT29 human tumor, with little reduction in the SCCVII/Ha murine and HX118 human tumors. Hydralazine 9-20 replication timing regulatory factor 1 Mus musculus 89-94 1943085-0 1991 Changes in aortic levels of tropoelastin mRNA following treatment of rats with the antihypertensive drugs captopril and hydralazine. Hydralazine 120-131 elastin Rattus norvegicus 28-40 1943085-6 1991 Hydralazine treatment resulted in a threefold increase in tropoelastin mRNA levels in both the SHR and the WKY animals (P less than 0.01). Hydralazine 0-11 elastin Rattus norvegicus 58-70 1657003-0 1991 The antihypertensive compounds hydralazine, dihydralazine and cadralazine and their metabolites inhibit myeloperoxidase activity as measured by chemiluminescence. Hydralazine 31-42 myeloperoxidase Homo sapiens 104-119 1664857-6 1991 Oxidation of hydralazine catalyzed by myeloperoxidase (MPO) produced the same metabolites and covalent binding to protein. Hydralazine 13-24 myeloperoxidase Homo sapiens 38-53 1664857-6 1991 Oxidation of hydralazine catalyzed by myeloperoxidase (MPO) produced the same metabolites and covalent binding to protein. Hydralazine 13-24 myeloperoxidase Homo sapiens 55-58 1650719-6 1991 The formation of TBA-reactive products was prevented by catalase, EDTA and scavengers of .OH radicals and enhanced by superoxide dismutase which suggests that .OH radicals formed by the Fenton mechanism mediate the DNA damage by hydralazine-Fe2+. Hydralazine 229-240 catalase Bos taurus 56-64 1848978-1 1991 Hydralazine caused site-specific DNA damage in the presence of Cu(II), Co(II), Fe(III), or peroxidase/H2O2. Hydralazine 0-11 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-77 1848978-2 1991 The order of inducing effect of metal ions on hydralazine-dependent DNA damage [Cu(II) greater than Co(II) greater than Fe(III)] was related to that of accelerating effect on the O2 consumption rate of hydralazine autoxidation. Hydralazine 46-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-106 1848978-2 1991 The order of inducing effect of metal ions on hydralazine-dependent DNA damage [Cu(II) greater than Co(II) greater than Fe(III)] was related to that of accelerating effect on the O2 consumption rate of hydralazine autoxidation. Hydralazine 202-213 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-106 1833321-10 1991 Treatment with hydralazine was effective in preventing increases in elastin (128 +/- 14 microns2) and in attenuating increases in smooth muscle (1,008 +/- 18 microns2). Hydralazine 15-26 elastin Rattus norvegicus 68-75 2022407-11 1991 Hydralazine given with angiotensin II prevented the rise of pressure and the cardiac effect but not the vascular changes. Hydralazine 0-11 angiotensinogen Rattus norvegicus 23-37 2022407-13 1991 Thus, although hydralazine inhibits the pressor and cardiac effects of angiotensin II, suggesting a pressor mechanism for the cardiac change, it does not inhibit structural vascular change, which suggests that at least part of the effect has a non-pressor mechanism. Hydralazine 15-26 angiotensinogen Rattus norvegicus 71-85 1848881-0 1991 Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. Hydralazine 117-128 myeloperoxidase Homo sapiens 37-65 1848881-1 1991 Autoantibodies against myeloperoxidase and elastase were found in a study of nine patients who had developed glomerulonephritis after treatment with hydralazine, but not in patients who were treated with hydralazine without side-effects. Hydralazine 149-160 myeloperoxidase Homo sapiens 23-51 2005584-8 1991 In rats with an intact beta adrenergic system, caffeine, but not DPSPX, increased the renin release response to low-dose hydralazine (1 mg/kg). Hydralazine 121-132 renin Rattus norvegicus 86-91 2005584-9 1991 Although both xanthines augmented the renin release response to high-dose hydralazine (10 mg/kg), caffeine was more efficacious in this regard. Hydralazine 74-85 renin Rattus norvegicus 38-43 1829659-0 1991 Atrial natriuretic factor release during volume expansion in the spontaneously hypertensive rat--effect of long-term hydralazine treatment. Hydralazine 117-128 natriuretic peptide A Rattus norvegicus 0-25 2110814-7 1990 The effect of hydralazine with RSU1069 although significant in the RIF-1 tumour, is modest compared to that for clamping. Hydralazine 14-25 replication timing regulatory factor 1 Mus musculus 67-72 2168822-5 1990 In another group of six patients with a SLE-like syndrome induced by anti-hypertensive treatment with the anti-hypertensive hydralazine, anti-MPO antibodies occurred in all six, and anti-elastase antibodies in five. Hydralazine 124-135 myeloperoxidase Homo sapiens 142-145 2110814-8 1990 Small enhancements of toxicity are seen with hydralazine in combination with misonidazole in the RIF-1 tumour and mitomycin C in both tumours. Hydralazine 45-56 replication timing regulatory factor 1 Mus musculus 97-102 2100625-4 1990 The plasma calibration curve of hydralazine is linear in the concentration range 10-500 ng ml-1. Hydralazine 32-43 interleukin 17F Homo sapiens 91-95 2107743-3 1990 Administration of hydralazine at either 50 mg bid or 100 mg bid for a week, doses commonly administered in clinical settings, was not associated with a statistically significant fall in mean blood pressure, although there was a tendency towards a decrease but did result in an increase in heart rate. Hydralazine 18-29 BH3 interacting domain death agonist Homo sapiens 46-49 2408216-2 1990 However, since traditional vasodilators, such as hydralazine, may cause retention of sodium and water, tachycardia and excessive stimulation of the renin-angiotensin-aldosterone system, they are not suitable for monotherapy. Hydralazine 49-60 renin Homo sapiens 148-153 34624627-4 2021 Extensive oxidation rates of BIBX1382 were observed in hepatocytes from humanized liver mice and were suppressed by the typical human AOX1 inhibitors raloxifene and hydralazine. Hydralazine 165-176 aldehyde oxidase 1 Homo sapiens 134-138 34951375-8 2021 Moreover, NAT2 slow acetylators showed an increased response to hydralazine in patients with resistant hypertension. Hydralazine 64-75 N-acetyltransferase 2 Homo sapiens 10-14 2173810-5 1990 By contrast, anti-MPO was found in a majority of vasculitis patients without extrarenal symptoms (6/9), including 3 patients treated with hydralazine. Hydralazine 138-149 myeloperoxidase Homo sapiens 18-21 2173810-6 1990 One of the patients treated with hydralazine had circulating ANCA in combination with anti-MPO. Hydralazine 33-44 myeloperoxidase Homo sapiens 91-94 33815485-4 2021 We then calculated in vitro kinetic parameters of four NAT2 alleles (NAT2*4, *5, *6, and *7) for N-acetylation of aminoglutethimide, diaminodiphenyl sulfone, hydralazine, isoniazid, phenelzine, procaineamide, sulfamethazine (SMZ), and sulfapyrizine. Hydralazine 158-169 N-acetyltransferase 2 Homo sapiens 55-59 33815485-4 2021 We then calculated in vitro kinetic parameters of four NAT2 alleles (NAT2*4, *5, *6, and *7) for N-acetylation of aminoglutethimide, diaminodiphenyl sulfone, hydralazine, isoniazid, phenelzine, procaineamide, sulfamethazine (SMZ), and sulfapyrizine. Hydralazine 158-169 N-acetyltransferase 2 Homo sapiens 69-73 34478692-7 2021 Hydralazine significantly decreased AGEs-induced RAGE, iNOS, and COX-2 expressions in RMC. Hydralazine 0-11 advanced glycosylation end product-specific receptor Rattus norvegicus 49-53 34478692-7 2021 Hydralazine significantly decreased AGEs-induced RAGE, iNOS, and COX-2 expressions in RMC. Hydralazine 0-11 nitric oxide synthase 2 Rattus norvegicus 55-59 34478692-7 2021 Hydralazine significantly decreased AGEs-induced RAGE, iNOS, and COX-2 expressions in RMC. Hydralazine 0-11 cytochrome c oxidase II, mitochondrial Rattus norvegicus 65-70 34478692-8 2021 Compared to the diabetic with AKI group, hydralazine decreased inflammation-related protein, and JAK2, STAT3 signaling in rat kidney tissue. Hydralazine 41-52 Janus kinase 2 Rattus norvegicus 97-101 34478692-8 2021 Compared to the diabetic with AKI group, hydralazine decreased inflammation-related protein, and JAK2, STAT3 signaling in rat kidney tissue. Hydralazine 41-52 signal transducer and activator of transcription 3 Rattus norvegicus 103-108 34275783-1 2021 To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain natriuretic peptide (BNP), left ventricular remodeling and prognosis in patients with chronic heart failure (CHF). Hydralazine 30-41 energy homeostasis associated Homo sapiens 83-90 34320266-21 2021 Upon HDZ treatment, NKA did not change, NKCC1 decreased in oVx HS rats, while SGK1 increased in both IF HS and oVx HS rats. Hydralazine 5-8 solute carrier family 12 member 2 Rattus norvegicus 40-45 34320266-21 2021 Upon HDZ treatment, NKA did not change, NKCC1 decreased in oVx HS rats, while SGK1 increased in both IF HS and oVx HS rats. Hydralazine 5-8 serum/glucocorticoid regulated kinase 1 Rattus norvegicus 78-82 34515895-4 2021 METHODS: In the present study, we retrospectively assessed the changes in aldosterone, renin, and aldosterone-to-renin values in essential hypertensive participants before and after treatment with either hydralazine (n = 26) or doxazosin (n = 20) or verapamil (n = 15). Hydralazine 204-215 renin Homo sapiens 87-92 34515895-4 2021 METHODS: In the present study, we retrospectively assessed the changes in aldosterone, renin, and aldosterone-to-renin values in essential hypertensive participants before and after treatment with either hydralazine (n = 26) or doxazosin (n = 20) or verapamil (n = 15). Hydralazine 204-215 renin Homo sapiens 113-118 34515895-6 2021 RESULTS: Hydralazine resulted in a borderline significant rise in active plasma renin concentration (19 vs 25 mIU/L, p = 0.067) and a significant fall in the aldosterone-to-renin ratio (38 vs 24, p = 0.017). Hydralazine 9-20 renin Homo sapiens 80-85 34515895-6 2021 RESULTS: Hydralazine resulted in a borderline significant rise in active plasma renin concentration (19 vs 25 mIU/L, p = 0.067) and a significant fall in the aldosterone-to-renin ratio (38 vs 24, p = 0.017). Hydralazine 9-20 renin Homo sapiens 173-178 34272718-0 2021 Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione. Hydralazine 112-123 aldehyde oxidase 1 Homo sapiens 85-101 34275783-1 2021 To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain natriuretic peptide (BNP), left ventricular remodeling and prognosis in patients with chronic heart failure (CHF). Hydralazine 30-41 natriuretic peptide B Homo sapiens 95-120 34275783-1 2021 To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain natriuretic peptide (BNP), left ventricular remodeling and prognosis in patients with chronic heart failure (CHF). Hydralazine 30-41 natriuretic peptide B Homo sapiens 122-125 34275783-8 2021 To sum up, hydralazine combined with sodium nitroprusside treatment can effectively reduce serum Adropin and BNP levels, and the risk of left ventricular remodeling and poor prognosis in patients with CHF. Hydralazine 11-22 energy homeostasis associated Homo sapiens 97-104 34275783-8 2021 To sum up, hydralazine combined with sodium nitroprusside treatment can effectively reduce serum Adropin and BNP levels, and the risk of left ventricular remodeling and poor prognosis in patients with CHF. Hydralazine 11-22 natriuretic peptide B Homo sapiens 109-112 2737292-2 1989 The effect of hydralazine treatment on 3 murine tumours (RIF-1, KHT and 16/C) was monitored using 31P-NMR. Hydralazine 14-25 replication timing regulatory factor 1 Mus musculus 57-62 35623171-0 2022 Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy. Hydralazine 102-113 nuclear factor, erythroid derived 2, like 2 Mus musculus 18-22 35623171-0 2022 Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy. Hydralazine 102-113 heme oxygenase 1 Mus musculus 32-48 35623171-2 2022 Hydralazine is an antihypertensive agent and may act as a xanthine oxidase (XO) inhibitor to reduce uric acid levels in a mouse renal injury model. Hydralazine 0-11 xanthine dehydrogenase Mus musculus 58-74 35623171-7 2022 Hydralazine downregulated NF-kappaB/p38 signaling pathways and reduced TNF-alpha/IL-6 expressions in high glucose-stimulated renal proximal tubular epithelial cells. Hydralazine 0-11 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 26-35 35623171-7 2022 Hydralazine downregulated NF-kappaB/p38 signaling pathways and reduced TNF-alpha/IL-6 expressions in high glucose-stimulated renal proximal tubular epithelial cells. Hydralazine 0-11 mitogen-activated protein kinase 14 Mus musculus 36-39 35623171-7 2022 Hydralazine downregulated NF-kappaB/p38 signaling pathways and reduced TNF-alpha/IL-6 expressions in high glucose-stimulated renal proximal tubular epithelial cells. Hydralazine 0-11 tumor necrosis factor Mus musculus 71-80 35623171-7 2022 Hydralazine downregulated NF-kappaB/p38 signaling pathways and reduced TNF-alpha/IL-6 expressions in high glucose-stimulated renal proximal tubular epithelial cells. Hydralazine 0-11 interleukin 6 Mus musculus 81-85 35623171-8 2022 Hydralazine reduced in vitro ROS production via XO inhibition and nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated heme oxygenase (HO)-1 activation. Hydralazine 0-11 nuclear factor, erythroid derived 2, like 2 Mus musculus 66-109 35623171-8 2022 Hydralazine reduced in vitro ROS production via XO inhibition and nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated heme oxygenase (HO)-1 activation. Hydralazine 0-11 nuclear factor, erythroid derived 2, like 2 Mus musculus 111-115 35623171-8 2022 Hydralazine reduced in vitro ROS production via XO inhibition and nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated heme oxygenase (HO)-1 activation. Hydralazine 0-11 heme oxygenase 1 Mus musculus 126-147 35623171-9 2022 Furthermore, hydralazine reduced high glucose-induced apoptosis by downregulating PARP/caspase-3 signaling. Hydralazine 13-24 poly (ADP-ribose) polymerase family, member 1 Mus musculus 82-86 35623171-9 2022 Furthermore, hydralazine reduced high glucose-induced apoptosis by downregulating PARP/caspase-3 signaling. Hydralazine 13-24 caspase 3 Mus musculus 87-96 35623171-12 2022 While both hydralazine and allopurinol downregulated XO and NADPH oxidase expression, only hydralazine upregulated Nrf2/HO-1 renal expression, suggesting the additional effects of hydralazine independent of XO/ NADPH oxidase inhibition. Hydralazine 91-102 nuclear factor, erythroid derived 2, like 2 Mus musculus 115-119 35623171-12 2022 While both hydralazine and allopurinol downregulated XO and NADPH oxidase expression, only hydralazine upregulated Nrf2/HO-1 renal expression, suggesting the additional effects of hydralazine independent of XO/ NADPH oxidase inhibition. Hydralazine 91-102 heme oxygenase 1 Mus musculus 120-124 35623171-13 2022 In conclusion, hydralazine protected renal proximal tubular epithelial cells against the insults of high glucose and prevented renal damage via XO/NADPH oxidase inhibition and Nrf-2/HO-1 activation, suggesting the comprehensive antioxidation and anti-inflammation mechanisms for the management of DN. Hydralazine 15-26 nuclear factor, erythroid derived 2, like 2 Mus musculus 176-181 35623171-13 2022 In conclusion, hydralazine protected renal proximal tubular epithelial cells against the insults of high glucose and prevented renal damage via XO/NADPH oxidase inhibition and Nrf-2/HO-1 activation, suggesting the comprehensive antioxidation and anti-inflammation mechanisms for the management of DN. Hydralazine 15-26 heme oxygenase 1 Mus musculus 182-186 35385506-8 2022 In the fully adjusted model, treatment with IV hydralazine led to 13 (-15.9, -10.1), 18 (-22.2, -14) and 11 (-14.1, -8.3) mmHg lower MAP, SBP, and DBP in the 6 hours following severe HTN development compared to no treatment. Hydralazine 47-58 selenium binding protein 1 Homo sapiens 138-141 35385506-8 2022 In the fully adjusted model, treatment with IV hydralazine led to 13 (-15.9, -10.1), 18 (-22.2, -14) and 11 (-14.1, -8.3) mmHg lower MAP, SBP, and DBP in the 6 hours following severe HTN development compared to no treatment. Hydralazine 47-58 D-box binding PAR bZIP transcription factor Homo sapiens 147-150 35385506-9 2022 Treatment with oral hydralazine and oral carvedilol also resulted in significantly lower BPs in the 6 hours following severe HTN development (6 (-9.1, -2.1 and -7 (-9.1, -4.2) lower MAP, respectively) compared to no treatment. Hydralazine 20-31 small proline rich protein 2A Homo sapiens 151-174 2575471-0 1989 CR1 polymorphism in hydralazine-induced systemic lupus erythematosus: DNA restriction fragment length polymorphism. Hydralazine 20-31 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 0-3 2575471-1 1989 The contribution of genetic factors in the reduction in erythrocyte CR1 levels observed in hydralazine (Hz) induced systemic lupus erythematosus (SLE) was investigated by determining the frequency of a HindIII restriction fragment length polymorphism (RFLP) in the CR1 gene. Hydralazine 91-102 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 68-71 2550032-6 1989 Oral administration of three different antihypertensive agents (propranolol, captopril, or hydralazine) for 12 weeks normalized blood pressure and POMC biosynthesis in the SHR but had no effect on either variable in the WKY. Hydralazine 91-102 proopiomelanocortin Rattus norvegicus 147-151 2737292-4 1989 Hydralazine is known to reduce temporarily blood flow in experimental tumours, and thus cause a transient increase in the RHF to 100% (in RIF-1 and KHT). Hydralazine 0-11 replication timing regulatory factor 1 Mus musculus 138-143 2737292-6 1989 Time-course data from the RIF-1 and KHT tumours show that maintenance of anaesthesia prolongs the hypoxia induced by hydralazine. Hydralazine 117-128 replication timing regulatory factor 1 Mus musculus 26-31 2523703-0 1989 Captopril and hydralazine suppress atrial natriuretic peptide (ANP) gene expression in the ventricles of spontaneously hypertensive rat. Hydralazine 14-25 natriuretic peptide A Rattus norvegicus 63-66 2715059-2 1989 Treatment of mice with hydralazine (5 mg/kg) 15 mins after melphalan increases by a factor of approximately 2.5 melphalan-induced delay in growth of either the RIF-1 or KHT tumors. Hydralazine 23-34 replication timing regulatory factor 1 Mus musculus 160-165 2715059-6 1989 Hydralazine (5 mg/kg) induces close to 100% radiobiological hypoxia in the RIF-1 and KHT tumors. Hydralazine 0-11 replication timing regulatory factor 1 Mus musculus 75-80 2770052-12 1989 These results suggest that, at least in part, the potentiation of epinephrine-induced hyperglycemia by dihydropyridines, non-dihydropyridines and hydralazine is related to the inhibition of peripheral glucose utilization produced by insulin. Hydralazine 146-157 insulin Homo sapiens 233-240 2523703-1 1989 We investigated the influences of captopril (CAP) and hydralazine (HYD) on the ANP mRNA level in the hypertrophied left ventricle (LV) of spontaneously hypertensive rats (SHR). Hydralazine 54-65 natriuretic peptide A Rattus norvegicus 79-82 2721176-0 1989 Size polymorphism of the erythrocyte complement receptor type 1 (CR1) in systemic lupus erythematosus induced by hydralazine. Hydralazine 113-124 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 37-63 2568436-2 1989 Administration of hydralazine (5 mg kg-1) or semicarbazide (100 mg kg-1), drugs which irreversibly inhibit semicarbazide-sensitive amine oxidases (SSAO) but not monoamine oxidase (MAO), enhanced MMA excretion by around three- to six-fold above pretreatment levels, whereas no effect of pargyline (25 mg kg-1), a selective irreversible inhibitor of MAO was found. Hydralazine 18-29 amine oxidase, copper containing 3 Rattus norvegicus 107-145 2568436-2 1989 Administration of hydralazine (5 mg kg-1) or semicarbazide (100 mg kg-1), drugs which irreversibly inhibit semicarbazide-sensitive amine oxidases (SSAO) but not monoamine oxidase (MAO), enhanced MMA excretion by around three- to six-fold above pretreatment levels, whereas no effect of pargyline (25 mg kg-1), a selective irreversible inhibitor of MAO was found. Hydralazine 18-29 amine oxidase, copper containing 3 Rattus norvegicus 147-151 2721176-0 1989 Size polymorphism of the erythrocyte complement receptor type 1 (CR1) in systemic lupus erythematosus induced by hydralazine. Hydralazine 113-124 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 65-68 3293682-7 1988 The degree of tachycardia and increase in plasma renin activity (PRA) for equivalent falls in mean blood pressure in both species was significantly less for flosequinan than for hydralazine (P less than 0.05). Hydralazine 178-189 renin Canis lupus familiaris 49-54 3374996-2 1988 Nutritionally deprived pups showed impaired development of sympathetic reflex stimulation as shown by the attenuation of the cardiac ornithine decarboxylase response to hydralazine-induced hypotension throughout the preweanling period. Hydralazine 169-180 ornithine decarboxylase 1 Rattus norvegicus 133-156 2833897-0 1988 Effects of chronic treatment with a novel angiotensin converting enzyme inhibitor, CS622, and a vasodilator, hydralazine, on atrial natriuretic factor (ANF) in spontaneously hypertensive rats (SHR). Hydralazine 109-120 natriuretic peptide A Rattus norvegicus 125-150 2953239-8 1987 Supine and standing plasma renin activity increased only during long-term treatment with hydralazine. Hydralazine 89-100 renin Homo sapiens 27-32 3288690-4 1988 Administration of 1 mg/kg of hydralazine to the control rats caused mean arterial pressure to fall from 120 +/- 2 mm Hg to 84 +/- 2 mm Hg and elicited an 11.2-fold increase in plasma renin activity and a 2.7-fold increase in plasma norepinephrine concentration. Hydralazine 29-40 renin Rattus norvegicus 183-188 3288690-6 1988 However, administration of 1 mg/kg of hydralazine to the lesion group caused arterial pressure to fall from 128 +/- 6 mm Hg to 64 +/- 2 mm Hg, in association with a 12.4-fold increase in plasma renin activity and a 1.6-fold elevation in plasma norepinephrine concentration. Hydralazine 38-49 renin Rattus norvegicus 194-199 3288690-7 1988 Atenolol, a beta 1-adrenoceptor antagonist, blocked 70% of the rise in plasma renin activity caused by 1 mg/kg of hydralazine in both groups of rats. Hydralazine 114-125 renin Rattus norvegicus 78-83 3288690-8 1988 In addition, prior renal denervation also markedly attenuated the rise in plasma renin activity caused by hydralazine in the lesion group. Hydralazine 106-117 renin Rattus norvegicus 81-86 3146461-3 1988 The C4A and C4B gene products differ in reactivity with C4A being more reactive with nitrogen nucleophiles, including hydralazine and isoniazid (drugs which induce SLE), than with oxygen nucleophiles. Hydralazine 118-129 complement C4A (Rodgers blood group) Homo sapiens 4-7 3146461-3 1988 The C4A and C4B gene products differ in reactivity with C4A being more reactive with nitrogen nucleophiles, including hydralazine and isoniazid (drugs which induce SLE), than with oxygen nucleophiles. Hydralazine 118-129 complement C4B (Chido blood group) Homo sapiens 12-15 3146461-3 1988 The C4A and C4B gene products differ in reactivity with C4A being more reactive with nitrogen nucleophiles, including hydralazine and isoniazid (drugs which induce SLE), than with oxygen nucleophiles. Hydralazine 118-129 complement C4A (Rodgers blood group) Homo sapiens 56-59 2434735-5 1986 Acute hydralazine-induced hypotension caused a slight rise in NPY and striking increases of CAs, which were accentuated in SHRSP. Hydralazine 6-17 neuropeptide Y Rattus norvegicus 62-65 3545618-5 1987 The hyperdynamic circulation seen with hydralazine is mostly beta mediated, primarily beta 1. Hydralazine 39-50 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 86-92 3468287-3 1987 To assess the relationship of hydralazine to human breast cancer, 3,419 women with breast cancer and 3,219 hospital control subjects were studied. Hydralazine 30-41 Breast cancer, type 3 Homo sapiens 51-67 2958187-1 1987 Family studies were carried out to look at CR1 expression in 24 hydralazine-induced SLE patients (Hz Reactors), who had been off the drug for at least 1 year and were clinically well at the time of the study. Hydralazine 64-75 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 43-46 3326679-8 1987 Controlled-release hydralazine BID produced statistically significant mean falls from baseline in sitting diastolic blood pressure and in standing systolic blood pressure and an almost significant drop in standing diastolic blood pressure. Hydralazine 19-30 BH3 interacting domain death agonist Homo sapiens 31-34 3084759-4 1986 However, in dogs pretreated with indomethacin (5 mg/kg) or sodium meclofenamate (3 mg/kg), inhibitors of cyclooxygenase, hydralazine injection resulted in an increase in renal artery blood flow of only 44 +/- 5.3 ml/min (19 +/- 2.7%) from 235 +/- 23 ml/min, an increase significantly different from that in control dogs (P less than .05). Hydralazine 121-132 prostaglandin-endoperoxide synthase 1 Canis lupus familiaris 105-119 4091799-0 1985 The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Hydralazine 19-30 amine oxidase, copper containing 3 Rattus norvegicus 38-75 2872354-5 1986 Furthermore, hydralazine also inhibited the dopamine beta-hydroxylase (DBH) in chromaffin granule membranes. Hydralazine 13-24 dopamine beta-hydroxylase Bos taurus 44-69 2872354-5 1986 Furthermore, hydralazine also inhibited the dopamine beta-hydroxylase (DBH) in chromaffin granule membranes. Hydralazine 13-24 dopamine beta-hydroxylase Bos taurus 71-74 2872354-6 1986 Hydralazine increased the apparent Km value of DBH for ascorbic acid without any change in the Vmax, and it decreased the Vmax of the enzyme for tyramine with no change in the apparent Km value. Hydralazine 0-11 dopamine beta-hydroxylase Bos taurus 47-50 3519923-12 1986 Intravenous injection of pinacidil or hydralazine produced a significant increase in the renin secretion rate. Hydralazine 38-49 renin Canis lupus familiaris 89-94 3878075-7 1985 Hydralazine increased both plasma renin activity and plasma aldosterone concentration and decreased sodium excretion. Hydralazine 0-11 renin Rattus norvegicus 34-39 3710285-3 1986 At 6 h the incubation COMT activity increased significantly following exposure to verapamil and hydralazine, while exposure to alpha methyldopa caused a significant suppression of the enzyme. Hydralazine 96-107 catechol-O-methyltransferase Homo sapiens 22-26 3710285-4 1986 At 24 h exposure to hydralazine significantly suppressed the COMT activity. Hydralazine 20-31 catechol-O-methyltransferase Homo sapiens 61-65 4091799-2 1985 Hydralazine is a potent irreversible inhibitor of the semicarbazide-sensitive amine oxidase (SSAO) found in brown fat. Hydralazine 0-11 amine oxidase, copper containing 3 Rattus norvegicus 54-91 4091799-2 1985 Hydralazine is a potent irreversible inhibitor of the semicarbazide-sensitive amine oxidase (SSAO) found in brown fat. Hydralazine 0-11 amine oxidase, copper containing 3 Rattus norvegicus 93-97 4091799-5 1985 The kinetic pattern of inactivation of SSAO by hydralazine is consistent with an active-site-directed site-saturable binding followed by the development of an irreversible enzyme-inhibitor complex. Hydralazine 47-58 amine oxidase, copper containing 3 Rattus norvegicus 39-43 4091799-6 1985 [3H]Hydralazine, used as an affinity label for SSAO, shows saturable binding to brown-fat membranes. Hydralazine 4-15 amine oxidase, copper containing 3 Rattus norvegicus 47-51 4091799-10 1985 3H-labelled material solubilized from [3H]hydralazine-treated membrane pellets by Triton X-100 at that detergent/protein ratio which releases SSAO from membranes shows the same gel-filtration characteristics as SSAO and appears by lentil lectin-agarose affinity chromatography to contain similar carbohydrate moieties. Hydralazine 42-53 amine oxidase, copper containing 3 Rattus norvegicus 142-146 4091799-10 1985 3H-labelled material solubilized from [3H]hydralazine-treated membrane pellets by Triton X-100 at that detergent/protein ratio which releases SSAO from membranes shows the same gel-filtration characteristics as SSAO and appears by lentil lectin-agarose affinity chromatography to contain similar carbohydrate moieties. Hydralazine 42-53 amine oxidase, copper containing 3 Rattus norvegicus 211-215 4091799-13 1985 Radiolabelled hydralazine may thus be used as a label for purified SSAO, but it is not specific enough to be suitable as a ligand in vivo. Hydralazine 14-25 amine oxidase, copper containing 3 Rattus norvegicus 67-71 3873356-6 1985 We show that hydralazine binds more efficiently to the C4A than to the C4B gene product and suggest that C4 type may predispose patients to hydralazine-induced SLE. Hydralazine 13-24 complement C4A (Rodgers blood group) Homo sapiens 55-58 3873356-6 1985 We show that hydralazine binds more efficiently to the C4A than to the C4B gene product and suggest that C4 type may predispose patients to hydralazine-induced SLE. Hydralazine 13-24 complement C4B (Chido blood group) Homo sapiens 71-74 2868061-1 1985 Isoniazid (INH) and hydralazine (HYD) are transglutaminase (TGase, E.C.2.3.2.13.) Hydralazine 20-31 transglutaminase 1 Homo sapiens 42-58 2859177-1 1985 Hydralazine was metabolized in vitro to phthalazine and phthalazine-1-one by microsomal enzymes requiring NADPH. Hydralazine 0-11 2,4-dienoyl-CoA reductase 1 Homo sapiens 106-111 3989691-1 1985 Hydralazine pyruvic acid hydrazone [2-(phthalazin-1-yl hydrazono)propionic acid; 1] is a major plasma metabolite of hydralazine in humans. Hydralazine 116-127 mediator complex subunit 25 Homo sapiens 75-82 3966370-9 1985 PEP decreased slightly after hydralazine and prazosin and increased slightly after treatment with the beta-blocking drugs, although none of these changes were significant except those during hydralazine treatment. Hydralazine 29-40 progestagen associated endometrial protein Homo sapiens 0-3 2868061-1 1985 Isoniazid (INH) and hydralazine (HYD) are transglutaminase (TGase, E.C.2.3.2.13.) Hydralazine 20-31 transglutaminase 1 Homo sapiens 60-65 3895329-8 1985 The hydralazine-induced renin release was remarkably suppressed by either indomethacin Or propranolol. Hydralazine 4-15 renin Rattus norvegicus 24-29 3895329-9 1985 These results suggest that SAC-induced renin release is mainly dependent on the prostaglandin system, whereas hydralazine-induced renin release is dependent on the prostaglandin and the adrenergic nervous system. Hydralazine 110-121 renin Rattus norvegicus 130-135 6387785-5 1984 Positive renal vein renin ratios (greater than or equal to 1.5) were seen in 52% of the hydralazine group at 0 minutes and in 69% post-hydralazine. Hydralazine 88-99 renin Homo sapiens 20-25 6387785-5 1984 Positive renal vein renin ratios (greater than or equal to 1.5) were seen in 52% of the hydralazine group at 0 minutes and in 69% post-hydralazine. Hydralazine 135-146 renin Homo sapiens 20-25 6387785-3 1984 During sampling, renin release was stimulated in 29 patients with intravenous hydralazine and in 11 with the tourniquet blood trapping test. Hydralazine 78-89 renin Homo sapiens 17-22 6150080-10 1984 Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide. Hydralazine 115-126 amine oxidase, copper containing 3 Rattus norvegicus 99-103 6394347-8 1984 Hydrallazine also caused a slight increase in plasma renin activity and urinary excretion of noradrenaline. Hydralazine 0-12 renin Homo sapiens 53-58 6327520-4 1984 However, hydralazine stimulated the renin-angiotensin system and elevated the plasma norepinephrine (NE) and epinephrine (E) levels, whereas MK-421 did not. Hydralazine 9-20 renin Rattus norvegicus 36-41 6518593-0 1984 Binding of hydralazine and a major metabolite, pyruvate hydrazone, to rat plasma protein and human serum albumin. Hydralazine 11-22 albumin Rattus norvegicus 99-112 6316059-0 1983 Influence of adrenergic nervous and prostaglandin systems on hydralazine-induced renin release. Hydralazine 61-72 renin Rattus norvegicus 81-86 6316059-2 1983 The plasma renin activity (PRA) response to intravenous hydralazine (0.25, 0.5 and 1 mg/kg body wt.) Hydralazine 56-67 renin Rattus norvegicus 11-16 6316059-11 1983 These results demonstrate that vasodilator-induced renin release is only partially mediated via the prostaglandin system, that the degree of this control is related to the intensity of vasodilator stimulus and that renin release following administration of hydralazine can be attributed almost entirely to activation of the beta-adrenergic nervous and prostaglandin systems. Hydralazine 257-268 renin Rattus norvegicus 51-56 6316059-11 1983 These results demonstrate that vasodilator-induced renin release is only partially mediated via the prostaglandin system, that the degree of this control is related to the intensity of vasodilator stimulus and that renin release following administration of hydralazine can be attributed almost entirely to activation of the beta-adrenergic nervous and prostaglandin systems. Hydralazine 257-268 renin Rattus norvegicus 215-220 6413220-5 1983 Plasma renin activity also increased acutely after hydralazine administration in dogs which myocardial infarction (1.05 +/- 0.26 to 8.99 +/- 0.79 ng ml-1 h-1; P less than 0.05); after 1 week of hydralazine, plasma volume had increased from 54.9 +/- 0.9 ml kg-1 to 74.5 +/- 4.9 ml kg-1 (P less than 0.05) and plasma renin activity remained higher than control (4.66 +/- 0.66 ng ml-1 h-1; P less than 0.01). Hydralazine 51-62 renin Canis lupus familiaris 7-12 6640879-7 1983 When CO is significantly reduced because of a short-term increase in PVR, hydralazine may be superior to nitroprusside in improving cardiopulmonary function. Hydralazine 74-85 PVR cell adhesion molecule Canis lupus familiaris 69-72 6615547-1 1983 The inhibition by hydralazine of the clorgyline-resistant amine oxidase (CRAO) and monoamine oxidase (MAO) activities in various rat tissues has been studied. Hydralazine 18-29 monoamine oxidase A Rattus norvegicus 83-100 6615547-1 1983 The inhibition by hydralazine of the clorgyline-resistant amine oxidase (CRAO) and monoamine oxidase (MAO) activities in various rat tissues has been studied. Hydralazine 18-29 monoamine oxidase A Rattus norvegicus 102-105 6615547-8 1983 However, in vitro inhibition by hydralazine of both MAO-A and B activities of rat liver mitochondrial fractions was found, and these effects were fully reversible by dialysis for 18 hr at 4 degrees. Hydralazine 32-43 monoamine oxidase A Rattus norvegicus 52-57 6413220-5 1983 Plasma renin activity also increased acutely after hydralazine administration in dogs which myocardial infarction (1.05 +/- 0.26 to 8.99 +/- 0.79 ng ml-1 h-1; P less than 0.05); after 1 week of hydralazine, plasma volume had increased from 54.9 +/- 0.9 ml kg-1 to 74.5 +/- 4.9 ml kg-1 (P less than 0.05) and plasma renin activity remained higher than control (4.66 +/- 0.66 ng ml-1 h-1; P less than 0.01). Hydralazine 51-62 renin Canis lupus familiaris 315-320 6413220-5 1983 Plasma renin activity also increased acutely after hydralazine administration in dogs which myocardial infarction (1.05 +/- 0.26 to 8.99 +/- 0.79 ng ml-1 h-1; P less than 0.05); after 1 week of hydralazine, plasma volume had increased from 54.9 +/- 0.9 ml kg-1 to 74.5 +/- 4.9 ml kg-1 (P less than 0.05) and plasma renin activity remained higher than control (4.66 +/- 0.66 ng ml-1 h-1; P less than 0.01). Hydralazine 194-205 renin Canis lupus familiaris 7-12 6338555-8 1983 Hydralazine produced a greater increase in renin, but more variable results. Hydralazine 0-11 renin Homo sapiens 43-48 7100630-3 1982 Kinetic studies indicated that the inhibitory natures of hydralazine were recognized as almost mixed types and a change in difference spectrum demonstrated that hydralazine could bind to cytochrome P-450 as a characteristic type II. Hydralazine 57-68 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 187-203 6866422-1 1983 The ATP content of a human pancreatic carcinoma, cultured as a xenograft in athymic nude (nu/nu) mice, dropped by 70% within 1 h of treating the hosts with hydralazine (10 mg/kg s.c.), while the energy charge fell from 0.79 to 0.53. Hydralazine 156-167 ATPase phospholipid transporting 8A2 Homo sapiens 4-7 6293295-5 1982 Hydralazine elevated aldosterone concentration by stimulating the renin-angiotensin system but nifedipine failed to do so despite its effect on the renin-angiotensin system in young individuals. Hydralazine 0-11 renin Homo sapiens 66-71 7100630-3 1982 Kinetic studies indicated that the inhibitory natures of hydralazine were recognized as almost mixed types and a change in difference spectrum demonstrated that hydralazine could bind to cytochrome P-450 as a characteristic type II. Hydralazine 161-172 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 187-203 7128484-4 1982 In control neonates, cardiac ODC responses to hydralazine were absent until the 3rd week of age, but the T3-treated animals showed increases as early as 8 days of age. Hydralazine 46-57 ornithine decarboxylase 1 Rattus norvegicus 29-32 7002082-0 1980 Inhibition of hydralazine-induced renin release by indomethacin in the rat. Hydralazine 14-25 renin Rattus norvegicus 34-39 6764863-6 1982 Results obtained in patients with renal artery stenosis suggest that stimulation of renin secretion by hydralazine may be of particular advantage prior to renal vein sampling. Hydralazine 103-114 renin Homo sapiens 84-89 7049441-6 1982 After 7 days of hydralazine or prazosin administration, plasma renin activity remained elevated and blood volume increased from baseline values. Hydralazine 16-27 renin Canis lupus familiaris 63-68 7002082-3 1980 Hydralazine increased the serum renin levels from 3.3 +/- 0.5 to 13.7 +/- 3.1 and 41.9 +/- 2.4 ng/ml/hr at the 1 and 10 mg/kg doses, respectively. Hydralazine 0-11 renin Rattus norvegicus 32-37 7128484-3 1982 To test baroreceptor-mediated reflexes, control and T3-treated rats of different ages were given hydralazine acutely to produce a decrease in blood pressure, which in adult rats results in a large, sympathetically-mediated stimulation of cardiac ornithine decarboxylase (ODC) activity. Hydralazine 97-108 ornithine decarboxylase 1 Rattus norvegicus 246-269 7023495-4 1981 After single oral administration, budralazine was about 8 times less potent than hydralazine in increasing plasma renin activity in normotensive rats. Hydralazine 81-92 renin Rattus norvegicus 114-119 7004877-5 1980 In a second child with renin-induced hypertension since the firth month of life, treatment wiht hydralazine, clonidine and hydrochlorothiazide was in part effective, but failure to thrive was progressive. Hydralazine 96-107 renin Homo sapiens 23-28 7453267-5 1980 For the whole survey population, 12 truly "non-PRN" drugs showed showed a considerable gradient in mean compliance rates, ranging from digoxin (76.6 per cent) to hydralazine (50.4 per cent). Hydralazine 162-173 cytosolic iron-sulfur assembly component 3 Homo sapiens 47-50 7002082-4 1980 Indomethacin inhibited this hydralazine-induced renin release by 100% at the 1 mg/kg dose and 36% at the 10 mg/kg dose even though the hypotensive effect of the drug was unaltered. Hydralazine 28-39 renin Rattus norvegicus 48-53 7002082-6 1980 The beta-blocker, propranolol, was as effective as indomethacin in attenuating hydralazine-induced renin release. Hydralazine 79-90 renin Rattus norvegicus 99-104 7002082-9 1980 Thus, renal PG"s appear to be important as mediators of hydralazine-stimulated renin release but no hydralazine-induced vasodilatation. Hydralazine 56-67 renin Rattus norvegicus 79-84 7002082-2 1980 Since the vasodilator hydralazine is thought to stimulate renin release by both of these mechanisms, we examined the effect of indomethacin, a PG synthetase inhibitor, on hydralazine-induced renin release. Hydralazine 22-33 renin Rattus norvegicus 58-63 7002082-2 1980 Since the vasodilator hydralazine is thought to stimulate renin release by both of these mechanisms, we examined the effect of indomethacin, a PG synthetase inhibitor, on hydralazine-induced renin release. Hydralazine 171-182 renin Rattus norvegicus 191-196 6103441-6 1980 If the slow acetylators treated with hydralazine were analysed as one group, it was observed that all women with DR4 developed hydralazine-induced SLE; the only men to do so were those with DR2 who were receiving 200 mg hydralazine per day. Hydralazine 127-138 major histocompatibility complex, class II, DR beta 4 Homo sapiens 113-116 7401402-3 1980 Clonidine and hydralazine significantly lowered phenylethanolamine N-methyltransferase (PNMT) activity elevated in the nucleus hypothalamicus posterior (NHP) of SHR to the level of KWR, and both drugs or alpha-methyldopa consistently increased PNMT in the nucleus paraventricularis (NPA). Hydralazine 14-25 phenylethanolamine-N-methyltransferase Rattus norvegicus 48-86 6103441-4 1980 The frequency of HLA-DR4 (73%) was significantly higher in the group with hydralazine-induced SLE than in the other groups (respectively 33%, 25%, and 25%). Hydralazine 74-85 major histocompatibility complex, class II, DR beta 4 Homo sapiens 21-24 6103441-6 1980 If the slow acetylators treated with hydralazine were analysed as one group, it was observed that all women with DR4 developed hydralazine-induced SLE; the only men to do so were those with DR2 who were receiving 200 mg hydralazine per day. Hydralazine 127-138 major histocompatibility complex, class II, DR beta 4 Homo sapiens 113-116 7401402-3 1980 Clonidine and hydralazine significantly lowered phenylethanolamine N-methyltransferase (PNMT) activity elevated in the nucleus hypothalamicus posterior (NHP) of SHR to the level of KWR, and both drugs or alpha-methyldopa consistently increased PNMT in the nucleus paraventricularis (NPA). Hydralazine 14-25 phenylethanolamine-N-methyltransferase Rattus norvegicus 88-92 7401402-3 1980 Clonidine and hydralazine significantly lowered phenylethanolamine N-methyltransferase (PNMT) activity elevated in the nucleus hypothalamicus posterior (NHP) of SHR to the level of KWR, and both drugs or alpha-methyldopa consistently increased PNMT in the nucleus paraventricularis (NPA). Hydralazine 14-25 phenylethanolamine-N-methyltransferase Rattus norvegicus 244-248 7401402-4 1980 Peripherally active hydralazine also increased PNMT activity in the NTS, and antagonized the activity elevated in the A1 cell area of SHR to the level of KWR. Hydralazine 20-31 phenylethanolamine-N-methyltransferase Rattus norvegicus 47-51 7008885-0 1980 Effect of indomethacin on hydralazine-induced renin and catecholamine release in the conscious rabbit. Hydralazine 26-37 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 46-51 7008885-14 1980 Indomethacin inhibits hydralazine-induced renin release in the presence of elevated concentrations of plasma catecholamines; these findings suggest that renal prostaglandins function as important mediators of sympathetically-induced renin release. Hydralazine 22-33 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 42-47 7437522-4 1980 Hydralazine was added to the drinking solution (1% NAC1) of one group of rats from the first day of treatment with DOCA. Hydralazine 0-11 nucleus accumbens associated 1 Rattus norvegicus 51-55 7008885-14 1980 Indomethacin inhibits hydralazine-induced renin release in the presence of elevated concentrations of plasma catecholamines; these findings suggest that renal prostaglandins function as important mediators of sympathetically-induced renin release. Hydralazine 22-33 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 233-238 386111-4 1979 Therefore, individuals who convert hydralazine to MTP slowly, the "slow acetylators", would be expected to be at risk. Hydralazine 35-46 microsomal triglyceride transfer protein Rattus norvegicus 50-53 228024-3 1979 Plasma renin activity increased significantly with hydralazine and was unchanged during prazosin administration. Hydralazine 51-62 renin Homo sapiens 7-12 228024-5 1979 Plasma renin activity and heart rate increased during hypoglycemia; the increases were greater in patients taking prazosin or hydralazine. Hydralazine 126-137 renin Homo sapiens 7-12 699502-8 1978 Plasma renin concentration and the aortic renin content of the spontaneously hypertensive rat showed divergent changes in response to a blood pressure fall associated with acute diuretic therapy, chronic administration of hydrallazine and in some animals in response to chronic administration of propranolol. Hydralazine 222-234 renin Rattus norvegicus 7-12 37256-3 1979 Hydralazine increased the serum renin levels from 3.1+/-0.8 to 16.7+/-3.0 ng/ml per h at a dose of 1 mg/kg. Hydralazine 0-11 renin Rattus norvegicus 32-37 37256-5 1979 Another PG synthetase inhibitor, meclofenamate, was also effective in attenuating hydralazine-induced renin release, urinary PGE(2) and PGF(2alpha) excretion, and arachidonate hypotension. Hydralazine 82-93 renin Rattus norvegicus 102-107 399592-6 1979 Plasma renin activity was higher in the supine and standing positions with hydrallazine than with oxprenolol alone and with the patients standing this high renin level was prevented by simultaneous treatment with oxprenolol. Hydralazine 75-87 renin Homo sapiens 7-12 399592-7 1979 With the patients supine, combination of oxprenolol with hydrallazine resulted in a mean plasma renin activity which was less than half that with hydrallazine alone, although this difference was not statistically significant. Hydralazine 57-69 renin Homo sapiens 96-101 45015-6 1979 2) It is likely that renin activated by Cl and Hydr partially blunts their hypotensive activity. Hydralazine 47-51 renin Homo sapiens 21-26 231700-5 1979 Plasma renin activity increased approximately 2-3 fold after hydralazine and 15-fold after captopril. Hydralazine 61-72 renin Rattus norvegicus 7-12 699502-8 1978 Plasma renin concentration and the aortic renin content of the spontaneously hypertensive rat showed divergent changes in response to a blood pressure fall associated with acute diuretic therapy, chronic administration of hydrallazine and in some animals in response to chronic administration of propranolol. Hydralazine 222-234 renin Rattus norvegicus 42-47 808562-0 1975 Induction of antibodies to nuclear antigens in rabbits by immunization with hydralazine-human serum albumin conjugates. Hydralazine 76-87 albumin Oryctolagus cuniculus 94-107 1199814-0 1975 Effect of alprenolol and hydralazine on plasma renin concentration in patients with arterial hypertension. Hydralazine 25-36 renin Homo sapiens 47-52 1199814-1 1975 The effect of alprenolol alone and in combination with hydralazine on plasma renin concentration has been studied in 25 patients with arterial hypertension. Hydralazine 55-66 renin Homo sapiens 77-82 26134-1 1978 Combination of a thiazide with methyldopa, and a beta-blocking agent with hydralazine]. Hydralazine 74-85 amyloid beta precursor protein Homo sapiens 47-53 893737-3 1977 However, in each of four patients who had high supine baseline plasma renin activity, propranolol enhanced the fall in blood pressure caused by hydralazine. Hydralazine 144-155 renin Homo sapiens 70-75 893737-7 1977 Pretreating with propranolol weakens homeostatic defenses against hydralazine such as rises in pulse rate and plasma renin activity. Hydralazine 66-77 renin Homo sapiens 117-122 893737-9 1977 In patients with high supine plasma renin activity, propranolol potentiates the fall in blood pressure induced by hydralazine, perhaps because the hypertension in such patients is renin dependent. Hydralazine 114-125 renin Homo sapiens 180-185 875465-0 1977 Physiologic mechanisms of bupicomide- and hydralazine-induced increase in plasma renin activity in hypertensive patients. Hydralazine 42-53 renin Homo sapiens 81-86 875465-1 1977 A study was made of the possible mechanisms underlying bupicomide- and hydralazine-induced increase of plasma renin activity. Hydralazine 71-82 renin Homo sapiens 110-115 875465-7 1977 Plasma renin activity during bupicomide and hydralazine administration correlated positively with control plasma renin activity (r = 0.98, P less than 0.001). Hydralazine 44-55 renin Homo sapiens 113-118 875465-9 1977 We conclude that control plasma renin activity is a major determinant of change in plasma renin activity during administration of bupicomide or hydralazine. Hydralazine 144-155 renin Homo sapiens 32-37 875465-9 1977 We conclude that control plasma renin activity is a major determinant of change in plasma renin activity during administration of bupicomide or hydralazine. Hydralazine 144-155 renin Homo sapiens 90-95 875465-10 1977 Both an increase in sympathetic activity and a decrease in perfusion pressure may contribute to the bupicomide- and hydralazine-induced increase in plasma renin activity, possibly by a baroreceptor-mediated increase in adrenergic tone. Hydralazine 116-127 renin Homo sapiens 155-160 1013157-0 1976 Effect of timolol on hydralazine-induced increase in plasma renin activity in spontaneously hypertensive and normotensive rats. Hydralazine 21-32 renin Rattus norvegicus 60-65 808562-3 1975 In this investigation, five groups of rabbits were studied: group I, 10 rabbits hyperimmunized with hydralazine conjugated to human serum albumin (HSA) in complete Freund"s adjuvant (CFA); group II, four rabbits with HSA in CFA; group III, four rabbits with CFA alone; group IV, five rabbits with hydralazine conjugated to rabbit serum albumin (RSA); and group V, four rabbits with a major metabolite of hydralazine conjugated to HSA. Hydralazine 100-111 albumin Oryctolagus cuniculus 132-145 236325-10 1975 Propranolol was demonstrated to block hydralazine-induced increases in serum renin activity in genetically hypertensive rats. Hydralazine 38-49 renin Rattus norvegicus 77-82 1167223-1 1975 The vasodilatory drugs, minoxidil and hydralazine, induce renin release in the rat, man and the dog. Hydralazine 38-49 renin Rattus norvegicus 58-63 1167223-4 1975 Minoxidil and hydralazine induced a time-related increase in both serum renin activity and serum aldosterone. Hydralazine 14-25 renin Rattus norvegicus 72-77 4303905-0 1969 Antagonism of angiotensin by hydralazine on renal blood flow and erythropoietin production. Hydralazine 29-40 erythropoietin Homo sapiens 65-79 4746367-0 1973 [Plasma renin activity in venous renal blood and its stimulation by hydralazine and theophylline (author"s transl)]. Hydralazine 68-79 renin Homo sapiens 8-13 4918551-0 1970 Observation on the mechanism of renin release by hydralazine in hypertensive patients. Hydralazine 49-60 renin Homo sapiens 32-37 5440311-0 1970 Influence of isoproterenol, hydralazine and phentolamine on the renin activity of plasma and renal cortex of rats. Hydralazine 28-39 renin Rattus norvegicus 64-69 5804376-0 1969 Post-hydralazine renin release in the diagnosis of renovascular hypertension. Hydralazine 5-16 renin Homo sapiens 17-22 5231564-0 1967 Effect of hydralazine and pentolinium on renin release caused by bleeding in rats. Hydralazine 10-21 renin Rattus norvegicus 41-46 5732199-0 1968 Renal juxtaglomerular cell granulation in acute and prolonged increase in renin production induced by hydralazine in the rat. Hydralazine 102-113 renin Rattus norvegicus 74-79 33355213-7 2021 The two enzymes were identified as AOX and ALDH1A1 based on inhibition of atRA formation by AOX inhibitor hydralazine (20-50% inhibition) and ALDH1A1 inhibitor WIN18,446 (50-80% inhibition). Hydralazine 106-117 aldehyde oxidase 1 Homo sapiens 35-38 5942939-0 1966 On the role of hydralazine in renal hemodynamics and secretion of renin. Hydralazine 15-26 renin Homo sapiens 66-71 33355213-7 2021 The two enzymes were identified as AOX and ALDH1A1 based on inhibition of atRA formation by AOX inhibitor hydralazine (20-50% inhibition) and ALDH1A1 inhibitor WIN18,446 (50-80% inhibition). Hydralazine 106-117 aldehyde dehydrogenase 1 family member A1 Homo sapiens 43-50 33355213-7 2021 The two enzymes were identified as AOX and ALDH1A1 based on inhibition of atRA formation by AOX inhibitor hydralazine (20-50% inhibition) and ALDH1A1 inhibitor WIN18,446 (50-80% inhibition). Hydralazine 106-117 aldehyde oxidase 1 Homo sapiens 92-95 33315911-7 2020 Administration of the antihypertensive agent hydralazine to SHRs significantly ameliorated HFC-induced liver fibrosis; it suppressed the aggregation of CD68-positive macrophages and the upregulation of platelet-derived growth factor receptor beta, and collagen, type 1, alpha-1 chain. Hydralazine 45-56 Cd68 molecule Rattus norvegicus 152-156 33555842-0 2021 The Therapeutic Value of Hydralazine in Reducing Inflammatory Response, Oxidative Stress and Mortality in Animal Sepsis: Involvement of the PI3K/AKT Pathway. Hydralazine 25-36 AKT serine/threonine kinase 1 Rattus norvegicus 145-148 33555842-12 2021 HDZ treatment increased the survival rate (from 50 to 90%), improved glycemia control, reduced the clinical severity sepsis and mean arterial pressure; and prevented increased MPO activity, TNF-alpha, IL-1beta, IL-10 levels, and oxidative damage markers. Hydralazine 0-3 myeloperoxidase Rattus norvegicus 176-179 33555842-12 2021 HDZ treatment increased the survival rate (from 50 to 90%), improved glycemia control, reduced the clinical severity sepsis and mean arterial pressure; and prevented increased MPO activity, TNF-alpha, IL-1beta, IL-10 levels, and oxidative damage markers. Hydralazine 0-3 tumor necrosis factor Rattus norvegicus 190-199 33555842-12 2021 HDZ treatment increased the survival rate (from 50 to 90%), improved glycemia control, reduced the clinical severity sepsis and mean arterial pressure; and prevented increased MPO activity, TNF-alpha, IL-1beta, IL-10 levels, and oxidative damage markers. Hydralazine 0-3 interleukin 1 alpha Rattus norvegicus 201-209 33555842-12 2021 HDZ treatment increased the survival rate (from 50 to 90%), improved glycemia control, reduced the clinical severity sepsis and mean arterial pressure; and prevented increased MPO activity, TNF-alpha, IL-1beta, IL-10 levels, and oxidative damage markers. Hydralazine 0-3 interleukin 10 Rattus norvegicus 211-216 33555842-13 2021 Additionally, HDZ significantly prevented the increase of Akt activation in the liver and kidney. Hydralazine 14-17 AKT serine/threonine kinase 1 Rattus norvegicus 58-61 33555842-14 2021 HDZ largely mitigated the effects of sepsis by suppressing inflammatory and antioxidant responses via the PI3K/Akt pathway. Hydralazine 0-3 AKT serine/threonine kinase 1 Rattus norvegicus 111-114 33386841-0 2022 Hydralazine protects the heart against acute ischemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. Hydralazine 0-11 collapsin response mediator protein 1 Mus musculus 87-91 33386841-3 2022 Here, we investigated whether hydralazine confers acute cardioprotection by inhibiting Drp1-mediated mitochondrial fission. Hydralazine 30-41 collapsin response mediator protein 1 Mus musculus 87-91 33386841-5 2022 In mouse embryonic fibroblasts (MEFs), pre-treatment with hydralazine attenuated mitochondrial fission and cell death induced by oxidative stress, but this effect was absent in MEFs deficient in the mitochondrial fission protein, Drp1. Hydralazine 58-69 collapsin response mediator protein 1 Mus musculus 230-234 33386841-6 2022 Molecular docking and surface plasmon resonance studies demonstrated binding of hydralazine to the GTPase domain of the mitochondrial fission protein, Drp1 (KD 8.6 +- 1.0 microM), and inhibition of Drp1 GTPase activity in a dose-dependent manner. Hydralazine 80-91 collapsin response mediator protein 1 Mus musculus 151-155 33094670-3 2021 We review several drugs (isoniazid, hydralazine, sulfamethazine, amifampridine, procainamide, sulfasalazine, amonafide and metamizole for which NAT2 phenotype-guided therapy may be important. Hydralazine 36-47 N-acetyltransferase 2 Homo sapiens 144-148 33315911-7 2020 Administration of the antihypertensive agent hydralazine to SHRs significantly ameliorated HFC-induced liver fibrosis; it suppressed the aggregation of CD68-positive macrophages and the upregulation of platelet-derived growth factor receptor beta, and collagen, type 1, alpha-1 chain. Hydralazine 45-56 platelet derived growth factor receptor beta Rattus norvegicus 202-246 33315911-7 2020 Administration of the antihypertensive agent hydralazine to SHRs significantly ameliorated HFC-induced liver fibrosis; it suppressed the aggregation of CD68-positive macrophages and the upregulation of platelet-derived growth factor receptor beta, and collagen, type 1, alpha-1 chain. Hydralazine 45-56 collagen type I alpha 1 chain Rattus norvegicus 252-277 32078182-4 2020 p53-binding protein 1 (53BP1, biomarker of DNA damage repair) nuclear bodies were increased in a dose-dependent manner in normal proliferating human mammary epithelial fibroblasts following treatment with compounds traditionally classified as either genotoxic (hydralazine) and nongenotoxic (low-dose aphidicolin, duvelisib, idelalisib, and amiodarone). Hydralazine 261-272 tumor protein p53 binding protein 1 Homo sapiens 23-28 32530271-8 2020 The HMOX1 transcript increase was inhibited by hydralazine, a carbonyl scavenger, suggesting that the carbonyl group of acrolein-adducted albumin mediated HMOX1 transcript increase. Hydralazine 47-58 heme oxygenase 1 Homo sapiens 4-9 32436179-5 2020 Further studies found that treatment with hydralazine (an acrolein scavenger) significantly reversed Drp1 translocation and the morphological damage of mitochondria after ICH. Hydralazine 42-53 dynamin 1-like Mus musculus 101-105 32530271-8 2020 The HMOX1 transcript increase was inhibited by hydralazine, a carbonyl scavenger, suggesting that the carbonyl group of acrolein-adducted albumin mediated HMOX1 transcript increase. Hydralazine 47-58 heme oxygenase 1 Homo sapiens 155-160 31940231-8 2020 Hydralazine decreased the levels of apoptosis, malondialdehyde, and NO, and increased the activities of FRAP and SOD in cells exposed to 6-OHDA. Hydralazine 0-11 superoxide dismutase 1 Homo sapiens 113-116 31940231-3 2020 This study explored the efficacy of hydralazine, a well-known antihypertensive agent, for restoring the impaired HIF-1 signaling in PD, with the aid of 6-hydroxydopamine (6-OHDA)-exposed SH-SY5Y cells. Hydralazine 36-47 hypoxia inducible factor 1 subunit alpha Homo sapiens 113-118 31940231-9 2020 Furthermore, hydralazine up-regulated the protein expression levels of HIF-1alpha, vascular endothelial growth factor, tyrosine hydroxylase, and dopamine transporter in the cells also exposed to 6-OHDA, by comparison with the cells exposed to 6-OHDA alone. Hydralazine 13-24 hypoxia inducible factor 1 subunit alpha Homo sapiens 71-81 31940231-9 2020 Furthermore, hydralazine up-regulated the protein expression levels of HIF-1alpha, vascular endothelial growth factor, tyrosine hydroxylase, and dopamine transporter in the cells also exposed to 6-OHDA, by comparison with the cells exposed to 6-OHDA alone. Hydralazine 13-24 vascular endothelial growth factor A Homo sapiens 83-117 31940231-9 2020 Furthermore, hydralazine up-regulated the protein expression levels of HIF-1alpha, vascular endothelial growth factor, tyrosine hydroxylase, and dopamine transporter in the cells also exposed to 6-OHDA, by comparison with the cells exposed to 6-OHDA alone. Hydralazine 13-24 solute carrier family 6 member 3 Homo sapiens 145-165 31940231-10 2020 In summary, hydralazine priming could attenuate the deleterious effects of 6-OHDA on SH-SY5Y cells by increasing cellular antioxidant capacity, as well as the protein levels of HIF-1alpha and its downstream target genes. Hydralazine 12-23 hypoxia inducible factor 1 subunit alpha Homo sapiens 177-187 32104886-6 2020 In IL-17A-infused mice, treatment with hydralazine and hydrochlorothiazide diminished blood pressure elevation, without modifying mechanical and structural properties of small mesenteric artery, suggesting a direct vascular effect of IL-17A. Hydralazine 39-50 interleukin 17A Mus musculus 3-9 32104886-6 2020 In IL-17A-infused mice, treatment with hydralazine and hydrochlorothiazide diminished blood pressure elevation, without modifying mechanical and structural properties of small mesenteric artery, suggesting a direct vascular effect of IL-17A. Hydralazine 39-50 interleukin 17A Mus musculus 234-240 32410850-7 2020 However, the IC50 of hydralazine was significantly higher in the rat compared to mouse VAP-1. Hydralazine 21-32 amine oxidase, copper containing 3 Mus musculus 87-92 31830459-10 2020 In addition, hydralazine also increased p-PI3K, p-AKT, p-eNOS expression and decreased Cleaved Caspase-3, Cleaved Caspase-9 expression in the hearts. Hydralazine 13-24 AKT serine/threonine kinase 1 Rattus norvegicus 50-53 31830459-10 2020 In addition, hydralazine also increased p-PI3K, p-AKT, p-eNOS expression and decreased Cleaved Caspase-3, Cleaved Caspase-9 expression in the hearts. Hydralazine 13-24 nitric oxide synthase 3 Rattus norvegicus 57-61 31830459-10 2020 In addition, hydralazine also increased p-PI3K, p-AKT, p-eNOS expression and decreased Cleaved Caspase-3, Cleaved Caspase-9 expression in the hearts. Hydralazine 13-24 caspase 9 Rattus norvegicus 114-123 31830459-11 2020 Our results suggest that the cardioprotective effect of hydralazine against I/R injury might be a cooperation of the inhibition of oxidative stress, inflammatory response, apoptosis with the motivation of eNOS phosphorylation via activating the PI3K/AKT signal pathway. Hydralazine 56-67 nitric oxide synthase 3 Rattus norvegicus 205-209 31830459-11 2020 Our results suggest that the cardioprotective effect of hydralazine against I/R injury might be a cooperation of the inhibition of oxidative stress, inflammatory response, apoptosis with the motivation of eNOS phosphorylation via activating the PI3K/AKT signal pathway. Hydralazine 56-67 AKT serine/threonine kinase 1 Rattus norvegicus 250-253 32410850-5 2020 Human VAP-1 was more sensitive compared to rat or mouse VAP-1 (lowest IC50 concentration) to semicarbazide but was least sensitive to hydralazine and LJP-1207. Hydralazine 134-145 amine oxidase copper containing 3 Homo sapiens 6-11 31180533-6 2019 The aim of the present study was to investigate the effects of sodium valproate (VPA), a histone deacetylase inhibitor, in combination with hydralazine hydrochloride (Hy), a DNA methylation inhibitor, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells. Hydralazine 140-165 TNF superfamily member 15 Homo sapiens 222-226 32927458-2 2020 Hydralazine hydrochloride undergoes metabolism by the N-acetyltransferase 2 (NAT2) enzyme. Hydralazine 0-25 N-acetyltransferase 2 Homo sapiens 54-75 32927458-2 2020 Hydralazine hydrochloride undergoes metabolism by the N-acetyltransferase 2 (NAT2) enzyme. Hydralazine 0-25 N-acetyltransferase 2 Homo sapiens 77-81 32927458-5 2020 We then assess the evidence available for genotype-guided therapy of hydralazine, specifically addressing associations of NAT2 acetylator status with hydralazine pharmacokinetics, antihypertensive efficacy, and toxicity. Hydralazine 150-161 N-acetyltransferase 2 Homo sapiens 122-126 32927458-12 2020 Key Messages: NAT2 slow acetylator status predicts increased hydralazine levels, which may lead to increased efficacy and adverse effects. Hydralazine 61-72 N-acetyltransferase 2 Homo sapiens 14-18 32927458-15 2020 With appropriate guidance on the usage of NAT2 genotype, clinicians can adopt a personalized approach to hydralazine dosing and prescription, enabling more efficient and safe treatment of resistant hypertension. Hydralazine 105-116 N-acetyltransferase 2 Homo sapiens 42-46 31710239-4 2020 Results: The tested compounds revealed potent to mild activity with EC50 values 0.339-114.300 muM compared with hydralazine EC50 = 18.210 muM. Hydralazine 112-123 latexin Homo sapiens 138-141 31889127-2 2019 We determined if combined treatment with broad spectrum DNA methyltransferase (DNMT) inhibitor hydralazine and histone deacetylase (HDAC) inhibitor valproic acid (VPA) will reverse this increased risk. Hydralazine 95-106 DNA methyltransferase (cytosine-5) 1 Mus musculus 56-77 31889127-2 2019 We determined if combined treatment with broad spectrum DNA methyltransferase (DNMT) inhibitor hydralazine and histone deacetylase (HDAC) inhibitor valproic acid (VPA) will reverse this increased risk. Hydralazine 95-106 DNA methyltransferase (cytosine-5) 1 Mus musculus 79-83 31889127-8 2019 In control mice not exposed to HF diet in utero, VPA/hydralazine increased mammary tumor incidence and burden, and elevated expression of the unfolded protein response and autophagy genes, including HIF-1alpha, NFkB, PERK, and SQSTM1/p62. Hydralazine 53-64 eukaryotic translation initiation factor 2 alpha kinase 3 Mus musculus 217-221 31889127-8 2019 In control mice not exposed to HF diet in utero, VPA/hydralazine increased mammary tumor incidence and burden, and elevated expression of the unfolded protein response and autophagy genes, including HIF-1alpha, NFkB, PERK, and SQSTM1/p62. Hydralazine 53-64 sequestosome 1 Mus musculus 227-233 31889127-8 2019 In control mice not exposed to HF diet in utero, VPA/hydralazine increased mammary tumor incidence and burden, and elevated expression of the unfolded protein response and autophagy genes, including HIF-1alpha, NFkB, PERK, and SQSTM1/p62. Hydralazine 53-64 sequestosome 1 Mus musculus 234-237 31257615-0 2019 Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. Hydralazine 68-79 N-acetyltransferase 2 Homo sapiens 10-31 31257615-1 2019 Hydralazine, an antihypertensive agent used during pregnancy, undergoes N-acetylation primarily via N-acetyltransferase 2 (NAT2) to form 3-methyl-1,2,4-triazolo[3,4-a]phthalazine (MTP). Hydralazine 0-11 N-acetyltransferase 2 Homo sapiens 100-121 31257615-1 2019 Hydralazine, an antihypertensive agent used during pregnancy, undergoes N-acetylation primarily via N-acetyltransferase 2 (NAT2) to form 3-methyl-1,2,4-triazolo[3,4-a]phthalazine (MTP). Hydralazine 0-11 N-acetyltransferase 2 Homo sapiens 123-127 31257615-8 2019 This study describes for the first time, the PK of oral hydralazine and its metabolite, MTP, during pregnancy, and confirmed that the PK of oral hydralazine is NAT2 genotype dependent during pregnancy. Hydralazine 56-67 N-acetyltransferase 2 Homo sapiens 160-164 31257615-8 2019 This study describes for the first time, the PK of oral hydralazine and its metabolite, MTP, during pregnancy, and confirmed that the PK of oral hydralazine is NAT2 genotype dependent during pregnancy. Hydralazine 145-156 N-acetyltransferase 2 Homo sapiens 160-164 31678759-9 2019 For successful treatment of severe hypertension, nifedipine was found to be superior to hydralazine (OR 4.13 [95% CrI 1.01-20.75]) but not labetalol (OR 3.43 [95% CrI 0.94-19.95]). Hydralazine 88-99 EP300 interacting inhibitor of differentiation 1 Homo sapiens 114-119 31180533-0 2019 Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. Hydralazine 22-33 TNF superfamily member 15 Homo sapiens 78-82 31180533-0 2019 Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. Hydralazine 22-33 vascular endothelial growth factor A Homo sapiens 114-118 30472201-6 2019 In addition, hydralazine also increased p-AKT, Bcl-2 expression and decreased iNOS, Bax, cleaved caspase-3 expression in the kidneys. Hydralazine 13-24 BCL2, apoptosis regulator Rattus norvegicus 47-52 30949126-0 2019 Hydralazine Protects Nigrostriatal Dopaminergic Neurons From MPP+ and MPTP Induced Neurotoxicity: Roles of Nrf2-ARE Signaling Pathway. Hydralazine 0-11 NFE2 like bZIP transcription factor 2 Homo sapiens 107-111 30949126-3 2019 Moreover, it was documented that hydralazine is a potent Nrf2 activator. Hydralazine 33-44 NFE2 like bZIP transcription factor 2 Homo sapiens 57-61 30949126-4 2019 In this study, we tested whether hydralazine can attenuate 1-Methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- induced neurotoxicity in vitro and in vivo by activating Nrf2 and its downstream network of antioxidative genes. Hydralazine 33-44 NFE2 like bZIP transcription factor 2 Homo sapiens 208-212 30949126-6 2019 In addition, hydralazine significantly promoted the nuclear translocation of Nrf2, and upregulated the expression of its downstream antioxidative genes. Hydralazine 13-24 NFE2 like bZIP transcription factor 2 Homo sapiens 77-81 30949126-7 2019 Further, knockout of Nrf2 abolished the protection conferred by hydralazine on MPP+ -induced cell death. Hydralazine 64-75 NFE2 like bZIP transcription factor 2 Homo sapiens 21-25 30949126-11 2019 Oral administration of hydralazine ameliorated oxidative stress, MPTP-induced behavioral disorder, and loss of neurons of dopaminergic system in the substantia nigra (SN) and striatum, all of which were attributed to its ability to activate the Nrf2-ARE pathway. Hydralazine 23-34 NFE2 like bZIP transcription factor 2 Homo sapiens 245-249 30949126-12 2019 Hydralazine increased the migration of Nrf2 to the nucleus in dopaminergic neurons, enhanced the expression of its downstream antioxidative genes. Hydralazine 0-11 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 30949126-13 2019 Together, these datasets show that the Nrf2-ARE pathway mediates the protective effects of hydralazine on Parkinson"s disease. Hydralazine 91-102 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 31043570-5 2019 Survival correlated inversely with the extent of ERK activation in the aortic wall, and strong protection was observed upon attenuation of ERK phosphorylation using an inhibitor of ERK kinase (MEK) or the U.S. Food and Drug Administration-approved medication hydralazine, offering potential therapeutic strategies for pregnancy-associated vascular catastrophe in the setting of MFS. Hydralazine 259-270 mitogen-activated protein kinase 1 Mus musculus 139-142 31043570-5 2019 Survival correlated inversely with the extent of ERK activation in the aortic wall, and strong protection was observed upon attenuation of ERK phosphorylation using an inhibitor of ERK kinase (MEK) or the U.S. Food and Drug Administration-approved medication hydralazine, offering potential therapeutic strategies for pregnancy-associated vascular catastrophe in the setting of MFS. Hydralazine 259-270 mitogen-activated protein kinase 1 Mus musculus 139-142 30448524-0 2019 Evaluation of Cytochrome P450 Selectivity for Hydralazine as an Aldehyde Oxidase Inhibitor for Reaction Phenotyping. Hydralazine 46-57 aldehyde oxidase 1 Homo sapiens 64-80 30448524-1 2019 Hydralazine has been reported as a selective mechanism-based inactivator of aldehyde oxidase (AO) and it is widely used in the pharmaceutical industry for reaction phenotyping to estimate fraction metabolized by AO and to identify AO substrates. Hydralazine 0-11 aldehyde oxidase 1 Homo sapiens 76-92 30448524-2 2019 In this study, however, hydralazine was found to inhibit CYP1A2, 2B6, 2D6, and 3A in human suspension hepatocytes under reaction phenotyping assay conditions, at concentrations that chemically knocked out most of the AO activities (>=50 muM). Hydralazine 24-35 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 57-63 30448524-2 2019 In this study, however, hydralazine was found to inhibit CYP1A2, 2B6, 2D6, and 3A in human suspension hepatocytes under reaction phenotyping assay conditions, at concentrations that chemically knocked out most of the AO activities (>=50 muM). Hydralazine 24-35 latexin Homo sapiens 240-243 30448524-3 2019 Furthermore, hydralazine is a time-dependent inhibitor of CYP1A2. Hydralazine 13-24 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 58-64 30472201-6 2019 In addition, hydralazine also increased p-AKT, Bcl-2 expression and decreased iNOS, Bax, cleaved caspase-3 expression in the kidneys. Hydralazine 13-24 nitric oxide synthase 2 Rattus norvegicus 78-82 30472201-6 2019 In addition, hydralazine also increased p-AKT, Bcl-2 expression and decreased iNOS, Bax, cleaved caspase-3 expression in the kidneys. Hydralazine 13-24 BCL2 associated X, apoptosis regulator Rattus norvegicus 84-87 30369391-0 2018 Hydralazine-induced MPO-ANCA Renal-Limited Vasculitis Masquerading as Lupus Nephritis. Hydralazine 0-11 myeloperoxidase Homo sapiens 20-23 29572254-6 2018 Results:131I-PARPi is a 1(2H)-phthalazinone, similar in structure to the Food and Drug Administration-approved PARP inhibitor AZD-2281. Hydralazine 24-43 poly (ADP-ribose) polymerase family, member 1 Mus musculus 13-17 29929470-4 2018 CASE PRESENTATION: A 79-year-old Japanese woman developed hydralazine-induced pauci-immune necrotizing crescentic glomerulonephritis with MPO-ANCA. Hydralazine 58-69 myeloperoxidase Homo sapiens 138-141 29018032-7 2017 Hydralazine NAT activities differed significantly (P < 0.001) among slow acetylator hepatocytes, (NAT2*5B/*5B > NAT2*5B/*6A > NAT2*6A/*6A). Hydralazine 0-11 N-acetyltransferase 2 Homo sapiens 101-105 30038842-9 2018 CONCLUSIONS: The results of this study and the preclinical and clinical evidence on the efficacy of combining HDACi with DNMTi strongly suggest that more studies are needed with this drug class combination in CTCL, particularly with the hydralazine-valproate scheme, which is safe, and these drugs are widely available and administered by oral route. Hydralazine 237-248 TSPY like 2 Homo sapiens 209-213 29615437-7 2018 A subset of novel AO substrates identified in this study was also subjected to two other methods for AO substrate determination: comparison of human liver microsome and hepatocyte stability, and the effect of hydralazine, an AO-specific inhibitor, on hepatocyte stability. Hydralazine 209-220 aldehyde oxidase 1 Homo sapiens 18-20 29490666-10 2018 Pressive Ang II stimulated TNF-alpha production in the hippocampus, and daily treatment with hydralazine prevented this increase. Hydralazine 93-104 tumor necrosis factor Mus musculus 27-36 29490666-11 2018 Hydralazine also reduced GFAP and Iba-1 levels. Hydralazine 0-11 glial fibrillary acidic protein Mus musculus 25-29 29263362-0 2017 Hydralazine induces stress resistance and extends C. elegans lifespan by activating the NRF2/SKN-1 signalling pathway. Hydralazine 0-11 BZIP domain-containing protein;Protein skinhead-1 Caenorhabditis elegans 93-98 29263362-3 2017 Here, we report that the FDA approved drug hydralazine is a bona fide activator of the NRF2/SKN-1 signaling pathway. Hydralazine 43-54 BZIP domain-containing protein;Protein skinhead-1 Caenorhabditis elegans 92-97 29263362-5 2017 We show that hydralazine-mediated lifespan extension is SKN-1 dependent, with a mechanism most likely mimicking calorie restriction. Hydralazine 13-24 BZIP domain-containing protein;Protein skinhead-1 Caenorhabditis elegans 56-61 29018032-0 2017 N-Acetyltransferase 2 Genotype-Dependent N-Acetylation of Hydralazine in Human Hepatocytes. Hydralazine 58-69 N-acetyltransferase 2 Homo sapiens 0-21 29018032-3 2017 After recombinant expression in yeast, human NAT2 exhibited an apparent Lineweaver-Burk constant (K-m) value (20.1 +- 8.8 muM) for hydralazine over 20-fold lower than the apparent K-m value (456 +- 57 muM) for recombinant human NAT1 (P = 0.0016). Hydralazine 131-142 N-acetyltransferase 2 Homo sapiens 45-49 29018032-3 2017 After recombinant expression in yeast, human NAT2 exhibited an apparent Lineweaver-Burk constant (K-m) value (20.1 +- 8.8 muM) for hydralazine over 20-fold lower than the apparent K-m value (456 +- 57 muM) for recombinant human NAT1 (P = 0.0016). Hydralazine 131-142 latexin Homo sapiens 122-125 29018032-3 2017 After recombinant expression in yeast, human NAT2 exhibited an apparent Lineweaver-Burk constant (K-m) value (20.1 +- 8.8 muM) for hydralazine over 20-fold lower than the apparent K-m value (456 +- 57 muM) for recombinant human NAT1 (P = 0.0016). Hydralazine 131-142 latexin Homo sapiens 201-204 29018032-3 2017 After recombinant expression in yeast, human NAT2 exhibited an apparent Lineweaver-Burk constant (K-m) value (20.1 +- 8.8 muM) for hydralazine over 20-fold lower than the apparent K-m value (456 +- 57 muM) for recombinant human NAT1 (P = 0.0016). Hydralazine 131-142 N-acetyltransferase 1 Homo sapiens 228-232 29018032-6 2017 Hydralazine NAT activities in vitro differed significantly with respect to NAT2 genotype at 1000 (P = 0.0319), 100 (P = 0.002), and 10 muM hydralazine (P = 0.0029). Hydralazine 0-11 N-acetyltransferase 2 Homo sapiens 75-79 29018032-6 2017 Hydralazine NAT activities in vitro differed significantly with respect to NAT2 genotype at 1000 (P = 0.0319), 100 (P = 0.002), and 10 muM hydralazine (P = 0.0029). Hydralazine 0-11 latexin Homo sapiens 135-138 29018032-7 2017 Hydralazine NAT activities differed significantly (P < 0.001) among slow acetylator hepatocytes, (NAT2*5B/*5B > NAT2*5B/*6A > NAT2*6A/*6A). Hydralazine 0-11 N-acetyltransferase 2 Homo sapiens 118-122 29018032-7 2017 Hydralazine NAT activities differed significantly (P < 0.001) among slow acetylator hepatocytes, (NAT2*5B/*5B > NAT2*5B/*6A > NAT2*6A/*6A). Hydralazine 0-11 N-acetyltransferase 2 Homo sapiens 118-122 29018032-8 2017 The in situ hydralazine N-acetylation rates differed significantly with respect to NAT2 genotype after incubation with 10 (P = 0.002) or 100 microM (P = 0.0015) hydralazine and were higher after incubation with 100 muM (10-fold) than with 10 muM (4.5-fold) hydralazine. Hydralazine 12-23 N-acetyltransferase 2 Homo sapiens 83-87 29018032-8 2017 The in situ hydralazine N-acetylation rates differed significantly with respect to NAT2 genotype after incubation with 10 (P = 0.002) or 100 microM (P = 0.0015) hydralazine and were higher after incubation with 100 muM (10-fold) than with 10 muM (4.5-fold) hydralazine. Hydralazine 12-23 latexin Homo sapiens 215-218 29018032-8 2017 The in situ hydralazine N-acetylation rates differed significantly with respect to NAT2 genotype after incubation with 10 (P = 0.002) or 100 microM (P = 0.0015) hydralazine and were higher after incubation with 100 muM (10-fold) than with 10 muM (4.5-fold) hydralazine. Hydralazine 12-23 latexin Homo sapiens 242-245 29018032-8 2017 The in situ hydralazine N-acetylation rates differed significantly with respect to NAT2 genotype after incubation with 10 (P = 0.002) or 100 microM (P = 0.0015) hydralazine and were higher after incubation with 100 muM (10-fold) than with 10 muM (4.5-fold) hydralazine. Hydralazine 161-172 N-acetyltransferase 2 Homo sapiens 83-87 29018032-8 2017 The in situ hydralazine N-acetylation rates differed significantly with respect to NAT2 genotype after incubation with 10 (P = 0.002) or 100 microM (P = 0.0015) hydralazine and were higher after incubation with 100 muM (10-fold) than with 10 muM (4.5-fold) hydralazine. Hydralazine 161-172 N-acetyltransferase 2 Homo sapiens 83-87 29018032-9 2017 Our results clearly document NAT2 genotype-dependent N-acetylation of hydralazine in human hepatocytes, suggesting that hydralazine efficacy and safety could be improved by NAT2 genotype-dependent dosing strategies. Hydralazine 70-81 N-acetyltransferase 2 Homo sapiens 29-33 29018032-9 2017 Our results clearly document NAT2 genotype-dependent N-acetylation of hydralazine in human hepatocytes, suggesting that hydralazine efficacy and safety could be improved by NAT2 genotype-dependent dosing strategies. Hydralazine 70-81 N-acetyltransferase 2 Homo sapiens 173-177 29018032-9 2017 Our results clearly document NAT2 genotype-dependent N-acetylation of hydralazine in human hepatocytes, suggesting that hydralazine efficacy and safety could be improved by NAT2 genotype-dependent dosing strategies. Hydralazine 120-131 N-acetyltransferase 2 Homo sapiens 29-33 29018032-9 2017 Our results clearly document NAT2 genotype-dependent N-acetylation of hydralazine in human hepatocytes, suggesting that hydralazine efficacy and safety could be improved by NAT2 genotype-dependent dosing strategies. Hydralazine 120-131 N-acetyltransferase 2 Homo sapiens 173-177 29552043-1 2017 An electroanalytical method has been introduced for highly sensitive determination of hydralazine hydrochloride (Hy-HCl) based on its oxidation at a glassy carbon electrode modified with multiwalled carbon nanotubes (MWCNT/GCE). Hydralazine 86-111 aminomethyltransferase Homo sapiens 223-226 29552043-1 2017 An electroanalytical method has been introduced for highly sensitive determination of hydralazine hydrochloride (Hy-HCl) based on its oxidation at a glassy carbon electrode modified with multiwalled carbon nanotubes (MWCNT/GCE). Hydralazine 113-119 aminomethyltransferase Homo sapiens 223-226 29552043-3 2017 The electrooxidation of Hy-HCl at MWCNT/GCE occurred at ~32 mV which was lower than that observed at bare GCE (~52 mV). Hydralazine 24-30 aminomethyltransferase Homo sapiens 40-43 29552043-3 2017 The electrooxidation of Hy-HCl at MWCNT/GCE occurred at ~32 mV which was lower than that observed at bare GCE (~52 mV). Hydralazine 24-30 aminomethyltransferase Homo sapiens 106-109 28707284-1 2017 INTRODUCTION: Based upon the findings of the African-American Heart Failure Trial, the US Food and Drug Administration approved the fixed-dose combination of isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD) (FDC-ISDN/HYD) as a new drug for treatment of heart failure (HF) in self-identified African Americans. Hydralazine 190-215 ubiquitin protein ligase E3 component n-recognin 5 Homo sapiens 217-220 29469750-4 2017 Tumor necrosis factor (TNF) inhibitors, propylthiouracil, levamisole-adulterated cocaine, hydralazine, and minocycline have been previously documented to induce ANCA-positive vasculitis (APV), which may present with conspicuously high ANCA titers. Hydralazine 90-101 tumor necrosis factor Homo sapiens 0-21 28419822-7 2017 Azelnidipine also inhibited angiotensin II-induced blood pressure elevation and augmentation of blood pressure variability; meanwhile, hydralazine attenuated the pressor effect of angiotensin II, but had no effect on blood pressure variability. Hydralazine 135-146 angiotensinogen Rattus norvegicus 180-194 28295336-3 2017 Here we determine the neurochemistry (using in situ hybridization) of catecholaminergic and noncatecholaminergic neurons which express c-Fos immunoreactivity throughout the rostrocaudal extent of the ventrolateral medulla, in Sprague Dawley rats treated with hydralazine or saline. Hydralazine 259-270 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 135-140 27663860-7 2017 Hydralazine treatment significantly attenuated renal damage that was found in L-FABP+/- AT1a-/--DOCA mice along with a reduction in blood pressure. Hydralazine 0-11 fatty acid binding protein 1, liver Mus musculus 78-84 27998008-0 2017 Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor-alpha inhibited endothelial nitric oxide synthase expression in endothelial-trophoblast cellular networks. Hydralazine 40-51 nitric oxide synthase 3 Homo sapiens 115-148 27998008-8 2017 Methyldopa, labetalol, hydralazine and clonidine reversed the inhibitory effect of TNF-alpha on eNOS mRNA expression. Hydralazine 23-34 tumor necrosis factor Homo sapiens 83-92 27998008-8 2017 Methyldopa, labetalol, hydralazine and clonidine reversed the inhibitory effect of TNF-alpha on eNOS mRNA expression. Hydralazine 23-34 nitric oxide synthase 3 Homo sapiens 96-100 28277033-1 2017 OBJECTIVES: To evaluate the activity and safety of hydralazine and valproate (Transkrip) in cutaneous T-cell lymphoma (CTCL). Hydralazine 51-62 TSPY like 2 Homo sapiens 119-123 28277033-2 2017 METHODS: Previously untreated and progressive/refractory CTCL patients received hydralazine at 83 mg or 182 mg/day for slow and rapid acetylators respectively plus magnesium valproate at a total dose of 30 mg/Kg t.i.d daily in continuous 28-day cycles in this phase II study. Hydralazine 80-91 TSPY like 2 Homo sapiens 57-61 28277033-11 2017 CONCLUSION: The combination of hydralazine and valproate is safe, very well tolerated and effective in CTCL. Hydralazine 31-42 TSPY like 2 Homo sapiens 103-107 28069864-0 2017 Hydralazine is involved in tele-methylhistamine metabolism by inhibiting monoamine oxidase B in pregnancy-associated hypertensive mice. Hydralazine 0-11 monoamine oxidase B Mus musculus 73-92 27752976-7 2017 Changes in cholinesterase enzyme function may affect the disposition of succinylcholine, benzylisoquinoline muscle relaxants, remifentanil, and hydralazine. Hydralazine 144-155 butyrylcholinesterase Homo sapiens 11-25 27663860-7 2017 Hydralazine treatment significantly attenuated renal damage that was found in L-FABP+/- AT1a-/--DOCA mice along with a reduction in blood pressure. Hydralazine 0-11 angiotensin II receptor, type 1a Mus musculus 88-92 27692563-6 2017 Administration of low-dose hydralazine effectively induced expression of hydroxylase TET3, which catalyzed RASAL1 hydroxymethylation and subsequent RASAL1 promoter demethylation. Hydralazine 27-38 tet methylcytosine dioxygenase 3 Mus musculus 85-89 27692563-6 2017 Administration of low-dose hydralazine effectively induced expression of hydroxylase TET3, which catalyzed RASAL1 hydroxymethylation and subsequent RASAL1 promoter demethylation. Hydralazine 27-38 RAS protein activator like 1 (GAP1 like) Mus musculus 107-113 27692563-6 2017 Administration of low-dose hydralazine effectively induced expression of hydroxylase TET3, which catalyzed RASAL1 hydroxymethylation and subsequent RASAL1 promoter demethylation. Hydralazine 27-38 RAS protein activator like 1 (GAP1 like) Mus musculus 148-154 27238871-6 2016 Notably, the acrolein scavenger, hydralazine prevented these promoter-associated epigenetic changes and inhibited FasL upregulation and apoptosis induced by the combination of AZT and acrolein, as well as AZT alone. Hydralazine 33-44 Fas ligand Homo sapiens 114-118 28479957-7 2017 Carbonyl scavengers hydralazine and bisvanillyl-hydralazone inhibited the nSMase2/SK1 pathway activation and the formation of tubes on Matrigel evoked by 4-HNE. Hydralazine 20-31 sphingomyelin phosphodiesterase 3 Homo sapiens 74-81 28479957-7 2017 Carbonyl scavengers hydralazine and bisvanillyl-hydralazone inhibited the nSMase2/SK1 pathway activation and the formation of tubes on Matrigel evoked by 4-HNE. Hydralazine 20-31 sphingosine kinase 1 Homo sapiens 82-85 27638854-3 2016 RESULTS: Angiotensinogen-transgenic mice developed hypertension and nephropathy, changes that were either partially or completely attenuated by treatment with losartan or dual renin-angiotensin system blockade (losartan and perindopril), respectively, while hydralazine prevented hypertension but not nephropathy. Hydralazine 258-269 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 9-24 26942461-4 2016 Here, we show that hydralazine induced caspase-dependent apoptotic cell death in human p53-mutant leukemic T cells. Hydralazine 19-30 tumor protein p53 Homo sapiens 87-90 26785703-0 2016 Biomolecular interaction study of hydralazine with bovine serum albumin and effect of beta-cyclodextrin on binding by fluorescence, 3D, synchronous, CD, and Raman spectroscopic methods. Hydralazine 34-45 albumin Homo sapiens 58-71 26785703-1 2016 Spectrofluoremetric technique was employed to study the binding behavior of hydralazine with bovine serum albumin (BSA) at different temperatures. Hydralazine 76-87 albumin Homo sapiens 100-113 26785703-2 2016 Binding study of bovine serum albumin with hydralazine has been studied by ultraviolet-visible spectroscopy, fluorescence spectroscopy and confirmed by three-dimensional, synchronous, circular dichroism, and Raman spectroscopic methods. Hydralazine 43-54 albumin Homo sapiens 24-37 26785703-4 2016 The experimental results showed a static quenching mechanism in the interaction of hydralazine with bovine serum albumin. Hydralazine 83-94 albumin Homo sapiens 107-120 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 117-128 caspase 9 Homo sapiens 15-24 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 117-128 BCL2 apoptosis regulator Homo sapiens 51-56 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 117-128 BCL2 like 1 Homo sapiens 62-68 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 180-191 caspase 9 Homo sapiens 15-24 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 180-191 BCL2 apoptosis regulator Homo sapiens 51-56 26942461-7 2016 Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway. Hydralazine 180-191 BCL2 like 1 Homo sapiens 62-68 26791524-3 2016 We find that the proportion of C1 pSer40TH-positive neurons in the central and medial region of the rat rostral ventrolateral medulla (RVLM) increases dramatically following hydralazine treatment, whereas phenylephrine treatment does not significantly change the pSer40TH/TH ratio in these regions compared to control. Hydralazine 174-185 tyrosine hydroxylase Rattus norvegicus 40-42 25688346-7 2015 On one hand, drugs with free hydroxyl on amino groups (e.g., hydralazine, procainamide) could interact with C4A, C4B, or C3 and cause an SLE-like disease. Hydralazine 61-72 complement C4B (Chido blood group) Homo sapiens 113-123 26506064-4 2015 We have identified protein kinase C beta (PKCbeta) as a critical mediator of this pathway and demonstrate that the PKCbeta inhibitor enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice, in association with reduced PKCbeta and ERK1/2 activation. Hydralazine 199-210 protein kinase C, beta Mus musculus 42-49 26506064-4 2015 We have identified protein kinase C beta (PKCbeta) as a critical mediator of this pathway and demonstrate that the PKCbeta inhibitor enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice, in association with reduced PKCbeta and ERK1/2 activation. Hydralazine 199-210 mitogen-activated protein kinase 3 Mus musculus 297-303 26176653-6 2015 RESULTS: SNX significantly increased SBP, which was comparably reduced to control levels by BAY 41-8543 and hydralazine. Hydralazine 108-119 spermine binding protein Rattus norvegicus 37-40 24990704-8 2015 The following predictors were found to be associated with EPO prescription: iron supplementation (odds ratio [OR] 52.70, 95% confidence interval [CI] 11.70-237.46), renal clinic appointment (OR 2.60, 95% CI 1.79-3.76), malignancy (OR 1.52, 95% CI 1.07-2.16) and use of hydralazine/nitrates (OR 1.41, 95% CI 1.03-1.92). Hydralazine 269-280 erythropoietin Homo sapiens 58-61 25091895-6 2014 Organ culture of normal C57BL/6J mouse aortas treated with either hydralazine or deferoxamine inhibited the effect of BMP-4 on impairment of acetylcholine-induced endothelium-dependent relaxation (EDR). Hydralazine 66-77 bone morphogenetic protein 4 Mus musculus 118-123 25717475-0 2015 Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease. Hydralazine 62-73 tet methylcytosine dioxygenase 3 Homo sapiens 13-17 25249692-8 2014 Inclusion of hydralazine, an irreversible inhibitor of AO, resulted in concentration-dependent decrease of hydroxylation activities, exceeding 90% inhibition of carbazeran 4-hydroxylation at 100 muM inhibitor. Hydralazine 13-24 aldehyde oxidase 1 Homo sapiens 55-57 25306451-0 2014 G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. Hydralazine 99-110 G protein subunit beta 3 Homo sapiens 0-16 25154405-3 2014 The combination of hydralazine-valproate (TRANSKRIP( )) is being repositioned as an oral DNMT and HDAC inhibitor. Hydralazine 19-30 DNA methyltransferase 1 Homo sapiens 89-93 24797896-5 2014 Herein, we evaluated the anti-cancer properties of hydralazine, a non-nucleoside DNA methyltransferases (DNMT) inhibitor, in PCa cell lines. Hydralazine 51-62 DNA methyltransferase 1 Homo sapiens 81-103 24797896-5 2014 Herein, we evaluated the anti-cancer properties of hydralazine, a non-nucleoside DNA methyltransferases (DNMT) inhibitor, in PCa cell lines. Hydralazine 51-62 DNA methyltransferase 1 Homo sapiens 105-109 24797896-9 2014 Following hydralazine exposure, decreased levels of DNMT1, DNMT3a and DNMT3b mRNA and DNMT1 protein were depicted. Hydralazine 10-21 DNA methyltransferase 1 Homo sapiens 52-57 24797896-9 2014 Following hydralazine exposure, decreased levels of DNMT1, DNMT3a and DNMT3b mRNA and DNMT1 protein were depicted. Hydralazine 10-21 DNA methyltransferase 3 alpha Homo sapiens 59-65 24797896-9 2014 Following hydralazine exposure, decreased levels of DNMT1, DNMT3a and DNMT3b mRNA and DNMT1 protein were depicted. Hydralazine 10-21 DNA methyltransferase 3 beta Homo sapiens 70-76 24797896-9 2014 Following hydralazine exposure, decreased levels of DNMT1, DNMT3a and DNMT3b mRNA and DNMT1 protein were depicted. Hydralazine 10-21 DNA methyltransferase 1 Homo sapiens 86-91 24797896-11 2014 Interestingly, hydralazine restored androgen receptor expression, with upregulation of its target p21 in DU145 cell line. Hydralazine 15-26 H3 histone pseudogene 16 Homo sapiens 98-101 25210633-0 2014 Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome. Hydralazine 0-11 proteinase 3 Homo sapiens 40-52 24702251-3 2014 Hydralazine is metabolized by the highly polymorphic N-acetyltransferase 2. Hydralazine 0-11 N-acetyltransferase 2 Homo sapiens 53-74 24467436-2 2014 The slow NAT phenotype increases susceptibility to hydralazine and isoniazid toxicity and to occupational bladder cancer. Hydralazine 51-62 bromodomain containing 2 Homo sapiens 9-12 24467436-5 2014 The human gene products NAT1 and NAT2 have distinct substrate specificities: NAT2 acetylates hydralazine and human NAT1 acetylates p-aminosalicylate (p-AS) and the folate catabolite para-aminobenzoylglutamate (p-abaglu). Hydralazine 93-104 N-acetyltransferase 1 Homo sapiens 24-28 24467436-5 2014 The human gene products NAT1 and NAT2 have distinct substrate specificities: NAT2 acetylates hydralazine and human NAT1 acetylates p-aminosalicylate (p-AS) and the folate catabolite para-aminobenzoylglutamate (p-abaglu). Hydralazine 93-104 N-acetyltransferase 2 Homo sapiens 33-37 24467436-5 2014 The human gene products NAT1 and NAT2 have distinct substrate specificities: NAT2 acetylates hydralazine and human NAT1 acetylates p-aminosalicylate (p-AS) and the folate catabolite para-aminobenzoylglutamate (p-abaglu). Hydralazine 93-104 N-acetyltransferase 2 Homo sapiens 77-81 24572430-10 2014 RESULTS: Methyldopa, labetalol, hydralazine, and clonidine increased trophoblast integration into TNF-alpha-preincubated endothelial cellular networks. Hydralazine 32-43 tumor necrosis factor Homo sapiens 98-107 25210633-0 2014 Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome. Hydralazine 0-11 myeloperoxidase Homo sapiens 20-35 24444407-0 2014 Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. Hydralazine 49-60 N-acetyltransferase 2 Homo sapiens 28-32 24444407-1 2014 AIM: Hydralazine, a vasodilator used in resistant hypertension (RH) treatment is metabolized by an acetylation reaction mediated by N-acetyltransferase 2, the activity of which depends on NAT2 polymorphisms. Hydralazine 5-16 N-acetyltransferase 2 Homo sapiens 132-153 24444407-1 2014 AIM: Hydralazine, a vasodilator used in resistant hypertension (RH) treatment is metabolized by an acetylation reaction mediated by N-acetyltransferase 2, the activity of which depends on NAT2 polymorphisms. Hydralazine 5-16 N-acetyltransferase 2 Homo sapiens 188-192 24444407-8 2014 CONCLUSION: The slow acetylation phenotype, determined by polymorphisms within NAT2, influenced both the antihypertensive and adverse effects of hydralazine in RH. Hydralazine 145-156 N-acetyltransferase 2 Homo sapiens 79-83 25210633-12 2014 To our knowledge, hydralazine-associated PR3 ANCA has not been previously reported. Hydralazine 18-29 proteinase 3 Homo sapiens 41-44 24126953-4 2013 Hydralazine down regulated the expression of Receptor for Advanced Glycation End products (RAGE), NADPH oxidase (NOX), and super oxide dismutase (SOD). Hydralazine 0-11 advanced glycosylation end product-specific receptor Mus musculus 45-89 24126953-4 2013 Hydralazine down regulated the expression of Receptor for Advanced Glycation End products (RAGE), NADPH oxidase (NOX), and super oxide dismutase (SOD). Hydralazine 0-11 advanced glycosylation end product-specific receptor Mus musculus 91-95 24621868-3 2013 Some of the benefits seen with hydralazine, including afterload reduction and attenuation of nitrate tolerance, have also been observed with angiotensin-converting enzyme inhibitors. Hydralazine 31-42 angiotensin I converting enzyme Homo sapiens 141-170 22522748-8 2012 Overall, these findings demonstrate that hydralazine, at a concentration of 25 to 50 muM, can be used in human hepatocyte incubations to estimate the contribution of AO to the hepatic clearance of drugs and other compounds. Hydralazine 41-52 latexin Homo sapiens 85-88 23462233-4 2013 The procedure was to reduce liver AOX activity by providing tungsten or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain. Hydralazine 72-83 acyl-Coenzyme A oxidase 1, palmitoyl Mus musculus 34-37 23462233-6 2013 Liver AOX activity was reduced by 45% with tungsten and 61% with hydralazine and 81% in AOX-deficient mice relative to controls. Hydralazine 65-76 acyl-Coenzyme A oxidase 1, palmitoyl Mus musculus 6-9 23462233-7 2013 When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice. Hydralazine 245-256 acyl-Coenzyme A oxidase 1, palmitoyl Mus musculus 155-158 23415681-12 2013 Hydralazine pretreatment reversed DE-induced TF, tPA, TNF-alpha, and MMP-2 expression but not eNOS, RAGE, and HMGB-1. Hydralazine 0-11 plasminogen activator, tissue type Rattus norvegicus 49-52 23415681-12 2013 Hydralazine pretreatment reversed DE-induced TF, tPA, TNF-alpha, and MMP-2 expression but not eNOS, RAGE, and HMGB-1. Hydralazine 0-11 tumor necrosis factor Rattus norvegicus 54-63 23415681-12 2013 Hydralazine pretreatment reversed DE-induced TF, tPA, TNF-alpha, and MMP-2 expression but not eNOS, RAGE, and HMGB-1. Hydralazine 0-11 matrix metallopeptidase 2 Rattus norvegicus 69-74 23195226-0 2013 Induction of a trophoblast-like phenotype by hydralazine in the p19 embryonic carcinoma cell line. Hydralazine 45-56 interleukin 23 subunit alpha Homo sapiens 64-67 23195226-8 2013 An irreversible loss of the pluripotent transcription factor Oct-4 was observed following hydralazine exposure. Hydralazine 90-101 POU class 5 homeobox 1 Homo sapiens 61-66 23195226-9 2013 In summary, hydralazine induces P19 cells to assume a trophoblast-like phenotype by upregulating Tead4 expression through a mechanism involving DNA demethylation. Hydralazine 12-23 interleukin 23 subunit alpha Homo sapiens 32-35 23195226-9 2013 In summary, hydralazine induces P19 cells to assume a trophoblast-like phenotype by upregulating Tead4 expression through a mechanism involving DNA demethylation. Hydralazine 12-23 TEA domain transcription factor 4 Homo sapiens 97-102 23006735-7 2012 Blood pressure reduction via administration of hydralazine phenocopied EP1-/- mice. Hydralazine 47-58 prostaglandin E receptor 1 (subtype EP1) Mus musculus 71-74 22869587-8 2012 Most strikingly, hydralazine selectively boosted the levels of cytoskeletal-associated Hsp90, including a high-mass species that was sensitive to the Hsp90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin. Hydralazine 17-28 heat shock protein 90 alpha family class A member 1 Homo sapiens 87-92 22869587-8 2012 Most strikingly, hydralazine selectively boosted the levels of cytoskeletal-associated Hsp90, including a high-mass species that was sensitive to the Hsp90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin. Hydralazine 17-28 heat shock protein 90 alpha family class A member 1 Homo sapiens 150-155 22869587-9 2012 Biochemical fractionation of acrolein- and hydralazine-treated cells revealed that hydralazine likely promoted Hsp90 migration from cytosol into other subcellular compartments. Hydralazine 43-54 heat shock protein 90 alpha family class A member 1 Homo sapiens 111-116 22869587-9 2012 Biochemical fractionation of acrolein- and hydralazine-treated cells revealed that hydralazine likely promoted Hsp90 migration from cytosol into other subcellular compartments. Hydralazine 83-94 heat shock protein 90 alpha family class A member 1 Homo sapiens 111-116 22522748-0 2012 Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Hydralazine 0-11 aldehyde oxidase 1 Homo sapiens 48-64 22522748-0 2012 Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Hydralazine 0-11 aldehyde oxidase 1 Homo sapiens 121-137 22522748-2 2012 We report a method using cryopreserved human hepatocytes and the time-dependent AO inhibitor hydralazine (K(I) = 83 +- 27 muM, k(inact) = 0.063 +- 0.007 min(-1)), which estimates the contribution of AO metabolism relative to total hepatic clearance. Hydralazine 93-104 latexin Homo sapiens 122-125 22522748-3 2012 Using zaleplon as a probe substrate and simultaneously monitoring the AO-catalyzed formation of oxozaleplon and the CYP3A-catalyzed formation of desethyzaleplon in the presence of a range of hydralazine concentrations, it was determined that >90% inhibition of the AO activity with minimal effect on the CYP3A activity could be achieved with 25 to 50 muM hydralazine. Hydralazine 191-202 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 116-121 22522748-3 2012 Using zaleplon as a probe substrate and simultaneously monitoring the AO-catalyzed formation of oxozaleplon and the CYP3A-catalyzed formation of desethyzaleplon in the presence of a range of hydralazine concentrations, it was determined that >90% inhibition of the AO activity with minimal effect on the CYP3A activity could be achieved with 25 to 50 muM hydralazine. Hydralazine 358-369 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 116-121 26105365-6 2012 OBJECTIVES: This study is to examine the effect of pharmacological dose of anti-hypertensive hydralazine, clonidine and labetalol on trophoblast cell integration into inflammatory TNF-a pre-exposed endothelial cellular networks. Hydralazine 93-104 tumor necrosis factor Homo sapiens 180-185 22522748-7 2012 Substrates with a CYP2D6 contribution to clearance were affected by hydralazine to a minor extent, because of weak inhibition of this enzyme. Hydralazine 68-79 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 18-24 22576685-5 2012 Both VPA and hydralazine increased the expression of cell-surface MICA and B in osteosarcoma cells, and their combination induced a greater increase in their expression. Hydralazine 13-24 MHC class I polypeptide-related sequence A Homo sapiens 66-70 26105365-14 2012 RESULTS: When HTR-8/SVneo trophoblast cells were co-cultured with TNF-a pre-incubated endothelial cells, hydralazine and clonidine can significantly increase the trophoblast integration into endothelial cellular networks. Hydralazine 105-116 telomerase RNA component Homo sapiens 14-17 26105365-14 2012 RESULTS: When HTR-8/SVneo trophoblast cells were co-cultured with TNF-a pre-incubated endothelial cells, hydralazine and clonidine can significantly increase the trophoblast integration into endothelial cellular networks. Hydralazine 105-116 tumor necrosis factor Homo sapiens 66-71 22357923-10 2012 Experiments with hydralazine and epithelial nitric oxide synthase-/- mice further suggested that Arap1 expression changed in parallel with angiotensin II, rather than with blood pressure per se. Hydralazine 17-28 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 Mus musculus 97-102 22113172-7 2012 Olmesartan and hydralazine, but not eplerenone, suppressed the AngII-salt hypertension. Hydralazine 15-26 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 63-68 22258030-9 2012 The coadministration of hydralazine with AngII completely inhibited the hypertensive effects of AngII (P 0.01) and resulted in minimal cellular infiltration and minimal collagen deposition. Hydralazine 24-35 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 96-101 22258030-10 2012 These findings were in the context of persistent RAS activation, which was evidenced by elevation in serum aldosterone levels in animals that received AngII or AngII+hydralazine compared with animals that received saline. Hydralazine 166-177 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 160-165 22258030-12 2012 We provide evidence that myocardial infiltration by fibroblast progenitor cells secondary to AngII and the resultant fibrosis can be prevented by the addition of hydralazine. Hydralazine 162-173 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 93-98 21535081-10 2011 Treatment with representative drugs that cause drug-induced lupus (chlorpromazine, procainamide and hydralazine) induced Herp expression and apoptosis in HeLa cells. Hydralazine 100-111 homocysteine inducible ER protein with ubiquitin like domain 1 Homo sapiens 121-125 22933069-6 2012 Mice receiving CD4+ T cells demethylated by a variety of agents including procainamide and hydralazine develop a lupus-like disease. Hydralazine 91-102 CD4 antigen Mus musculus 15-18 22427797-6 2012 Treatment with hydralazine reversed gemcitabine resistance and led to hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner. Hydralazine 15-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-75 22427797-6 2012 Treatment with hydralazine reversed gemcitabine resistance and led to hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner. Hydralazine 15-26 dreadlocks Drosophila melanogaster 80-83 22427797-9 2012 Hydralazine inhibited G9A methyltransferase activity in vitro and depletion of the G9A gene by iRNA restored gemcitabine sensitivity. Hydralazine 0-11 euchromatic histone lysine methyltransferase 2 Homo sapiens 22-25 22427797-11 2012 Hydralazine reverts gemcitabine resistance in cervical cancer cells via inhibition of G9A histone methyltransferase. Hydralazine 0-11 euchromatic histone lysine methyltransferase 2 Homo sapiens 86-115 21747360-7 2011 Additionally, hydralazine (10 and 30 muM) decreased the expression of DNA methyltransferase 1. Hydralazine 14-25 DNA methyltransferase 1 Rattus norvegicus 70-93 21930124-0 2011 Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARgamma up-expression in MDA-MB-231 cells. Hydralazine 37-48 peroxisome proliferator activated receptor gamma Homo sapiens 99-108 21930124-3 2011 In TNBC cells, combined treatment with thiazolidinedione and demethylation drugs Hydralazine up-regulated protein and mRNA levels of PPARgamma. Hydralazine 81-92 peroxisome proliferator activated receptor gamma Homo sapiens 133-142 21805029-0 2011 Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Hydralazine 79-90 killer cell lectin like receptor K1 Homo sapiens 16-21 21805029-6 2011 The results show that hydralazine and valproic acid not only increase the expression of MICA and MICB ligands of target cells, but also reduce their shedding to the supernatant. Hydralazine 22-33 MHC class I polypeptide-related sequence A Homo sapiens 88-92 21805029-6 2011 The results show that hydralazine and valproic acid not only increase the expression of MICA and MICB ligands of target cells, but also reduce their shedding to the supernatant. Hydralazine 22-33 MHC class I polypeptide-related sequence B Homo sapiens 97-101 21805029-9 2011 In conclusion, our results demonstrate the ability of hydralazine and valproate to increase the NK activity against epithelial cancer cell lines and suggest that these drugs could reduce the levels of soluble MICA and MICB helping in avoiding tumor-induced suppression of NK cytotoxicity against the tumor. Hydralazine 54-65 MHC class I polypeptide-related sequence A Homo sapiens 209-213 21805029-9 2011 In conclusion, our results demonstrate the ability of hydralazine and valproate to increase the NK activity against epithelial cancer cell lines and suggest that these drugs could reduce the levels of soluble MICA and MICB helping in avoiding tumor-induced suppression of NK cytotoxicity against the tumor. Hydralazine 54-65 MHC class I polypeptide-related sequence B Homo sapiens 218-222 21373977-8 2011 Compared with the control, hydralazine treatment to lower blood pressure blocked angiotensin II-induced fibrosis and reduced Mac-2(+) inflammatory cell infiltration and proinflammatory cytokine expression. Hydralazine 27-38 lectin, galactose binding, soluble 3 Mus musculus 125-130 20922525-5 2011 The combination of hydralazine and valproate (Transkrip ), a DNMT and HDAC inhibitor, respectively), has been developed as epigenetic therapy under the drug repositioning concept. Hydralazine 19-30 DNA methyltransferase 1 Homo sapiens 61-65 21263123-8 2011 Normalization of blood pressure by hydralazine (500 mg/L in drink solutions) attenuated the hydromineral phenotypes and renal renin suppression effects of DOCA-salt but had no effect on the elevated metabolic rate. Hydralazine 35-46 renin Homo sapiens 126-131 19919978-8 2009 In the placebo arm, multivariable analysis demonstrated that the corin I555(P568) allele was associated with increased risk for death or heart failure hospitalization (relative risk 3.49; 95% CI, 1.45 to 8.39; P=0.005); however, in the treatment arm (fixed-dose combination isosorbide-dinitrate/hydralazine), the corin I555(P568) allele was not associated with adverse outcomes. Hydralazine 295-306 corin, serine peptidase Homo sapiens 65-70 21084406-8 2011 The decrease in AT(2)R expression and renal damage observed in SHR remained even after treatment with hydralazine. Hydralazine 102-113 angiotensin II receptor, type 2 Rattus norvegicus 16-22 20339522-3 2010 Here we report a mycosis fungoides patient having a dramatic response to hydralazine and valproate, two repositioned drugs as HDAC and DNA methylation inhibitors, respectively. Hydralazine 73-84 histone deacetylase 9 Homo sapiens 126-130 19854888-0 2009 Assessment of the toxicity of hydralazine in the rat using an ultrasensitive flow-based cardiac troponin I immunoassay. Hydralazine 30-41 troponin I3, cardiac type Rattus norvegicus 88-106 19854888-2 2009 A single dose of hydralazine caused an increase of cTnI concentrations at six hours post-dose, followed by a sharp decrease at twenty-four hours and a return to baseline at forty-eight hours. Hydralazine 17-28 troponin I3, cardiac type Rattus norvegicus 51-55 19854888-3 2009 The second dose of hydralazine caused a smaller magnitude increase in cTnI concentrations at six hours as compared to the first dose. Hydralazine 19-30 troponin I3, cardiac type Rattus norvegicus 70-74 19854888-8 2009 In conclusion, the increases in cTnI concentrations six hours after the administration of hydralazine were indicative of a myocardial damage that did not consistently have a microscopic correlate. Hydralazine 90-101 troponin I3, cardiac type Rattus norvegicus 32-36 21058733-0 2010 Hydralazine modifies Abeta fibril formation and prevents modification by lipids in vitro. Hydralazine 0-11 amyloid beta precursor protein Homo sapiens 21-26 21058733-4 2010 Hydralazine, a smooth muscle relaxant, is a potential drug candidate for AD drug therapy as it reduces Abeta production and prevents oxidative damage via its antioxidant hydrazide group. Hydralazine 0-11 amyloid beta precursor protein Homo sapiens 103-108 21058733-5 2010 We evaluated the efficacy of hydralazine, and related hydrazides, in reducing (1) Abeta misfolding and (2) Abeta protein modification by the reactive lipid 4-hydroxy-2-nonenal (HNE) using transmission electron microscopy and Western blotting. Hydralazine 29-40 amyloid beta precursor protein Homo sapiens 82-87 21058733-5 2010 We evaluated the efficacy of hydralazine, and related hydrazides, in reducing (1) Abeta misfolding and (2) Abeta protein modification by the reactive lipid 4-hydroxy-2-nonenal (HNE) using transmission electron microscopy and Western blotting. Hydralazine 29-40 amyloid beta precursor protein Homo sapiens 107-112 21058733-7 2010 Hydralazine prevented lipid modification of Abeta, and Abeta was used as a proxy for classes of proteins which either misfold or are modified by HNE. Hydralazine 0-11 amyloid beta precursor protein Homo sapiens 44-49 21058733-10 2010 Thus, hydrazides reduced lipid oxidative damage, and hydralazine additionally reduced Abeta misfolding. Hydralazine 53-64 amyloid beta precursor protein Homo sapiens 86-91 20015613-6 2010 For example, DNA hypomethylation may occur with hydralazine, which leads to increased transcription, increased LFA-1, the generation of autoreactive T cells and a breakdown in peripheral tolerance. Hydralazine 48-59 integrin subunit alpha L Homo sapiens 111-116 20136844-0 2010 Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. Hydralazine 25-36 natriuretic peptide receptor 1 Mus musculus 115-133 20136844-11 2010 CONCLUSIONS AND IMPLICATIONS: The vasodilator hydralazine induced AT(2) receptor-mediated cardiomyocyte growth under conditions of GCA deficiency. Hydralazine 46-57 angiotensin II receptor, type 2 Mus musculus 66-80 19961364-3 2010 Hydralazine is a lupus-inducing drug that also decreases T cell DNA methylation by inhibiting the ERK signaling pathway, replicating the defect found in lupus T cells. Hydralazine 0-11 mitogen-activated protein kinase 1 Homo sapiens 98-101 19961364-5 2010 The signaling defect in hydralazine-treated and lupus T cells has now been mapped to protein kinase C delta. Hydralazine 24-35 protein kinase C delta Homo sapiens 85-107 19415296-5 2009 In this study, we have evaluated the potential of one such agent under study, namely hydralazine, which was shown earlier to enhance hypoxia inducible factor-1alpha (HIF-1alpha) levels in experimental animal systems. Hydralazine 85-96 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 133-164 19415296-5 2009 In this study, we have evaluated the potential of one such agent under study, namely hydralazine, which was shown earlier to enhance hypoxia inducible factor-1alpha (HIF-1alpha) levels in experimental animal systems. Hydralazine 85-96 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 166-176 19415296-6 2009 Our aim was to determine whether enhanced levels of HIF-1alpha via pre-treatment with hydralazine had a reno-protective effect after ischemic injury. Hydralazine 86-97 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 52-62 19415296-9 2009 RESULTS: In our system, we found that hydralazine pre-treatment, even though it enhanced HIF-1alpha levels in the kidney, it also increased serum creatinine and worsened the morphological damage to the renal tubules in the ischemic kidney. Hydralazine 38-49 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 89-99 19919978-10 2009 The corin I555(P568) allele is associated with an increased risk for death or heart failure hospitalization in patients receiving standard neurohormonal blockade, but the addition of fixed-dose combination isosorbide-dinitrate/hydralazine ameliorates this risk. Hydralazine 227-238 corin, serine peptidase Homo sapiens 4-9 19252100-9 2009 Alternatively, administration of hydralazine (250 mg/l) to ANG II-infused apoE(-/-) mice (1,000 ng.kg(-1).min(-1)) lowered systolic blood pressure (day 28: ANG II, 157 +/- 6; ANG II/hydralazine, 135 +/- 6 mmHg) but did not prevent AAA formation or atherosclerosis. Hydralazine 33-44 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 59-65 19174306-3 2009 METHODS: Interference with ENTPDase activity in platelets of hypertensive patients and healthy donors was evaluated for arginine, sodium nitroprusside, and hydralazine. Hydralazine 156-167 ectonucleoside triphosphate diphosphohydrolase 8 Homo sapiens 27-35 19252100-9 2009 Alternatively, administration of hydralazine (250 mg/l) to ANG II-infused apoE(-/-) mice (1,000 ng.kg(-1).min(-1)) lowered systolic blood pressure (day 28: ANG II, 157 +/- 6; ANG II/hydralazine, 135 +/- 6 mmHg) but did not prevent AAA formation or atherosclerosis. Hydralazine 33-44 apolipoprotein E Mus musculus 74-78 19252100-9 2009 Alternatively, administration of hydralazine (250 mg/l) to ANG II-infused apoE(-/-) mice (1,000 ng.kg(-1).min(-1)) lowered systolic blood pressure (day 28: ANG II, 157 +/- 6; ANG II/hydralazine, 135 +/- 6 mmHg) but did not prevent AAA formation or atherosclerosis. Hydralazine 33-44 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 156-162 19252100-9 2009 Alternatively, administration of hydralazine (250 mg/l) to ANG II-infused apoE(-/-) mice (1,000 ng.kg(-1).min(-1)) lowered systolic blood pressure (day 28: ANG II, 157 +/- 6; ANG II/hydralazine, 135 +/- 6 mmHg) but did not prevent AAA formation or atherosclerosis. Hydralazine 33-44 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 156-162 19722378-2 2009 OBJECTIVES: We sought to analyze exercise-derived mean pulmonary artery pressure (mPAP)-cardiac index (CI) relationship to expand the concepts regarding its nature and to better identify pulmonary hemodynamic responders to acute oxygen breathing (AO2B-99.5%) and to hydralazine (H) in extrinsic allergic alveolitis (EAA) and chronic interstitial lung disease (CILD) pulmonary hypertension (PH) patients. Hydralazine 266-277 phospholipid phosphatase 1 Mus musculus 82-86 19322801-0 2009 Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. Hydralazine 53-64 DNA methyltransferase 1 Homo sapiens 76-99 19322801-2 2009 In the present study, a binding model for hydralazine, with a validated homology model of human DNMT, was developed by the use of automated molecular docking and molecular dynamics simulations. Hydralazine 42-53 DNA methyltransferase 1 Homo sapiens 96-100 19322801-4 2009 The inhibitory activity of hydralazine toward DNMT may be rationalized at the molecular level by similar interactions within the binding pocket (e.g., by a similar pharmacophore) as established by substrate-like deoxycytidine analogues. Hydralazine 27-38 DNA methyltransferase 1 Homo sapiens 46-50 18835925-10 2008 There were more detectable dilated and dysplastic capillaries (2.4+/-0.3 or 2.0+/-0.4 dysplasia index; P<0.01) in the brains of ALK1+/- mice treated with AAVVEGF and hydralazine or nicardipine compared with the mice treated with them individually. Hydralazine 169-180 activin A receptor, type II-like 1 Mus musculus 131-135 19188760-7 2009 WWOX mRNA and protein expression was greatly reduced in MDA-MB-231 cells, partly due to the methylation of WWOX CpG islands, and recovered after hydralazine treatment. Hydralazine 145-156 WW domain containing oxidoreductase Homo sapiens 0-4 18521605-0 2009 Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Hydralazine 0-11 APC regulator of WNT signaling pathway Homo sapiens 84-87 18521605-4 2009 The purpose of this study was to evaluate the effects of hydralazine on APC reactivation and the inhibition of human cervical cancer cells in vitro. Hydralazine 57-68 APC regulator of WNT signaling pathway Homo sapiens 72-75 18521605-6 2009 beta-Catenin protein that correlates closely with APC was detected by immunohistochemistry method after treatment with hydralazine. Hydralazine 119-130 catenin beta 1 Homo sapiens 0-12 18521605-6 2009 beta-Catenin protein that correlates closely with APC was detected by immunohistochemistry method after treatment with hydralazine. Hydralazine 119-130 APC regulator of WNT signaling pathway Homo sapiens 50-53 18521605-9 2009 Hydralazine induces APC expression and promotes demethylation in HeLa and CaSki cells. Hydralazine 0-11 APC regulator of WNT signaling pathway Homo sapiens 20-23 18521605-14 2009 The expression of beta-catenin protein in the cell membrane was observed after the treatment with hydralazine. Hydralazine 98-109 catenin beta 1 Homo sapiens 18-30 18521605-15 2009 CONCLUSIONS: Hydralazine, an effective inhibitor of APC methylation and promoter of APC re-expression, can inhibit cell growth in human cervical cancer in vitro and be potentially used for the clinical treatment of human cervical cancer. Hydralazine 13-24 APC regulator of WNT signaling pathway Homo sapiens 52-55 18521605-15 2009 CONCLUSIONS: Hydralazine, an effective inhibitor of APC methylation and promoter of APC re-expression, can inhibit cell growth in human cervical cancer in vitro and be potentially used for the clinical treatment of human cervical cancer. Hydralazine 13-24 APC regulator of WNT signaling pathway Homo sapiens 84-87 19109942-6 2009 Losartan completely, but hydralazine only partially, suppressed the angiotensin II-induced intracardiac lipid deposition and increase in tissue triglyceride content. Hydralazine 25-36 angiotensinogen Rattus norvegicus 68-82 19198701-5 2008 In a racially mixed population, treatment with a combination of ISDN and hydralazine reduced mortality compared to placebo to a nearly statistically significant extent in the first Vasodilator Heart Failure Trial (V-HeFT I) but was inferior to treatment with angiotensin-converting enzyme (ACE) inhibitor enalapril in the V-HeFT II study. Hydralazine 73-84 angiotensin I converting enzyme Homo sapiens 259-288 19075673-8 2008 We suggest that exercise, Cobalt compounds or hydralazine may reverse the age-related decline by up-regulating HIF-1-mediated signaling. Hydralazine 46-57 hypoxia inducible factor 1 subunit alpha Homo sapiens 111-116 19198701-5 2008 In a racially mixed population, treatment with a combination of ISDN and hydralazine reduced mortality compared to placebo to a nearly statistically significant extent in the first Vasodilator Heart Failure Trial (V-HeFT I) but was inferior to treatment with angiotensin-converting enzyme (ACE) inhibitor enalapril in the V-HeFT II study. Hydralazine 73-84 angiotensin I converting enzyme Homo sapiens 290-293 18504326-7 2008 Antihypertensive medication consistent of hydrochlorothiazide, hydralazine, and reserpine ameliorated the histopathologic changes and attenuated p16(INK4a) expression in kidneys of deoxycorticosterone acetate-salt-treated rats. Hydralazine 63-74 cyclin-dependent kinase inhibitor 2A Rattus norvegicus 145-148 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 0-11 tachykinin receptor 3 Rattus norvegicus 48-52 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 0-11 arginine vasopressin Rattus norvegicus 106-108 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 0-11 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 136-141 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 0-11 arginine vasopressin Rattus norvegicus 156-158 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 13-16 tachykinin receptor 3 Rattus norvegicus 48-52 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 13-16 arginine vasopressin Rattus norvegicus 106-108 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 13-16 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 136-141 18650316-2 2008 Hydralazine (HDZ)-induced hypotension activates NK3R expressed by magnocellular neurons, increases plasma VP and OT levels, and induces c-Fos expression in VP and OT neurons. Hydralazine 13-16 arginine vasopressin Rattus norvegicus 156-158 18554582-11 2008 We therefore conclude that hydralazine reduces leukocyte migration by different mechanisms in SHR and Wistar rats, specifically by reducing ICAM-1 expression in the former and P-selectin expression in the latter. Hydralazine 27-38 intercellular adhesion molecule 1 Rattus norvegicus 140-146 18554582-11 2008 We therefore conclude that hydralazine reduces leukocyte migration by different mechanisms in SHR and Wistar rats, specifically by reducing ICAM-1 expression in the former and P-selectin expression in the latter. Hydralazine 27-38 selectin P Rattus norvegicus 176-186 18812494-8 2008 Blood pressure was significantly decreased in irbesartan- and hydralazine-treated ApoE(-/-) mice (p < 0.05) compared with controls and wild-type mice. Hydralazine 62-73 apolipoprotein E Mus musculus 82-86 18688015-10 2008 Moreover, cerebral inflammation was also prevented by valsartan more than hydralazine, being associated with more suppression of monocyte chemotactic protein-1 and tumor necrosis factor-alpha expressions by valsartan. Hydralazine 74-85 C-C motif chemokine ligand 2 Rattus norvegicus 129-191 18701622-7 2008 MAP reductions by hydralazine (1 mg/kg) or isoproterenol (10 microg/mouse) were significantly greater in NKCC1-/- than WT mice. Hydralazine 18-29 solute carrier family 12, member 2 Mus musculus 105-110 18680473-1 2008 Polymorphic N-acetyl transferases (NAT) 1 and 2 are involved in detoxification of xenobiotic arylamines and hydralazines. Hydralazine 108-120 N-acetyltransferase 1 Homo sapiens 12-47 18680473-6 2008 NAT2 slow metabolizers are more prone to the side effects of polymorphically acetylated drugs, as is the SLE-like syndrome induced by hydralazine and procainamide, the side effects due to sulphasalazine and the skin rash secondary to many sulphonamides. Hydralazine 134-145 N-acetyltransferase 2 Homo sapiens 0-4 18504326-7 2008 Antihypertensive medication consistent of hydrochlorothiazide, hydralazine, and reserpine ameliorated the histopathologic changes and attenuated p16(INK4a) expression in kidneys of deoxycorticosterone acetate-salt-treated rats. Hydralazine 63-74 cyclin-dependent kinase inhibitor 2A Rattus norvegicus 149-154 18031714-9 2008 The density of GluR1 puncta in the NTS was significantly reduced by hydralazine treatment in the SHR model. Hydralazine 68-79 glutamate ionotropic receptor AMPA type subunit 1 Rattus norvegicus 15-20 18473772-9 2008 This paper discusses evidence suggesting that depressed HIF-1 alpha-mediated gene programming is the most fundamental of all cardiovascular risk factors and discusses the manipulation of this system with existing drugs such as cobalt or hydralazine. Hydralazine 237-248 hypoxia inducible factor 1 subunit alpha Homo sapiens 56-67 18394600-6 2008 Using SKOV3 cells as a model, the link between DNA demethylation and STC2 expression was consistently demonstrated with hydralazine treatment, which was shown to reduce the protein level of DNA methyltransferase 1 (DNMT1) but stimulated STC2 expression. Hydralazine 120-131 stanniocalcin 2 Homo sapiens 69-73 18394600-6 2008 Using SKOV3 cells as a model, the link between DNA demethylation and STC2 expression was consistently demonstrated with hydralazine treatment, which was shown to reduce the protein level of DNA methyltransferase 1 (DNMT1) but stimulated STC2 expression. Hydralazine 120-131 DNA methyltransferase 1 Homo sapiens 190-213 18394600-6 2008 Using SKOV3 cells as a model, the link between DNA demethylation and STC2 expression was consistently demonstrated with hydralazine treatment, which was shown to reduce the protein level of DNA methyltransferase 1 (DNMT1) but stimulated STC2 expression. Hydralazine 120-131 DNA methyltransferase 1 Homo sapiens 215-220 18394600-6 2008 Using SKOV3 cells as a model, the link between DNA demethylation and STC2 expression was consistently demonstrated with hydralazine treatment, which was shown to reduce the protein level of DNA methyltransferase 1 (DNMT1) but stimulated STC2 expression. Hydralazine 120-131 stanniocalcin 2 Homo sapiens 237-241 18094148-8 2008 The changes in MP expression in HtP were largely prevented by treatment with the antihypertensive medicine hydralazine. Hydralazine 107-118 protein phosphatase 1, regulatory subunit 12A Rattus norvegicus 15-17 17923586-5 2007 Hydralazine was administered with Ang II infusion (n=10). Hydralazine 0-11 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 34-40